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Abstract
The purpose of this study was to detennine the genetic cause of hearing loss in28
Newfoundland families with Autosomal Dominant hearing loss. AD hearing loss is
highly genetically heterogeneous, and is mainly associated with a lateonset,progressive
phenotype. After a comprehensive literature search,genotype-phenotypeevaluations,and
afunctionalcandidategeneapproach,all28probandsweresequencedtoidentify
mutations in four genes known to cause autosomal dominant hearing loss, COCH,
KCNQ4, TECTA, and MYOJA. First, a known Dutch founder mutation within exon 4 of
COCH, c.151 C>CT, was found in a Newfoundland proband of Family 2094. All affected
family members (n=7) shared this mutation, while unaffected members did not. This is
only the second family found to harbor this mutation outside of Europe. This mutation is
strongly associated with severe vestibular decline. Affected Family 2094 members
carrying the mutation do present vestibular decline in the fonn of vertigo and balance
difficulties. As this mutation is considered to be a Dutch founder mutation, DNA samples
from a Dutch p.P51P/S family were genotyped and compared with Family 2094
genotypes. Fragment analysis confinned haplotype sharing of five markers closely
bordering the c.151 C>CT mutation between Newfoundland and Dutch mutation carriers.
Second, a novel3bp deletion in exon 5 of KCNQ4 was found in 13 affected members of
Family 2071. While the mutation was not seen in four other affected family members,
audiology test results suggest that these four individuals arephenocopies.Sequencingof
the full KCNQ4 gene was done in all individuals, to rule out another mutation on the
same gene. Further investigation, through the construction of an intragenic haplotype,did
notpointtoanyfurtherhearinglossassociatedvariantswithinKCNQ4,andconfirmed
that all deletion carriers share a common hearing loss haplotype and deletion. Third,a
nonsense mutation was found in exon 4 of MYOIA in the proband ofNewfoundland
Family 2102. This is a C7T nucleotide substitution (c.2435 C>CT) that causes a change
(p.R93X) in the motor domain of myosin lAo Offour individuals in Family 2102, three
were found to carry the p.R93X mutation, while one unaffected sibling was not. This
mutation has been reported once before in a small Italian family. No mutations were
discovered in the TECTA gene. When each of the causative mutations in COCH, KCNQ4,
and MYOIA was detected, additional Newfoundland hearing loss probands were
screened, to rule out the possibilityofa founder mutation. In no case were additional
mutation carriers identified. While no founder mutations were discovered in this study,
the genetic cause of hearing loss was identified in three families.
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Chapter 1: Introduction
Purpose
The aim of this research project is to determine the genetic etiology of autosomal
dominant (AD) hearing loss in 28 Newfoundland families.
Overview
Hearing loss is the most common sensory disorder in humans. For example, one
in every 500 newborns has hearing loss (Morton & Nance, 2006). The prevalence of
hearing loss increases dramaticaJly with age, and by puberty, the number of affected
persons doubles (Morton & Nance, 2006). Hearing loss is even more prevalent in adults,
as 60 % of people older than 70 years have a hearing loss of25 dB or more (Gratton &
Vazquez,2003).
Hearing loss is a multi-factorial disorder caused by both genetic and
environmental factors. Genetic factors account for 50 % of all hearing loss cases, while
environmental factors cause 25 %. The remaining 25 % are classified as being of
unknown etiology (Willems, 2001). Environmental causes of hearing loss include
exposure to high sound decibel levels, head trauma, prematurity,neonatal hypoxia, low
birth weight, prenatal infections from "TORCH" organisms (i.e., toxoplasmosis, rubella,
CMV, and herpes), and postnatal infections like bacterial meningitis (Willems, 2001;
Bitner-Glindzicz, 2002).
Approximately 30 % of genetic cases aresyndromic: the phenotype includes 0 ther
signs and symptoms throughout the body in addition to deafuess. Over 400 genetic
syndromes include some degree of hearing loss (Gorlin et al. 1995; Nie et al. 2008). Two
examples are Usher syndrome (USH): hearing loss accompanied by retinitis pigmentosa,
and Pendred syndrome: a hearing loss disorder accompanied by goiter, whichisa
swelling in the thyroid gland. However, the vast majority, around 70%, of inherited
hearing disorders are non-syndromic (Cremers et al. 1991; Van Camp et a!. 1997).
Worldwide, within non-syndromic cases, 88 % of the hearing loss genes identifiedcause
autosomal recessive (AR) hearing loss, II % AD, and the remaining 1% either
mitochondrial or X-linked (Smith & Van Camp, 2007).
Thefivefactorsusedtodescribehearinglossareageofonset,soundfrequencies
affected (low, middle or high), degree of hearing loss (measured indBs), affected part of
the auditory system (conductive, sensorineural or mixed), and configuration(unilateral,
or bilateral).
Hearing loss has a high degree of genetic heterogeneity. A large numher of
mutations within many different genes cause similar hearing loss phenotypes. As of May
2010, the Hereditary Hearing Loss Homepage listed 141 non-syndromic deafness loci
that haveheen mapped and 50 genes that have been identified. Twenty-two 0 fthe50
known genes harbor mutations that cause AD hearing loss (Table 1.1), 33 cause AR
hearing loss, and 2 cause X-linked hearing loss (Van Camp G, Smith RJH
http://hereditaryhearingloss.org). Loci for non-syndromic hearing loss are denoted
'OFNA' for AD inheritance, 'DFNB' for AR inheritance and 'OFN' for X-linked
inheritance (Griffith & Friedman, 2002). Some genes cause both AD and AR hearing
loss. For example, Grifa et al. (1999) found a C7T change in gap junction protein, beta 6
(GJB6) that resulted in the substitution ofa highly conserved threonine residuefora
methionine at amino acid position 5 (p.T5M), resulting in nonsyndromic AD hearing
loss. While this GJB26 mutation causes AD hearing loss, Del Castillo et al. (2002)
identified a342 kb deletion in GJB6by studying 422 unrelated subjectsfromSpainand
Cuba with an AR pattern of inheritance.
Pedigrees
When studying hearing loss, or any hereditary disorder, family members are
visualized on a pedigree chart, which in this study shows all known hearing 10ss
phenotypes presented at the time of clinical and audiological testing.Thisallowseasier
identification of the inheritance pattern and of the relationshipsamonghaplotypes.A
haplotype is a combination of alleles that are transmitted together. When a causative
mutation is found, alleles oflinked markers are assessed in order to develop a haplotype,
or pedigree that illustrates shared genetic variants between farnily members.These
haplotypes are then compared between members of the same family or between members
of different families that share the same mutation. A common haplotype with the same
mutation suggests a common ancestor for that mutation. Furthermore, a haplotype can
point to associations between different variants that may be combining to affect the
phenotype.
Audiograms
Audiograms are graphs of the minimal level of sound that a given person can hear
at various frequencies (Figure 1.1; Figure 1.2). They are produced using an audiometer, a
machine that tests hearing by exposing patients to a range of sounds at differentpitches
and decibel (dB) levels. During hearing tests, separate audiograrns are obtainedforeach
ear. Each line on the audiogram represents one ear. The y-axis measures sound intensity
in units of dB, which increases logarithmically. The x-axis of the audiogram measures the
frequency, or pitch, of a sound in Hz (Hertz). Low pitch sounds have low frequencies «
500 Hz), medium pitch sounds have medium frequencies (500 - 2000 Hz), and high pitch
sounds have high frequencies (> 2000 Hz). Hearing loss is characterizedbyintensity,
which can be mild, moderate,severeorprofound,and by which frequency isaffected,
such as low, middle or high.
An individual with normal hearing can detect soundsbetweenOdB and 20 dB.
The minimum level of hearing, 0 dB, is equivalent to a barely audible whisper. Those
affected with hearing loss, however, have a higher than normal minimum hearing level.
This means that any given sound intensitymustbegreaterthanOdB for them to hear il.
People with a mild degree of hearing loss can only hear sound at intensitiesbetween20-
40 dB for the frequencies of 500 - 4000 Hz. Individuals with moderate hearing loss can
only hear sound from40-70dB,andthosewith severe hearing loss can only hear sound
between 70-95 dB in intensity. Lastly, those with profound hearing loss cannot detect
soundatallunlessitis95dBorgreater(suchasthesoundproducedbyan.MP3player
at maximum volume; Mazzoli et aI. 2003).
Figure 1.1 shows a series of simple audiograms: audiogram A shows an
individual with normal hearing, B an individual with moderate bilateral (affecting both
ears)hearingloss,andCanindividualwithseverebilateralhearingloss.However,
audiograms are often not so simple to read. Figure 1.2 shows two additional audiograms:
audiogram A shows an individual with moderate to mild hearing loss in the left ear and
normal hearing in the right ear (unilateral),and B shows an individual with bilateral
hearing loss sloping to moderate and profound at the higher frequencies. This
audioprofile is typical ofpresbyacusis, or age-related hearing loss. 40 % of the population
older than 65 yearsofageisaffected,and 80 % of hearing loss cases occur in elderly
people (Gates & Mills, 2005). It is now generally accepted that presbyacusis is most often
caused by age-related declines in the auditory system, such as lossordeteriorationof
sensory cells within the cochlea. Moreover,impairedtemporalprocessingisassociated
with age-related factors that affect neural synchrony of hearing (Schuknechtetal.1993;
Friedman 2003; Wu et aI. 2003; Fitzgibbons et al. 2010). Temporal processing refers to
the processing of acoustic stimuli overtime. Temporal processing allows us to
distinguish speech from background noise, as the decibel levels of the background noise
Another common and important characteristic of presbyacusis, and of any
sensorineural hearing loss, is the level of speech discrimination a patient demonstrates.
Hearing a sound does not always translate into properly distinguishing speech. Tests are
also performed to determine a patient's speech discrimination. The measure of speech
discrimination is often a percentage, and describes the ability ofa patient to correctly
identifY words when the sound is loud enough for them to comfortably hear. When a
patienthaslowspeechdiscrimination,ahearingaidwillsuccessfullyamplifYsoundin
the patient's ear, but will not necessarily improve speech perception. The amplified sound
remains gibberish to the patient because he/she is unable to identifY the words.
(McAlister, 1990; Kodera et al. 1994). A cochlear implant, a surgically implanted
electronic device that provides sound to profoundly deaf or severely hard of hearing
individuals,hasbeenfoundinmanycasestomarkedlyimprovespeechdiscrimination
(Leung et a1. 2005; Cambron, 2006; Yueh & Shekelle, 2007).
Autosomal Dominant Hearing Loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) accounts for
approximately 15 % of inherited hearing loss (Hildebrand etal. 2008). To date, 59 loci
for ADNSHL have been identified, along with 22 causally related genes (Table 1.1; Van
Camp G, Smith RJH. Hereditary Hearing Loss Homepage.
hllp://hereditaryhearingloss.org). The majority of AR hearing loss cases are caused by
mutations in just a few genes, most notably gap junction protein beta 2 (GJB2) and GJB6.
This contrasts sharply with AD hearing loss, which is significantly more genetically
heterogeneous (Griffith & Friedman,2002),makingcost-effectivescreening for
diagnosis in a clinical selling highly problematic. Mutations within the genes wolfram
syndrome I (WFSI), cochlin (COClf), potassium voltage-gated channel 4 (KCNQ:f), and
tectorin alpha (TECTA) are marginally more frequently reported in comparison to the
other reported causative genes. The audioprofilesometimesprovides clues to the
underlying causative gene. For example, WFSJ harbors mutations found in 75 % of
families segregating for AD, non-syndromichearing loss that initially affect only the low
frequencies(youngetal. 2001; Bespolovaetal. 2001).
ADNSHL is often characterized by a post-lingual, late-onset, progressive
phenotype that affects mainly adults. Post-lingual hearing loss is muchmorefrequent
thanpre-lingualhearingloss,andaffectsI0%ofthepopulationbytheageof60(Van
Camp et al. 1997). This most often results from damage to auditory hair cells (AHCs) or
their innervation (Gates & Mills, 2005). For example, one late-onset progressive hearing
loss associated gene is eyes absent homolog 4 (EYA4), a member of the vertebrate Eya
family of transcriptional activators. Mutations in this gene were found in Belgian and
USA families, and create premature stop codons leading to post-lingual, progressive, AD
hearing loss. EYA4 was subsequently shown to be critical in the continued function of the
mature organ of Corti, an organ in the cocWea that contains the AHCs (Wayne et a1.
2001).
Critical Considerations When Researching Autosomal Dominant
Hearing Loss
Of the 28 farnilies researched in this study that are classified as having an AD
pattem of inheritance, one or more may have been incorrectly classified duetoalackof
sufficient data. Many individuals in these pedigrees (Figure 2.1) areascertained through
relatives' word of mouth. For this reason, itisimportanttodiscusstherolethatdifferent
factors may be playing in confusing the ascertainment of individuals and thus the search
for causative hearing loss mutations.
Digenic inheritance is when a phenotype is expressed only if an interaction
between two mutant alleles in two separate genes occurs (Strachan & Read, 2003).
Digenic inheritance does not cause AD hearing loss, butdigenic inheritance may play a
role in the hearing loss of one of the families under investigation in this srudy. For
example, Chen et al. (1997) reported a small consanguineous family with three affected
and three unaffected members. Two regions shared by the three affected individuals were
identified, one on 3q21.3-q25.2 (LOD =2.78) and 19p13.3-p13.1 (LOD = 2.78). LOD
(Logarithm (base 10) of odds) isa statistical test used to determine the likelihood of
obtaining test data if two loci are linked compared to the likelihood ofobserving the data
by chance. Chenetal. (1997) speculated that two non-allelic recessivemutations
accounted for the profound congenital deafness in this family. In a Chinese family, Liu et
al. (2009) demonstrated through DNA sequencing that mutations in GJB2 and GJB3
interact to cause hearing loss in digenic heterozygotes. To supportthis, they discovered
overlapping expression patterns of GJB2 and GJB3 in the cocWea, along with co-
assembly of the GJB2 and GJB3 proteins when co-transfected in human embryonic
kidney (HEK) cells (Liu et al. 2009). And a third example was seen recently when
mutations within ATP sensitive inward rectifier potassium channel 10 (KCNJI0) and
solute carrier family 26, member 4 (SLC26A4) were found to cause digenic non-
syndromichearing loss associated with enlargedvestibularaqueductsyndrome(EVA)
(Yang et aI. 2009). Mutations in SLC26A4 were previously shown to cause Pendred
syndrome (PS), agenetic disorder leading to hearing loss and goiterwithoccasional
hypothyroidism. Many individuals with an EVAlPS phenotype had only one disease-
causing variant in SLC26A4. Yang et al. (2009) identified double heterozygosity in
affected individuals from two separate families. These patients carry single mutations in
both KCNJIO and SLC26A4, and the mutation in SLC26A4 has been previously
associated with the EVAlPS phenotype. The KCNJIO mutation reduces potassium
conductance activity, which is critical for generating and maintaining proper ion
homeostasis in the ear. To add further support to theirdigenic interaction hypothesis,
Yang et al. (2009) demonstrated haploinsufficiency ofSlc26a4 in Slc26a4+/- mouse
mutants resulted in reduced protein expression of KcnjIO in the inner ear.
One important term to keep in mind when researching AD hearing loss is
penetrance.Penetrancereferstotheproportionofindividualswitha mutation who
exhibit clinical symptoms. For example, if a mutation in a gene responsible for a type of
AD hearing loss is 95 % penetrant, then 95 % of individuals with the mutation will
exhibit symptoms, while 5 % will not during their lifetime. Penetrance is often expressed
as a frequency at different ages because, for many hereditarydiseases,onsetofsymptoms
is age-related (Strachan & Read, 2003). This is particularly important because AD
hearing loss is often late-onset and progressive. Forthisreason,afamily'sinheritance
pattemcould appear to be sporadic, when in fact the disorder segregatesautosomal
dominantly, and the individuals under study simply haven't yet presented the hearing loss
phenotype, as the age of onset varies widely and can range well into 50 years of age. A
related but distinct potential problem is expressivity. Expressivityrefers to variations ofa
phenotype for a particular genotype. When a condition has higWy variable signsand
symptoms, it can be difficult to diagnose.
Mitochondrial inheritance could also be confusing the ascertainment ofthe
families investigated in this study. Mitochondrial inheritance is the inheritanceofatrait
encoded in the mitochondrial genome, and is always of maternal origin. It is therefore
often also called maternal inheritance. When a woman harbors a mitochondrial mutation,
and her egg cells are forming an ovary, these egg cells contain a random distribution of
both normal and mutated copies of the mitochondrial gene(St.Johnetal.2010).
Therefore, all children of this mother may inherit some mutated mitochondria, but if the
number of mutated mitochondria reaches a critical level, termed the"thresholdeffect",
then an adverse phenotype is seen (St. John et al. 2010; Van Camp G, Smith RJH.
Hereditary Hearing Loss Homepage). These mitochondrial hearing loss mutations can be
late-onset, or if the carrier is administered certain antibiotics, the phenotypewillbe
"drawn out". This is the case with mutations in MT-RNRI, which are known to cause
non-syndromic deafness (Casano et al. 1999; Bates 2003). Mitochondrial mutations are
beyond the scope of this study, but have previously been shown to cause late-onset
hearing loss that is comparable to the phenotypes of Families 2093, 2112,and2125
investigated here (Casano et al. 1999). While there are no incidences of male to male
transmission in these families, additional clinical ascertainrnentcouldpotentially reveal a
mitochondrial inheritance pattern. This study primarily targets only genesandmutations
known to be associated with AD hearing loss, but the possibility of maternally inherited
mutations causing hearing loss in the above mentioned families should not be ruled out,
and should be investigated in future studies.
As a result of random genetic drift in the founder population ofNewfoundland,
there is an elevated incidence ofparticular rare disorders, such as Bardet-Biedlsyndrome
(Webb et al. 2009). This makes the founder population ofNewfoundland ideal for the
study of genetic disorders and increases the chance of detecting novelcausativegenes
and mutations. However, due to the nature ofNewfoundland as a genetic isolate, some
potential pitfalls arise. One potential pitfall is the uncertainty ininheritance
ascertainment. For example, assortative mating could confuse the ascertainment of
families and therefore the search for hearing loss mutations. Assortative mating occurs
when sexually reproducing organisms choose to mate with individuals that are similar
(positiveassortativemating)ordissimilar(negativeassortativemating) to themselves in
some specific way. One family under investigation in this study (Family 2069) is a
potential example of positive assortativemating (seep.42, bottom pedigree,sth
generation). This is critically important. Positive assortative matingcouldresultinboth
parents carrying a mutation that causes hearing loss. This may, however, simply be a
result of studying a genetic disorder in a highly isolated population, and it is possible that
thismatingtookplacenotbecausebothindividualswereaffectedbyhearingloss,but
instead due simply to the low level of mating choice in small out-port community. Either
way, our current inheritance classification ofNewfoundland Family 2069 could possibly
be incorrectly stated as AD, and our candidate gene selection would thenbe based on
unfounded and false assumptions. It is important to keep this possibility under
unfounded and false assumptions. It is important to keep this possibility under
consideration, and to investigate and screen for commonly occurring recessivemutations
intbe proband of Family 2069 as well as dominant mutations. Pseudo-dominanceshould
also be taken intoaccounl. This istbe situation where tbe inheritance ofan ARtrait
mimics an AD pattem, and due to tbe limited extent of clinical ascertainment intbese
families' histories, it is possible tbat one oftbese AD families is in fact affected by an AR
mutation segregating in a pseudo-dominant fashion.
Anotbercriticalfactortojudgewhenresearchinggenetichearinglossistbe
possible presence of phenocopies. A phenocopy is an affected individualwhohastbe
same disease, but due to a different cause, as relatives affected witb tbegeneticcondition
under study. Hearing loss is a very common type of sensory loss in humans. Many types
ofenvironmentalandgeneticfactorsaccountforhearinglosssoindividualswitbin
families affected witb hearing loss can beaftlicted due to apletboraofdifferentreasons
(Griffith & Friedman 2002). For example, a study of heterozygous WFSI mutations in
two low frequency sensorineural hearing loss families showed tbat tbese two families'
hearing loss were linked to adjacent but non-overlapping loci on4pl6, DFNA6and
DFNAI4 (Van Camp et ai. 1999). Upon further study, it was found tbat an individual in
tbe DFNA6 family who had a recombination event excluding tbe DFNAl4 candidate
region was actually a phenocopy. The cause of hearing loss in this phenocopy was
reported as unknown, but as a consequence tbey were able to detennine tbat DFNA6 and
DFNAI4areallelic(BespalovaetaI.2001).
Throughout this study genes are investigated through targeted genesequencing.
However, it must be mentioned that it is possible larger genomic abnormalities may
account for hearing loss in some of the Newfoundland families under investigation
(Lisenkaetal. 2003; Shafferetal.2006). Large genomic rearrangements, deletions,
inversions, etc. can cause and affect the degree and severity of diseases, and these large-
scale anomalies are not detected through traditional DNA sequencing methods (Lisenka
etal. 2003; Idbaihetal. 2010).
The Pioneering of Hearing Loss Gene Discovery
The fIrst genes to be implicated in hearing loss were found in the syndcomic
disorders. Syndromic forms of hearing loss are classified by their associated symptoms.
For example, Waardenburg syndrome (WS) is the most common cause of AD syndromic
hearing loss. WS is characterized by varying degrees of hearing loss associatedwith
pigmentation anomalies and neural crest defects. It was frrstdescribedin 1951, but it took
several decades to identify the causative genes. Asher and Friedrnan (1990) studied mice
and hamsters with four mutations causing phenotypes similar to those seen in human WS
patients. They used the chromosomal locations and syntenic relationships associatedwith
three of these four mutant mouse genes to predict human chromosomal locations for the
causativeWSgene.Syntenyisthesituationwherebyorganismsofrelativelyrecent
divergence show similar blocks of genes in the same relative positions in the genome.
Asher and Friedman (1990) predicted four possible locations forthecausative gene, and
one turned out to be correct. In 1992,mutationscausing WS were discoveredinthe
paired box gene (PAX3) gene (on chromosome 2q) (Tassabehji et al. 1992). A second
common cause of AR syndromic hearing loss is Usher syndrome (Toriello et al. 2004).
Usher syndrome was first described in 1858 when Van Graefe reported the case of a deaf
and "dumb" male patient presenting with retinal pigment degeneration, who had two
similarly affected brothers (Van Graefe, 1858). This was the first syndrome to
demonstrate that phenotypes, in this case deafness and blindness, could be inherited in
tandem.Ushersyndromeischaracterizedbyprofoundcongenitalhearingimpairment,
retinitispigmentosa, and vestibular dysfunction. It has three clinical types,denotedasI,
II,andlII,indecreasingorderofseverity(Saihanetal. 2009). In 1995 one of several
causative genes for Usher Syndrome Type I was discovered. WeiI et aJ. (1995) chose
myosin 7A (MYOVlIA) as a functional candidate gene, based on observations that
cytoskeletal abnormalities seen in Usher syndrome patients are also seen in mouse
mutants with myosin mutations. Two different premature stop codons, a six bp deletion,
and two different missense mutations were detected in five unrelated families. In one
family, these mutations were identified in both alleles, and resulted in the absence ofa
functionalproteinandsubsequentUshersyndrome(WeiletaJ.I995).Currently,IO
different types of Usher syndrome have been recognized, with more than 100 pathogenic
mutations alone for the two most common molecular forms, Usher IB (USHI B) and
Usher 2a (USH2A; Ahmed etal. 2003; SaihanetaJ.2009).
The first ADNSHL family investigated was from the small town of Taras, Costa
Rica. The hearing loss was described as low frequency AD with a post-lingual age of
onset at 10 years of age (Leon et aI. 1981). Leon et al. (l992)perfonned linkage analysis
to detennine that the causative gene was linked to markers defining a 7 cM critical region
on chromosome 5q31. Genetic markers are DNA sequences with a known location on a
chromosome, and are useful in linkage analysis because they are easily identifiable,
associated with a specific locus, and highly polymorphic. LODscoresfor linkage of
deafness to markers in the 7 cM region showed a score of 13.55 at markers D5S2119 and
D5S2010 (Leon et al. 1992). This was not only the first AD critical region described, but
the first autosomal non-syndromic hearing loss gene to be mapped altogether. It was not
until 1997,26 years afterfirstbeingreported,thattheregionwas narrowed down further.
Positionalcloning,sometimesreferredtoasreversegenetics,isthecloning of an area
known to be associated with a disease. It involves the isolation of overlapping DNA
segments that progress along the chromosome toward a candidate gene. Lynch et aI.
(1997)perfonned fine mapping using positional cloning techniques to narrow the critical
region to 1 cM. This revealed protein diaphanous homolog 1 (DIAPHI), a previously
unidentified human gene. DIAPHI, in this case, is a positional candidate gene, a gene
identified based upon a detennined critical region. Thisdiffersfrom functional candidate
genes, which are known to play a role in the disease pathology, or have been previously
shown to harbor mutations that cause a disease,like the p.A716T mutation in WFSI in
Newfoundland (Young et aI. 2001; Bespalova et aI. 2001). Lynch et al. (1997) sequenced
the positional candidate gene DIAPHI in all affected family members using Single Strand
Confonnation Polymorphism (SSCP) analysis. SSCP is the electrophoretic separation of
single-strandednucleicacidsbasedondifferencesinsequenceswhichbringabouta
different secondary structure and thus a measureable difference in mobility through a gel.
The causative mutation, a G7T substitution, was now revealed, and DlAPHl was also
found to be higWyexpressed in the cochlea (Lynch et aI. 1997). Lynch eta1.(1997)
speculate that the protein this gene encodes, protein diaphanous homolog I, plays a role
in the regulation of actin polymerization in the hair cells of the cocWea.
Founder Populations & Mutations
No surnmary of hearing loss associated genes and mutations would becomplete
without mentioning the irnportanceoffounderpopulations, thefoundereffect,and
foundermutations.Afounderpopulationisasmallsubpopulationthat has been isolated
due to geography, culture, religion or a combination of these. Thissubpopulationhasa
significantly decreased amount of genetic diversity, causing certain genetic traits to either
vanish or become very abundant in further generations. When a founder populationis
isolated individuals in later generations are likely to share many genes,becausea
mutation in a founder will be passed onto a large proportion of the populationin
subsequent generations (Nurhousen, 2000). Founder populations, therefore, possess much
promise in determining the genes involved in genetic diseases. As there is little genetic
heterogeneity, the majority of the individuals with a given disease will carry the same
gene mutation. For example, the Ashkenazi Jews were a reproductively isolated
population in Europe for rougWy a thousand years, with very littleout-migration or inter-
marriage with other groups (Nebel et aI. 2005). As a result of this event, the GJB2
mutation c.167delTwas found to be highly prevalent in the Ashkanazi Jewish population
(Morell et aI. 1998). Other examples of founder populations include the Canadian
province of Quebec, which was established by as few as 2600 individuals, the United
States Amish population, and the population ofPingelap, a small island in Micronesia.
A founder mutation is a mutation found as an allele and shared by several
individualsfromafounderpopulationandderivedfromasingleancestor.Forexample,
CaCH p.P51P/S mutation carriers are considered to have originated from a common
ancestor (de Kok et aI. 1999). A second example was recently seen when Park et aI.
(2010) investigated the 3-bp deletion in intron 7 (c.991-15_991-13del) ofDFNA5, and
identified a conserved haplotype between a Korean family and a Chinese family
segregating the deletion in DFNA5,suggestingthatthis deletion represented a founder
mutation originating from a common ancestor.
Colonization of Newfoundland: A Founder Population
The island ofNewfoundland makes up a large part of the Canadian province of
Newfoundland & Labrador. It is the most easterly landmass on the North American
continent. In 1497 the European explorer Giovanni Gabotto (John Cabot) "discovered"
Newfoundland, though Vikings had landed earlier. Europeans voyaged across the North
AtlanticfromEngland,Scotland,lreland,FranceandPortugaltoharvesttherichfish
stocks. When each fishing season ended they returned to their countries, as permanent
those consideringpennanent settlement, and with a lack of basic supplieseven aone year
stay would have been very difficult (Poole & Cuff, 1994). This deterrence lessened
throughouttheI7 th century,however,assmailgroupsofEnglish,Scottish,and Irish
settlerssetsailfromwesternEngiandinl6l0andthroughoutthel7'h century.These
colonists excluded other nations from fishing off ofNewfoundland's east coast, but were
discouraged in their settlement by the English government, who saw their presence as a
threat to the monopoly control that Western England fishing centers had established.
Meanwhile, fishennan from France dominated the island's south coast and northern
peninsula(Bennett,2002). Throughout the l600s, the French began to pennanently settle,
but in l713,withtheTreatyofUtrecht, the English gained control of the south and north
shores of the island. Pennanent settlement increased rapidly by the latel8 th century,
peakingintheearlyyearsofthel800s.
The colonization ofNewfoundland began in earnest in the early 19th century
mainly from Southwest England and Southeast Ireland. Fishennan brought their families
totheisland,intendingtosettlepennanently,andthesefamiliesarethefoundersofmuch
oftoday's Newfoundland population. Ninety percent ofNewfoundland's population
descends fromrougWy 30 000 founders (Parfrey etal. 2009). Farniliessettled in small
inlets along Newfoundland's coast in groups of one or two families. These communities
developed in geographical and cultural isolation, and can be characterized by large
families, and a strong founder effect (Bear et al. 1987). This isolation also directly led to
manygenerationsofinterbreeding(poole&Cuff,1994;Hancock,1989).
families, and a strong founder effect (Bear et a1. 1987). This isolation also directly led to
many generations of interbreeding (poole & Cuff, 1994; Hancock, 1989).
Large extended pedigrees from genetic isolates have been instrurnental in the
identificationofgeneticcausesofhereditarydisorders.Severalfounder mutations have
been identified in Newfoundland. For example, an exon 8 deletion in MSH2, a gene
causing hereditary non-polyposis colorectal cancer, has been found in five different
Newfoundland families (N=74 carriers), and an intron 5 splice site mutation
(c.942+3A>T) has been found in 12 different Newfoundland families (N=151 carriers)
(Frogattetai, 1996; Stucklessetal. 2006). A third example is a founder mutation
(c.782+3delGAG) found in the deafness gene TMPRSS3 in two different Newfoundland
families (Ahmed et a1. 2004; Young et a1. unpublished data). These are just a few
examples of founder mutations identified in Newfoundland, and serve to highlight the
importance of genetically isolated Newfoundland families in the study of hearing loss. At
the beginning of this study, only six hearing loss associated genes had beenidentifiedin
the Newfoundland population (Table 1.2). There is a possibility that a founder mutation
exists and could be found in some of these 28 Newfoundland families. When a founder
mutation is identified, the prevalence of this mutation in different worldwidepopulations
canbecompared,andbetterestimatesofriskforindividualsinthefounderpopulation
can be calculated. The presence of founder mutations in Newfoundland could thus have
strong clinical irnplications in terms of improved diagnosis and the ability to routinely
screen individuals if a founder mutation is common enough in the population.
with Bardet-Biedl syndrome (Webb et al. 2009). So while many Newfoundlanders can
trace their roots to roughly 30 000 founders, it is critical to keep inmind that these
founders came from different towns and different regions. The current population of
Newfoundland & Labrador, according to a 2006 census, is 505 469. A map of
Newfoundland & Labrador is seen in Figure 1.3.
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Figure 1.1 Examples of Audiograms. A) Audiogram of an individual witb normal
bearing in botb ears. B) Audiogram of an individual witb moderate bearing loss in
botb ears. C) Audiogram of an individual with severe bearing loss in both ears.
A)
~ "f---.,..--+---~~----!--l---+------1
!:f---"'---+---+~--'il~~--:I~==--'~l---+------1
~ 70 f---'--+---+--*""""F----->~,,~=---+I__..----1
"&--~
Figure 1.2 Examples of More Complex Audiograms A) Audiogram of an individual
with moderate hearing loss in the low frequencies sloping upwards to mild hearing
loss in the mid-to high-frequencies for the left ear only. Hearingin the right ear is
normal. B) Audiogram of an individual with progressive hearing loss showing a
mild loss at low frequencies which slopes downwards to a severe bilateral loss in the
mid-to high-frequencies.
Figure 1.3 Map of the Island of Newfoundland. AD Families under investigationinthis
study are indicated with their geographic location.
Table 1.1 AD Non-Syndromic Deafness Genes Identified Worldwide to Date (Van
Camp G, Smith RJH. Hereditary Hearing Loss Homepage.
http://bereditaryhearingloss.org,May2010)
Mu-crystallinhomolo Ion Homeostasis
Protein diaphanous homolog HairBundle,Cytoskeletal
I Formation
Ga "unctionbeta-3 rotein Ion Homeostasis
KCN04
Potassium voltage-gated
channel subfamily KQT
member 4 Ion Homeostasis
Unknown
COCH
COLLliA2
Non-syndromichearing
im airment rotein 5 Unknown
Wolfr Ion Homeostasis
AI ha-tectorin Extracellular Matrix
CocWin Extracellular Matrix
E esabsenthomolo 4 Transcription Factor
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Grainyhead-like2
Mosin-Ia
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Transmembrane channel-
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containin ~ Protein 50
Transcription Factor
Hair Bundle, Motor Protein
HairBundle,Cytoskeletal
Formation
Hair Bundle, Motor Protein
Transcription Factor
Hair Bundle, Motor Protein
Unknown
HairBundIe,CytoskeletaI
Formation
Table 1.2 Deafness Genes Identified in the Newfoundland Population at Beginning
of This Study.
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Chapter 2: Methods & Materials
Human Subjects & Pedigrees
This study is one partofa larger study to detennine the genetic cause of hearing
loss in Newfoundland & Labrador. Family members were recruited through the
Newfoundland Provincial Genetics Program, and a province-wide ascertainment drive.
Informed consent was obtained from all participants, granting researchers permission to
access medical records and family history. Blood samples were collected and genomic
and mitochondrial DNA was extracted from peripheral leukocytes from participants.
Audiological tests were performed to determine the type of hearing lossofeachsubject
and to confirm normal hearing in unaffected subjects. Audiograms are available for all
individuals marked with an asterisk in Figure 2.1, and for each of these individuals
several audiograms are available at different test ages, withnewonesroutinelybeing
collected. DNA from several Dutch individuals was provided by Dr. Hannie Kremer of
the Radboud University Medical Centre in Nijmegen, Netherlands. This project was
approved by The Human Investigations Committee (HIC) (Research Ethics Board of
Memorial University, Newfoundland & Labrador) (# 01.186).
So far, 128 probands have been recruited to the study. All probands in the study
were routinely screened for mutations previously identified to cause hearing loss in the
Newfoundland population. Of these, 28 probands are members of multiplex families with
a family history of hearing loss consistent with AD inheritance, and were chosen for this
study (Figure 2.1). Inheritance patterns weredeterrnined through an extensivefamily
history questionnaire, and pedigrees were electronically stored usingthecomputer
program Progeny. Many individuals' hearing loss was determined by word of mouth
from family members. In these cases, the age of onset and the degree and severity of
hearing loss are not known. For this reason, the determination of an AD pattern of
inheritance is not certain in some cases, but these families were deemed to likely have an
AD form of hearing loss, and it was therefore worth testing them for potential AD
hearing loss mutations. Due to the extent of genealogy work possible in Newfoundland
up to this point, it is important to keep other potential formsofinheritedhearingloss,
such as mitochondrial inheritance, in mind when searching forcausati vemutations.
Experimental Design: Functional Candidate Gene Mutation Screening
Genomic DNA from probands (n=28) was screened using a functional candidate
gene approach. A comprehensive literature search was done to collect information on all
AD hearing loss genes. One recent review (Hilgert et al. 2009) discussed in depth the
genes causing AD hearing loss. It describes how each gene associated with AD hearing
loss functions in the ear, and what types of hearing loss they cause. For each of these
genes, the mutations found both worldwide and within Caucasianpopulationsare
described in detail. Many of these genes may be causative in Newfoundland families
(Table 2.1).
This literature search formed the basic foundation from which genotype-
phenotype evaluation was performed. Potential candidate genes were investigated for
specificcase-by-case details on the hearing loss phenotype each mutationcaused, and in
what population and ethnicity they were reported. These phenotypes were then cross
checkedwiththephenotypesofthe28farniliestofurthernarrowdownthefunctional
candidate gene list to four: COCH, KCNQ4, TECTA, and MYOIA (see Figure 2.2). This
approach is a form of audioprofiling, a method of categorizing phenotypic data to make
genotypic correlations. The audiological data of several membersinafarnily,orinthis
case several probands from different families, associates with a specific unknown
genotype as a function of time (Meyer et al. 2007). From this, we have drawn correlations
to the overall phenotype of the group of probands and used this as afoundation for
selecting candidate genes previously reported to cause hearing loss with a similar
phenotype.
Information on all known hearing loss mutations in these four candidate genes
was next collated, including which domain and exon each mutation was reported in
(Appendix A). This allowed the identification of the exons most likely to harbor
causative mutations in the Newfoundland probands. For example, the majority of
mutations reported in COCH are reported in the factor c homologous (FeR) domain,
spanning exons 4 and 5, and so this area of COCH was screened first.
COCHhas a total ofl2 exons, and causes a late-onset, progressive hearingloss
most often associated with vestibular dysfunction (Kemperman et al. 2005), which
correlates with several AD Newfoundland families. COCH is important in maintaining
structural support within the cochlea (Kommareddi etal. 2007). Exons screened
were 2-5, and 12. Two deletions within KCNQ4 have been reported to cause a late-onset,
progressivehearingloss(CouckeetaI.1999;Kamadaetal.2006),matchingthe
phenotype of many AD Newfoundland probands. This gene is critical in ion homeostasis
with the ear (Kubisch et al. 1999), and is coded by 14 exons, all of which werescreened.
Missense mutations within TECTA, a second gene important in structural support within
the auditory system, have been shown to cause late onset hearing loss 0'erhoevenetal.
1998). Coded by 23 exons in total, exons 5, 9-14, 17, 18, and 20 were screened. The last
candidategene,MYOIAisthoughttoplayaroleinsoundprocessingthroughion
transport (Donaudy et al. 2003), and again, causes alate-onset, progressive hearing loss
phenotype. Coded by a total of28 exons,exons3,4,6,7, 10-12, 18, and 22 were
screened.
Whilethemore"targeted"candidategeneapproachoutlinedaboveislikely to
lead to the identification of mutations, it does restrict the chance of identifying potential
"genetic surprises" regarding genotype-phenotype. This method allows for a complete
investigation ofpossible genetic mutations in a given set ofpromisingcandidategenes
within the two-year time frame ofaMaster's thesis. However, exons within these
candidate genes that have never before been associated with hearing Iossmutationsare
bi-directionallysequencedinthisstudy,andsothereispotentialfor"genetic surprises".
Because Newfoundland is a founder population, it is possible that families would
share the same mutation, particularly if those families are from the same geographicarea.
When a mutation is discovered in an AD Newfoundland proband, all otosclerosis, AD,
and AR Newfoundland probands (n=68) are subsequently screened for that mutation.
When appropriate, apparent founder mutations are confirmed by haplotype analysis, to
determine the level of sharing fora selection of linked microsatellite markersbetween
families with the same mutation (see Figure 2.2).
General Strategy for PCR and Sequencing of Candidate Genes
Both forward and reverse strands of specific exon PCRproducts in each gene were bi-
directionallysequenced,alongwithallintron/exonboundariestoensurethe entire coding
region of each exon was covered. PCR primers were designed using Primer 3 software (v.
OA.0,http://frodo.wi.mit.edu/primer3/).Theseprimersequencescanbe found in
AppendixB.
DNA Preparation, PCR Thermocycling, and Electrophoresis
DNA was extracted from whole blood and diluted tolO nglill. This blood was
stored at 4 °c (performed by research assistant). I ilL of diluted (stock) DNA was added
to 2 ilL lOX PCR Buffer (containing MgCh), OAIlL dNTPs (10 mM), 0.08 ilL KapaTaq
DNA Polymerase (5 UlIlL) (Kapa Biosystems, Boston, MA), 12.92 ilL of distilled dH20,
1.0 ilL offorward primer (10 11M) and 1.0 ilL of reverse primer (10 11M), as per standard
PCR protocol. The amount of dH20 was reduced to add betaine or Dimethyl Sulfoxide
(DMSO) when necessary to achieve a successful amplified PCR product. This mix was
centrifuged and addeqd to wells in 20 flL aliquots in a 96-well PCR plate, where it was
then sealed, centrifuged, and placed in the GeneAmp PCR System 9700 thermal cycler
(Applied Biosystems, Foster City, CA). PCR products were electrophoresed on a 1%
agarose gel (1.5 g agarose/lOO mL TBE) stained with SybrSafe and viewed under UV
light on a Kodiak GEL LOGIC 100 Molecular Imaging system (Rochester, Y, Version
4.01,2005).
Preparation for ABI Cycle Sequencing
Sephacryl S-300HR was resuspended and 300 flL a1iquots were added to wells
on a Millipore Multi-screen HTS plate, which was placed over a corresponding 96-well
waste plate to catch flow-through. Plates were then balanced and centrifugedat3000rpm
for 5 minutes. Flow-through was discarded and PCR products were added to wells on the
Multi-screen HTS plate. The Multi-screen HTS plate was then positioned and placed over
a clean PCR plate, balanced, and centrifuged at 3000 rpm for 5 minutes. The flow-
through product collected in the PCR plate contains the purified PCRproducts.
Successfully amplified PCR products, visualized as bands of the correctsize
(using a 100 bpmarker) when electrophoresed on an agarose gel, were cyclesequenced
using the following reaction mix: 0.5 flL of Big Dye Terminator V. 3.1 Sequencing Mix,
2 flL of 5X sequencing buffer, 0.32 flL of Primer (10 flM), I flL of purified PCR product
DNA template, and 16.18 flL of dH20, per the Big Dye Terminator V. 3.1 protocol
(Applied Biosystems, Foster City, CA). This equals a total reaction volume of20 flL per
well in a sequencing plate. The resulting plate was centrifuged briefly, loaded onto the
thennal cycler, and subjected to a thermal cycling program according to ABI BDT V. 3.1
protocol (Applied Biosystems, Foster City, CA).
Upon completion,S ilL of 125 mM EDTA followed by 65 ilL of95% Ethanol
(EtOH) was added to each reaction well. Plates were briefly centrifuged and then
incubated overnight in the dark at ambient temperature. The plate was then centrifuged at
3000xgfor30minutes,invertedtodecantEtOH,andbrieflycentrifugedwhiIe inverted
at 200 rpm for4-5 seconds with folded paper towels placed undemeaththesequencing
plate to absorb residual ethanol. ISO ilL ono % EtOH was added to each sample, and the
plate was centrifuged at 3000 gfor 15 minutes. The plate was again invertedtodecant
ethanol and spun at 200 rpm for 4 - 5 seconds over a paper towel. Samples were left to
air dry in the dark at room temperature for 10 - IS minutes. IS ilL of Hi-Di Formamide
was subsequentJy added to each well and the plate wasvortexed and centrifugedbriefly.
The final mix was denatured at 95°C for 2 minutes on a thermal cycler. Once denatured,
samples were kept on ice until placed in the ABI 3130 XL DNA Analyzer.
Automated Sequencing Using the ABI 3130 XL
Automated sequencing was performed using either the ABI 3130 XL DNA
Analyzer (Applied Biosystems, Foster City, CA) available in the lab or the ABI 3730
DNA Analyzer in the Genomic & Proteomics Facility, at CREAlT, Memorial University
ofNewfoundland. The raw sequence data were initially analyzed for quality using
Sequencing Analysis software (Version 5.2, Applied Biosystems, Foster City, CA). High
quality sequences were imported into Mutation Surveyor (Version 3.O,Softgenetics, State
College, PA). Mutation Surveyor identifies DNA sequence variants in the sample
sequence DNA by comparing it to a reference gene sequence.
Tracing Variants Through Families: Genotype & Haplotype Analysis
Sequencing variants were traced through the pedigrees to see if they co-
segregated with hearing loss. Haplotype analysis was performed when necessary. Table
3.4 is a list of microsatellite markers used to characterize the p.P5IPIS haplotype shared
between a Newfoundland family and a Dutch family. This was done to confirm the
founder hypothesis for the CaCH mutation p.P51 PIS (de Kok et aI. 1999), identified in
this study in a Newfoundland proband. Markers were selected based on location as well
as degree of heterozygosity in order to confirm haplotype sharingbetween the two
families, which provided furtherevidencethatp.P5lP/S is a Dutch foundermutation.
Initial setup for genotyping required running PCRunder standard conditions.
Each reaction mix contained 8.5 ~L ofHi-Di Formamide, 0.5 ~L Genotyping Size
Standard GS500 (-250) LIZ, and 1 ~L of DNA, per manufacturers standard protocol
(Applied Biosystems, Foster City, CA). Post-PCR products were electrophoresed on a
1% agarose gel (I g agarose/l 00 mL TBE, pH 8.0) containing 4.0 ~L of SybrSafe ID-
ODO X concentrate in DMSO (Invitrogen, Eugene, OR) and viewed under UV light on a
Kodiak GEL LOGIC 100 Molecular Imaging system (Rochester, NY, Version 4.01,
2005). The PCR product was then diluted based on its band intensity to a suitable
concentration. Optical plates containing these samples were briefly vortexed and then
centrifuged at 1250 rpm for 10 seconds, denatured on a thermal cycler, and immediately
loaded onto the ABI 3130 XL DNA Analyzer for genotyping. The PCR products from
the fluorescently labeled primers were detected by the ABI Prism 3130 XL DNA
Analyzer and genotyped using GeneMapper Software (ABI Prism, Version 4.0).
GeneMapperassistedinmakingallelecallsateachmarkerforeachindividual,
which were then compared with other individuals and families. Once a pedigree was
constructed using the software Progeny (progeny Software LLC, Delray Beach, FL),
markers were integrated for each selected individual. Allele calls, SNPs, and/or common
variants were then inputted into each individual's data set to create a pedigree illustrating
the segregation of different haplotypes (Progeny Software LLC, Delray Beach, FL;
Figure 3.5; Figure 3.10).
Figure 2.128 Newfoundland Families with AD hearing loss
Figure2.128 Newfoundland Families with AD hearing loss (cont).
Figure2.128NewfoundlandFamilieswithADhearingloss(cont).
Figure2.128 Newfoundland Families with AD hearing loss (cont).


Figure 2.2 Flow Chart Demonstrating Experimental Design and Progression
Table 2.1 Candidate genes for Newfoundland Families Having Late-Onset AD
Hearing Loss (Adapted from Hilgert et al. 2009).
Candidate Number of Number of Original
Gene Mutations Mutations Reference
Found Found in
Worldwide Caucasians
KCNQ4
COCH
MY06
GJB3
POU4F3
COUfA2
CRYM
Unknown
HairBundle,Cytoskeletal
Fonnation
Transcri tionFactor
Unknown
Hair Bundle, Motor Protein
Hair Bundle, Motor Protein
HairBund1e,Cytoskeletal
Fonnation
Ion Homeostasis
Ion Homeostasis
Kubischet
al.1999
Robertson
etal.1998
Donaudyet
al.2003
Verhoeven
etal.1998
Zhuetal.
2003; Van
Wijketal.
2003
Wayneet
al.2001
Donaudyet
al.2004
Melchionda
etal.2001
Uuetal.
1997
Nazetal.
2004
Van Laeret
al.1998
Xiaetal.
1998
Vahavaet
al.1998
Kurimaet
al.2002
McGuirtet
al.1999
Abe et al.
2003
Peters et al.
2002
Table 2.1 Candidate Genes for Newfoundland Families Having Late-Onset AD
Hearing Loss (Adapted from Hilgert et aI. 2009) (cont).
Hair Bundle, Motor Protein
HairBundle,Cytoskeletal
Formation
HairBundle,Cytoskeletal
Formation
Lalwaniet
al.2000
Modarnio-
Hoybjoret
al.2007
Lynchet
al.1997
Chapter 3: Results
Overview
The purpose of this study was to detennine the genetic etiology of hearinglossin
28 autosomal dominant hearing loss Newfoundland probands using a functional
candidate gene approach. Candidate genes COCH, TECTA, KCNQ4, and MYOJA were
chosen primarily because they have a higher frequency of mutations in autosomal
dominant families (Hilgert et aI. 2009). The full GJB2 gene and the de113S1830 mutation
in GJB6, which underlies the majority of congenital deafness worldwide, were first
excluded in all 28 probands. A heterozygous mutation in WFSJ - a gene now known to
cause both syndromic andnon-syndromic deafness (Young et aI. 2001; Bespalovaetal.
2001)-previouslyfound to cause autosomal dorninanthearingloss (p.A716T) ina large
Newfoundland family (Young et al. 2001) was also excluded in all 28 probands. Figure
2.2 illustrates the research projects experimental progression.
Results of candidate gene screening revealed three distinct mutationscausing
hearing loss in three separate Newfoundland families. First, a C~T base change in exon
4 of COCHin the proband of Family 2094 resulted in the substitutionofaconserved
proline residue fora serine residue at amino acid position 51 (p.P5 1P/S).Second,anovel
3bp heterozygous deletion in exon 5 of KCNQ4 was found in the proband of Farnily
2071. Third,anonsense mutation was discovered at amino acid position93withinexon4
of MYOJA. This nonsense mutation, p.R93X, is due to a C~T nucleotide change, and
was found in the proband ofNewfoundland Family 2102.
Family 2094
Within COCH, exons 2, 3, 4, 5, and 12 were sequenced in all 28 AD hearing loss
families. Of the 28 probands, one proband was identified with a C~T base change in
exon 4 of COCH The proband is a member of a family (Family 2094) with four
generations of documented hearing loss. The complete pedigree documents 44
individuals and extends back six generations. A partial pedigree is seen in Figure 3.1.
Twelve family members have been diagnosed with AD hearing loss. A summary of
audiologyreportsandaphenotypesummaryarefoundinTables3.2and3.3respectively.
Theproband0l-2,Figure3.l),isa39-year-oldfemalepresentingwithhearingloss.
Reports showed a bilateral hearing loss sloping to moderate loss athigh-frequencies
(Figure 3.3). Three more audiology tests were conducted over the next threeyears,
showing a gradual worsening of high-frequency hearing loss.
The proband is heterozygous for the C~T base change in exon 4 of COCH,
which substitutes a highly conserved proline residue fora serine residueat amino acid
position 51 (p.P51P/S) (Figure 3.2). Upon identification ofp.P51P/S inthe proband,
DNA from all available individuals was amplified and sequenced for exon 4. Seven out
of seven with documented hearing loss harbored the C~T transition; one unaffected (IV-
10) did not.
Search for a Vestibular Phenotype in Family 2094 Mutation Carriers
Previous studies of mutation carriers ofp.P5IP/S show severe vestibular
phenotypes associated with hearing loss (de Kok etal. 1999), so medicaI and audiological
records for all available family members were reviewed (see Figure 3.1). The proband
(V-2) has not yet had any episodes of vertigo or associated vestibularproblems.Shehad
a Computed Tomography (CT) scan at 40 years of age which did not detect any
abnormalities. Theprobandscousin,V-6, complained of episodes 0 fdizzinessand
vertigo at age 32. She has had two CT scans at ages 36 and 38, which did not detect any
abnormalities. Her hearing loss was first reported at age 35 as mild hearing loss in the
high-frequency range. This cousin also first reported a scratch on her left cornea at age
31.IV-Ihasstatedhehashadbalanceproblemswhenwalkingatnightsinee his early
50's. He had a CT scan at age 62, which detected no abnormalities. His hearing loss was
diagnosed at age 49 as moderate in the high-frequency range. IV-5 reportedbalance
problems and episodes of dizziness from the age of 50. Audiologytestingatage57
showedamoderatebilaterallossthatoverthefollowingl5yearsprogressedtosevere
hearing loss across all frequencies. IV-7presented the typical p.P51 P/Shearingloss
phenotype, and also had occupational noise exposure. IV-IO is an unaffected woman
who has not reported any vestibular problems and is not affected withhearingloss. IV-II
reported spinning dizziness and unsteadiness, along with balance problems in his early
30s.Hishearinglosswasfirstdocumentedatage49,andfurtheraudiology tests over the
following 15 years show bilateral loss beginning in the high-frequencies and then
flaneningout later in life to profound hearing loss across all frequencies. III-6had
documented hearing loss from rniddle age, but no other data was available.
Because Newfoundland is a founder population, and this study is focused 0 nthe
identification of founder mutations, all otosclerosis, AD, and AR probands in the
Newfoundland hearing loss study (n=40) were screened for this mutation, but no
additional cases were found.
Identification of a Dutch Founder Mutation
Asp.P5IP/8iswidelybelievedtobeaOutchfoundermutation(deKoketal.
1999; Fransen et aI. 2001), we genotyped the seven affected Family 2094 members, along
with three Outchp.P5IP/8 carriers, for seven rnicrosatellite markerscloselyflankingthe
COCHgene, (Fransenet aI. 2001) in order to construct an ancestral haplotype. Affected
Family 2094 individuals and the Dutch affected individuals share a contiguousfive-
rnicrosatellite-marker haplotype at markers 0148257, 01481071, 01481040, 01481034,
and 01481060: 179-281-234-169-201. COCHsits -0.4 Mb downstream of marker
0148257. These markers closely flank the COCH gene and constitute a total minimum
shared region of -2.1 Mb on chromosome 14q 12 (Figure 3.4; Table 3.5). The full hearing
loss haplotype shared among Newfoundland and Dutch families is shown in their
respective pedigrees in Figure 3.5. Unaffected individual N-IOdoesnot share this
haplotype. Furthergenotypingwasconductedforadditionalrnicrosatellitemarkers
upstream of 01481060. Markers 014870 and 01481014 both displayed allelic disparity
between the two families, demonstrating the relatively short length of this putative
ancestral haplotype (Table 3.5).
Family 2071
Of the 28 probands, one proband was identified to have a novel 3 bpdeletion,
p.8er269del in exon 5 of KCNQ4 (DFNA2A). The proband is a member of a family
(Family 2071) with four generations of documented hearing loss. The complete pedigree
documents 97 individuals, extends back five generations, and reports no cases of
consanguinity (Figure 3.7). Twenty-four family members have been diagnosed with AD
non-syndromichearingloss.Asummaryofaudiologyreportsforparticipating
individuals is found in Table 3.7, with phenotype data shown in Table 3.6.
The proband(III-12,Figure 3.7) is a 62-year-old male presenting with a bilateral
hearing loss sloping to moderate loss at mid-frequencies and profound at high-
frequencies. The proband harbors a novel heterozygous 3 bpdeletion,p.8er269del,in
exon 5 of KCNQ4 (Figure 3.8). All available family members were sequenced for exon 5.
Thirteen members with documented hearing loss shared p.8er269del. No unaffected
family members (n=18) carried the deletion, and of90 ethnically matched population
controls, none carried the deletion. While p.8er269del is not seen in four members with
hearing loss, these four individuals present a distinctly different audioprofile(Figure3.9;
Table 3.6). Audiology reports of affected relatives with the novel deletion show a high-
frequency, late onset hearing loss (Figure 3.9).
This deletion predicts an in-frame removal ofa serine residue at amino acid
position 269 within the P-Ioop domain of the KCNQ4 protein (Figure 3.10). We next
constructed an intragenic haplotype using commonly occurring SNPs and variantswithin
and surrounding exon 5 of KCNQ4. This was done to determine whether or not any
interesting and possibly causative variants within KCNQ4 were shared by affected
individuals of Family 2071, and to determine the level of sharing among of intragenic
SNPs and variants among deletion carriers. No markers brought any additional interesting
information, and no family members without the deletion, or without hearing loss, shared
this hearing loss haplotype.
Upon discovering this novel deletion, all otosclerosis, AD, and AR probands in
the Newfoundland hearing loss study (n=68) were screened to determine whether or not
any additional Newfoundland families shared the mutation, thereby suggestingapossible
founder mutation. However, no additional cases outside of Family 2071 were detected.
All exons (1-14) were sequenced in the 28 AD probands for this gene.
Family 2102
A third proband was identified with a C7T base change in exon 4 ofMYOJA
(DFNA48). The proband is a member of a family (Family 2102) with four generations of
documented hearing loss. The complete pedigree documents 22 individuals, extends back
five generations, and indicates two consanguineous marriages in earlygenerations
(Figure 3.12). Three family members have been diagnosed with AD non-syndrornic
hearing loss from age 5 with progressive deterioration. A summary of audiology reports
is found in Table 3.9. The proband (IV-I) is heterozygous for a C7T nucleotide change,
which substitutes a highly conserved arginine residue fora stop signal at amino acid
position 98 in exon 4 ofMYOIA (Figure 3.13). DNA from four available family members
was sequenced for exon 4 ofMYOIA. Three members with documented hearing loss (III-
I; IV-I; IV-5) shared the mutation, and one unaffected (III-2) did not. All affected
individuals first reported their hearing loss near the age of five, with hearing coming and
going but progressively deteriorating (Figure 3.14).
Again, all otosclerosis, AD, and AR probands in the Newfoundland hearing loss
study (n=68) were screened to determine if this was a Newfoundland founder mutation.
Noadditionalcaseswerefound.Exons3-4,6-7,IO-12,18,andexon22were sequenced.
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Figure 3.1 A Six Generation Newfoundland Family (2094) Segregating an
Autosomal Dominant Form of Late-Onset Progressive Hearing Loss (partial
pedigree). The proband (pID V-2: arrow) was first found to carry the p.P5IP/S
mutation. DNA from all available affected relatives were screened and also carry
the p.P5IP/S mutation. Unaffected individual IV-IO does not carry the mutation.
c.151C>CT:p.P51P/S
PIDV-2
Family 2094
Figure 3.2 Electropherogram of the Substitution Mutation in COCH
(c.151C>CT:pP51P/S) Identified in All Affected Family Members. The top trace is
from the proband (PID IV-2); the bottom trace is from a reference sequence
(obtained from NCBI; NM_004086).
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Figure 3.3 Hearing Loss Phenotype of COCH p.P51P/S carriers 111-6 ,IV-U, and V-
2 in Newfoundland Family 2094 (Figure 3.1). Hearing loss is most pronounced in the
high frequencies. *Audiology reports were randomly selected,andthesametrendis
observed for for remaining Family 2094 members, which can be seen in Table 3.2.
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Figure 3.4 Genetic Map of Markers Used to Construct the p.P51P/S Deafness
Haplotype for Newfoundland & Dutch Carriers. YeUow denotes minimum shared
region between families. Markers start from centromere. Markers selected from
Fransen et al (2001).
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Figure 3.5 p.P51P/S Family Haplotypes. A) Haplotype for Newfoundland p.P51P/S
Family 2094 (partial pedigree). Sharing between families is seen for markers
D14S257, D14S1071, D14S1040, D14S1034, and D14S1060, spanning a minimum
shared regionof-2.1 Mb.
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0145257 179191 179191
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01451040 234232 234232
01451034 189175 169175
01451060 201207 201207
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Figure 3.5 p.P51P/S Family Haplotypes. B) Haplotype for Outch p.P51P/S family
(partial pedigree); associated haplotype is colored yellow. Sharingbetweenfamilies
is seen for markers 014S257, 014S1071, 014S1040, 014S1034, and 014S1060,
spanning a minimum shared region of -2.1 Mb.
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Figure 3.6 Genotype Examples From Fragment Analysis of Newfoundland and
Dutch Families. Homozygosity and Heterozygosity at a marker is described in
GeneMapper by the number of times a strong vertical peak is present. If only one
strong vertical peak is present, the person is a homozygote; ifmorethan one strong
vertical peaks are seen, the person is heterozygous. The numbers in the boxes under
these vertical peaks represent the genotypes, or alleles, for that individual. A) II-I is
a Dutch individual (Figure 3.SB) and is a heterozygote (262, 268) for marker
DI4SI021. B) Family 2094 individual IV-I (Figure 3.1) is a homozygote (262) for
marker D14S1021. C) Family 2094 individual IV-I 0 (Figure 3.1) is a heterozygote
(262,274) for marker D14S1021.
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Figure 3.7 Family 2071. A five generation Newfoundland family affected with
autosomal dominant, late-onset, progressive hearing loss (partialpedigree);the3bp
deletion in KCNQ4 (DFN2A) was first detected in the proband (arrow).
Figure 3.8 Electropherogram ofthe3 bp Deletion in (p.Ser269del) Identified in 13
Affected Family 2071 Individuals. The heterozygous deletion causes a 3 bp shift in
theElectropherogram of the affected proband's forward and reversestrands,
causing the above bidirectional pattern. The top and bottom traces are from a
reference sequence, while the middle two traces are the forward and reverse strand
traces of the proband ID-12 (obtained from NCBI; NM_004700). The bottom trace
is from the proband (pID ID-12).
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Figure 3.9 Audiological Summary of Family 2071 Family Members. A: Hearing loss
phenotype ofKCNQ4 deletion carriers 111-12, V-I, and IV-I (Figure 3.7) Remaining
2071 deletion carriers all present the same trend observed above, and can be
observed in Tables 3.6 & 3.7. Audiology reports were randomly selected. Hearing
loss is most pronounced in the high frequencies. B: Hearing loss phenotype of
affected family members not carrying the deletion: 111-9,11-3, and IV-8.
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Figure 3.10 Family 2071 Pedigree With Haplotype. The deafness associated
haplotype is shown in yellow. The proband (III-12) and 13 first and second degree
relatives harbor the KCNQ4 deletion. Normal hearing individuals do not carry the
deletion.
Figure 3.11 Structure of KCNQ4. Arrow denotes novel3bp deletion discovered in
Newfoundland Family 2071. Also shows previously reported missense and deletion
mutations found to cause hearing loss. Adapted (Jentsch, 2000).
• Itral AulOlOmal Domklanl Progrtssivt Heal1ngloss
~ Proba~ 1
Figure 3.12 Pedigree of Newfoundland Family 2102. A five generation family
originating from Fogo Island, Newfoundland, segregating an apparent AD form of
late onset progressive hearing loss. DNA not available for individuals 1-5 and n-l.
p.R93X
PIDIV-l
Family 2102
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Figure 3.13 Electropherogram of p.R93X Mutation in MYOIA. Individual IV-l of
Family 2102 (Figure 3.12).
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Figure 3.14 Hearing Loss Phenotype of Newfoundland Family 2102 MY01A
Nonsense Mutation Carriers IV-I, III-I, and IV-S (Figure 3.12). Onset of hearing
loss is 5 years of age.
Candidate Gene
Table 3.1 Candidate Genes Screened For Mutations in Newfoundland Families
Having Late-Onset Autosomal Dominant Hearing Loss.
Number of Number of
Mutations Found Mutations
in Caucasian Associated with
I---K=C=JV,-:::-4,.------t--:-1o-,nH,.,--o-me-os-tas-,---is-+------=..cPo"'-'u~~a=tion=s --t....:...Pr=o=re=ss:::-:~e=AD=HL=--j
COCH Extracellular Matrix 8 6
MY01A Unknown 8 4
TECTA Extracellular Matrix 7 7
Table 3.2 Audiology Summary For Family 2094 Family Members (pedigree shown
in Figure 3.1).
familyMemberAgeOnsel(yrsl Sex Hearing Threshold (dBI
------ ----
Right left Right left Right left Right left Right left
female 30 35 50 40 60 60 85 90 90 90 63
Male N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male 65 55 70 65 65 65 80 80 110 110 62
Male 50 45 70 70 90 110 100 110 95 100 63
female 45 30 55 40 70 60 90 90 100 100 30
female 45 40 60 50 70 70 85 90 100 100 18
female 10 10 20 10 30 25 35 30 25 20 35
Table 3.3 Phenotype Summary of Family 2094 Individuals (pedigree shown in
Figure 3.1).
F1milyMtmbtr v.riont SlItus Roconltd Gonder Eor Noiso HiCh Mid low Ac"Tost-
VlSllbulorDofodsl AfItctod Exposv" Ftequoncy Ftequoncy Ftequoncy Ac'
V-2 ,.,."" ""'"
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Table 3.4 Physical Location of Markers Used to Create the p.P51P/S Deafness
Haplotype. The markers were taken from Fransen et aI, 2001.
Genomic Starting Type of Nucleotide Heterozygosity
Position on 14q12 Repeat
(bp)
DI48262 28,630,354 Dinucleotide
DI48975 29,749,271 Dinucleotide
DI481021 30,341,868 Dinucleotide
CaCH 30,413,441 N/A N/A
014S257 30,799,447 Dinucleotide 0.69
D1481071 30,898,090 Dinucleotide 0.72
01481040 31,281,164 Dinucleotide 0.73
01481034 31,537,191 Dinucleotide 0.75
D1481060 32,485,191 Dinucleotide 0.79
014870 33,528,945 Dinucleotide 0.76
Table 3.5 Haplotype Sharing Across Markers Nearby the COCH Gene Between
Newfoundland Family 2094 and a Dutch p.P51P/S Family.
28,630,354 014S261
l'J,749,ln 0145975
30,34~868 01451021
30,413,441 COCH~1SlDCl
30,799,447 0145257
30,898,Il1O 014510n
3~2!~1i4 01451040
31,537,191 01451034
32,485,191 014511160
33,528,945 OI45Jll
JSOJ.182 OP06-115 JC07·184KMQ6.127APOH60P07·270CP07·1B7CCll7·26! 19126 19149 19135
200 200 200 200 200 200 200 200 2lI4 200 200
173 173 173173173173173173173173173
262 262 262 262 262 262 262 262 268 262 262
C T T T T T T T T T T
173 179 179 179 179 179 179 179 179 179 179
liS 1I1 1I1 1I1 1I1 1I1 1I1 1I1 1I1 1I1 1I1
134 134 134 134 134 134 214 214 214 214 214
173 15l 15l 15l 15l 15l 15l 15l IIll IIll 15l
207 201 201 201 201 Jl1 201 201 201 201 201
214 214 214 214 214 214 214 214 210 214 214
Table 3.6 Phenotypic Features of Affected Family 2071 Individuals. Shown first are
family members with the deletion, and at the bottom, those without the deletion
(pedigree shown in Figure 3.7).
FamllyMlmbar Variant Hllrinr Glndar Eor Nol.. HI.h Mid Low All Tolt-
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Table 3.7 Audiology Testing Results of Affected Family 2071 Individuals. Sbown
first are family members with the deletion, and then those without the deletion
(pedigree shown in Figure 3.7).
Olnk'Allfemresoffamltymemberswtth806_808de1CCT
Family Member Age sex HearingThresholdld8)
------ ----
Rieht left Right left Right left Right left Right left
70 Male 30 35 50 40 60 60 g5 90 90 90 63
60 Female N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
67 Male 65 55 70 65 65 65 BO BO 110 110 62
66 Male 50 45 70 70 90 110 100 110 95 100 63
39 Female 45 30 55 40 70 60 90 90 100 100 30
20 Female 45 40 60 50 70 70 g5 90 100 100 18
64 Female N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
94 Female 110 75 115 BO 120 100 120 100 100 100 90
44 Male 25 30 55 40 55 50 60 75 60 60 40
40 Female 30 30 35 35 45 45 70 70 85 70 39
38 Female 25 25 30 35 35 35 60 65 90 90 33
43 Female 30 25 35 40 50 50 50 45 70 60 41
34 Female 50 50 60 55 60 55 85 85 90 90 32
OlniQIFeatu~sofAffectedFamiIyMembm;w/outdeletlon
55 Female N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
71 Male 10 BO 10 75 10 70 50 BO 30 BO 67
86 Male 30 30 35 50 40 50 60 70 60 70 83
46 Female 10 60 15 50 10 35 5 40 15 40 44
Table 3.8 KCNQ4 Variants Used to Create the Intragenic KCNQ4 Haplotype
KCNQ4SequencingVariants Exon/lntron Pathogenic
c.34690A>AT Exon3 41056458 No
35184G>GC 41056958 No
35224A>AG 41056992 No
c.35905T>TC 41057674 No
c.35934_35936del Exon5 41057702 Yes
c.47646T>TG Exon10 41069414 No
Table 3.9 Audiological Summary of Family 2102 Individuals Witb & Without the
p.R93X Nonsense Mutation.
Stat.. God.r Ear HiP Mid Low Ac.I..I-
Afl'ededFreq•••cy Freq...cy Freq•••cy Ac.
IV-I pJlJJl
ill-I pJlJJl
IV-5 pJlJJl M .... r...J.
ModUlI.
ModUlI.
ModUlI.
ModUlI.
Modmt,
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Chapter 4: Discussion
The aim of this thesis was to detennine the genetic etiology oflate onset
autosomal dominant (AD) hearing loss in 28 Newfoundland families. This was
investigated by screening the genomic DNA of28 probands for mutations in four genes
known to cause AD hearing loss, specifically KCNQ4, COCH, TECTA, and MYOJA. All
28 families were first genotyped to exclude the p.A7l6T mutation in WFSJ, a mutation
previously found to cause AD hearing loss in the Newfoundland population, as well as
the full GJB2 gene and the de1l3S 1830 mutation in GJB6.
Family 2094 Hearing Loss Caused by COCH Mutation
Of the 28 probands, one was found to have a mutation in COCH. COCH encodes
cochlin,and has previously been shown to be prominently expressed inaribbon-like
pattern in the basilar membrane of the cochlea, providing evidence that itis involved in
the structural regulation of that membrane (Kommareddi et al. 2007). Cochlin's exact
role, however, remains unknown. COCHmaps to chromosome l4qI2-l3. Cochlin is
predicted to be 550 amino acids long and is highly conserved. It comprises a short
predicted signal peptide, anN-terrninal factor C homology domain, and two von
Willebrand factor A-like domains.
Seven missense mutations within COCHthat cause hearing loss have previously
been reported: six of these cause a very recognizable phenotype characterized byalate
onset, progressive hearing loss associated with parallel vestibulardecline. All six are
found in the Factor C Homologous (FCH) domain of the cochlin protein (Kemperman et
al. 2005). Of the FCH domain mutations, three originate in North America (p.V66G,
p.G88E, and p.WI17R); one is a founder mutation (p.P5IP/S) present in many Dutch and
Belgian families, one originated in Australia (p.I109N), and one in Japan (p.AI19T). This
audiological phenotype oflate-onset high-frequency hearing loss caused bythese
mutations is inclose correlation with the audiological phenotype of many 0 fthe28 AD
Newfoundland probands being studied in this research project and was the primary
reason for choosing this gene for screening.
In Newfoundland Family 2094 a known mutation causing a heterozygous C7T
base change was found in the proband. This resulted inthesubstitulionofa conserved
proline residue for a serine residue at amino acid position 51 (p.P5IP/S) (Figure 3.2). All
seven affected members of Family 2094 shared the mutation, while an unaffected relative
did not harbor the mutation (Figure 3.1). lndividuals harboring the p.P5IP/S variant
suffer from a late onset, progressive, high-frequency hearing loss with an obviousonset
from -40 years of age onwards (Bischoff, 2005). All affected family members share the
same audiological profile (Figure 3.3),matching the pattern of hearing loss seen in
previous cases (deKok etal. 1999). The progressive nature of hearing loss in Family
2094 also matches previously reported cases ofp.P5IP/S carriers (de Kok etal. 1999).
This mutation is also associated with vestibular dysfunction, such as motion
sickness and vertigo, which in most cases develops to complete vestibularareflexiaor
vestibularhyporeflexia(Verhagenetal. 2001; Bischoffetal.2005). Onsetofprogressive
vestibular failure presents earlier, from the fourth into the sixth decade ofli fe,declines
more rapidly, and is eventually more complete than the associated hearing impairment
(Bischoffetal.2005). Five out of seven Family 2094 members have so far experienced
these vestibular problems.
1n2009,Hildebrandetal.reportedap.P5IP/Scasewiththeveryraredisease
Superior Semicircular Canal Dehiscence (SSCD), which is characterized by the absence
ofboneoverlyingthesuperiorsemicircularcanal,creatingathirdlabyrinthinewindow.It
was suggested that individuals with COCH mutations like p.P51 PIS should be given a CT
scan to screen for SSCD (Carey et a1. 2007). Of the Family 2094 individuals who have
had CT scans; V-2, V-6, and IV-I, none were diagnosed with SSCD, though it has been
suggested that diagnosis ofSSCD often requires the doctor to be specifically looking for
the defect (Hildebrand et al. 2009). Thisthereforerepresentsbothaclinicalanda
scientific opportunity to learn more about this possible association. Carrierscould
undergoaCTscantolookforthisraredefect,andiffound,thatindividual can have
surgery done, as SSCD's severe vestibular symptoms can be fully corrected with surgery
(Carey et al. 2007). This would also add to the current literature on the possible
association between these two rare disorders.
Previous studies have also demonstrated a link between COCH mutations like
p.P5IP/S and vertical corneal striae. Two families carrying the p.P5IP/S mutationwere
found to havea93 %anda78 % prevalence of these striae, respectively; ageofonsetis
late 40s to late 50s (Bischoffet a1. 2007). InFamily2094,V-6 was reported to have a
corneal scratch in the right eye. This was first reported at the age of31, which falls close
to the previously reported age of onset for corneal striae inp.P5IP/S carriers. This scratch
was not reported to be due to any physical injury to the eye, though no othermedical
information is available. Clinical follow-up is currently ongoing; this may be further
evidenceofa link between vertical corneal striae and hearing loss mutationswithin
caCH,likep.P5IP/S.
Confirmation of p.P51P/S as a Dutch Founder Mutation
Thep.P5IP/SmutationhasbeenreportedintenBelgian,sevenDutch, and one
American family and is widely accepted to be a Dutch founder mutation (de Kok et al.
1999; Fransen et al. 2001). This study is only the second reported occurrence of this
mutation outside of Europe. An opportunity to confirm this Newfoundland p.P5IP/S
occurrence as a Dutch founder mutation arose at the 2010 Associationfor Research in
Otolaryngology MidWinter conference. While attending this conference, I met with Dr.
Hannie Kremer, a scientist working in the Netherlands, who has published on the
p.P5IP/S vestibular phenotype (Bischoffetal. 2005). Dr. Kremer offeredtocontribute
Dutch p.P5IP/S DNA, allowing me to confirm the Dutch founder hypothesis. Using
DNA from this Dutch family and Newfoundland Family 2094, a series of microsatellite
markers were genotypedto develop ancestral haplotypes(Figure 3.5). Thesehaplotypes
demonstrate allelic sharing between the two families for five contiguous markers close to
the CaCH gene, spanning a total genetic distance of-2.1 Mb (Figure 3.4; Table 3.5).
The probability of these two families sharing this five marker haplotype by chance is low,
and therefore, it is likely that these two families are distantly related and originate from a
cornmon ancestor in the Netherlands. The genealogy of this shared ancestry was not
followed upon, as the objective was to provide further support to the current Dutch
founderhypothesisforp.PSIP/SDNA,andbecausenofurthergenealogyonthese
families is available. However, individuals in Family 2094 couId be researched using the
Newfoundland Genealogy Database and the Heritability Analytics Infrastructure
(population Therapeutics Research Group, St. John's, Newfoundland & Labrador) to
trace the genealogy of Family 2094. IfsuccessfuI,thiswouIdprovidetheopportunityto
increase the power of this linkage association, and possibly directly Iink it to the Dutch
family with which it shares an ancestral haplotype. This avenue warrants further
investigation. It is interesting to note that mutation carriers inFami ly2094 possess an
uninterruptedNewfoundlanderancestry,goingbackatleast six generations. Up until
recently,p.PSIP/ShadneverbeenseenoutsideofcentraIEurope(FransenetaI.2001).
Its recent discovery in a United States family (Hildebrand et aI. 2009), and now in a
family living here inNewfoundland,Canada,couldbeevidenceofanancientorigin.If
true, this wouId have strong implications for cochIeovestibuIar diagnostic screeningof
p.PSIP/S and other mutations within the CaCH gene, as the older a mutation's origin,
the more likely it is to be widespread throughout all popuIations and ethnicities.
Family 2071 Hearing Loss Caused By Novel KCNQ4 Deletion
KCNQ4 (potassium Voltage-Gated Channel 4) encodes the protein potassium
voltage-gated channel subfamily KQT member 4. This protein is part of a family that
forms channels to transport positively charged potassium ions between neighboringcells.
More importantly for hearing, the potassium channels that this protein forms are thought
to play an indispensable role in the regulation of neuronal excitability,particularly in the
sensorycellsofthecochlea(innerear),wheretheyareexpressed(Kubischetal.1999).
Expression gradients of KCNQ4 in spiral ganglion and in these cochlear hair cells
correlate very closely with progressive hearing loss (Beisel etal. 2001).
Twelve mutations have been reported in KCNQ4 (DFNA2): ten missense and two
deletions. The missense mutations are believed to cause hearing Iossbeginningata
young age (Hilgertet al. 2009). The deletions are thought to cause a milderphenotype,
have an older age of onset and primarily affect perception of high frequencies(Topsakal
etal.2005). While both late-onset and early-onset hearing loss can be caused by
mutations in KCNQ4, this gene is also associated with age-related hearing loss. One
research team has demonstrated that several SNPs associated with age-related hearing
loss in two independent Caucasian populations were all located in the same 13 kbregion
in the middle of the KCNQ4 gene (Van Eyken et al. 2006).
The first KCNQ4 deletion (c.2lldel13) was discovered in a Belgian family.
Affected individuals lacked 13nucleotidesbetweenpositions2ll and 224. This resulted
in a frame-shift after Gly70 (p.fsX71), followed by 63 novel amino acids and a premature
stop codon (Couckeetal. 1999). Consequently, the protein is truncated before the first
transmembrane domain and is rendered nonfunctional (Nie, 2008; Figure3.11 ).More
recently, the second deletion was found in a Japanese family, and isaI bpdeletion
(c.211delC).Similarlytothepreviouscase,atruncated,nonfunctionaIKCNQ4proteinis
generated (Kamadaetal. 2006). The milder high frequency phenotype of cases reported
to harbor these two KCNQ4 deletions correlates closely with the phenotype of several of
the 28 Newfoundland probands under study in this research project, and so KCNQ4 was
chosen as a functional candidate gene to screen for potential causativemutations.
The proband ofNewfoundland Family 2071, III-I 2 (Figure 3.7), was found to
carry a novel3bp heterozygous deletion in exon 5 of KCNQ4 (Figure 3.8). Upon
sequencing other Family 2071 individuals, thirteen affected individuals were found to
share the 3 bp deletion. This is the third deafness causing deletion found in KCNQ4, and
the first outside of exon 1 (Coucke et al. 1999; Kamada et aI. 2006). Audiology reports of
deletion carriers demonstrate a high-frequency, late-onset hearing loss (Figure 3.9),
supporting the current genotype-phenotype correlation that KCNQ4 deietionsassociate
with a late-onset and milder hearing irnpairrnent (high-frequency loss) than
corresponding KCNQ4 missense mutations (Kamada et aI. 2006).
This deletion predicts an in-frame removal ofa serine residue at amino acid
position 269 within the P-Ioop domain of the KCNQ4 protein (Figure 3.11). Interestingly,
the P-loop domain is a mutational hotspot where ten missense mutationscausingearly
onset hearing loss have previously been described (Couckeetal. 1999; Kubischetal.
1999; Talebizadeh et aI. 1999; Van Hauwe et aI. 2000; Kamada et aI. 2006).
Inordertodetenninethelevelofvariantsharingamongdeletioncarriersand
betweenallindividualsofFamily207l,andtoverifywhetherfurtherhearingloss
pattems might be seen, we next constructed an intragenichaplotype usingcornmonly
occurring variants within and flanking exon 5 of KCNQ4. While these markers did not
singuIarlyprovideanyadditionalinterestinginformationregardingaffectedindividuals
not harboring the deletion, all deletion carriers shared this deafness associatedhaplotype.
Additionally, of90 ethnically matched controls, and of all unaffected relatives, none
shared this deafness associated haplotype. Thishaplotype,used primarily asamethodof
further investigation and mutationconfinnation, contrasts sharply with the
aforementionedp.P51P/S haplolype, which was constructed to demonstrateancestral
linkage between Newfoundland Family 2094 and a Dutch family, and which can be taken
as evidence forp.P5lP/S being a Dutch founder mutation.
While this deletion is not seen in four Family 2071 members, these four
individuals present a distinctly different audioprofile compared to deletioncarriers
(Figure 3.10; Table 3.6; Table 3.7). The cause of hearing loss for these fourindividualsis
likely due to several separate genetic or environmental predispositions, thus making them
phenocopies. Environmental factorscouId also be the cause of hearing loss inthese
individuals. The medical records show no indication of noise exposure or physical injury
to the ears in these four individuals. To rule out a different mutation on the same gene as
the cause of hearing loss in these individuals, they were screened for all exonswithin
KCNQ4. No additional mutations were detected, and they did not share any particular
variants orSNPs at the locus when observed in the intragenichaplotype.
A further avenue of research for Family 2071 would be functional studies.
Because KCNQ4 is strongly expressed in the sensory cells of the cochlea (Kubisch et al.
1999;Beiseletal.2001),studiesondeletioncarriersshouldbeconducted to investigate
whether the 3 bp deletion negatively affects the potassium ion channels formed by
KCNQ4, whether these ion channels remain structurally and functionally intact, and
whether potassium ions are able to effectively move through these channels to complete
themechanoelectrical transduction pathway. This could potentially shed further light on
the molecular pathways underlying this hearing loss mutation and could provide added
credence to the current genotype-phenotype correlation.
Family 2102 Hearing Loss Caused By MY01A Mutation
MYOIA encodes the protein myosin la, which is present in the inner ear and plays
a role in human hearing (Donaudy et al. 2003). Donaudyetal. (2003) postulated that
MYOIA plays a role in ion transport. More recently, Hilgert & Smith (2009) present a
slightly different hypothesis. At the brush border surface of intestinal epithelialcells,
myosinlaisamajorcomponentoftheactin-richcytoskeleton,whereitis involved in
membrane trafficking. ltcould serve the same function in the inner ear, because the
cytoskeleton of the intestinal cells and the inner ear cells (hair cells and supporting cells)
are very similar. The specific expression panem in the inner ear has not yet been
established,bymayprovidefurthercluesinthefuture(Hilgert&Smith,2009).
MY01A was chosen as a candidate gene for the same reason as all the functional
candidate genes in this study: a phenotype correlation between individuals with hearing
loss due to mutations previously found within MY01A and the audioprofile seen in some
of the 28 Newfoundland probands under study. While most of the 28 probands suggest a
late-onset hearing loss, some are reported as early-onset, but still progressive and
autosomal dominant. Four mutations in MYOIA have been associated with an early-onset
AD, progressive, phenotype (Donaudy et aI. 2003). These four mutations were all found
in Italianprobands.
A heterozygous nonsense mutation was discovered at amino acid position 93
within exon 4 ofMYOlA in the Family 2102 proband IV-3 (Figure 3.12). This nonsense
mutation, p.R93X substitutes an arginine residue for a stop signal in the motor domain
(Figure 3.13). All three affected Family 2102 individuals shared the mutation, and
reported their first hearing loss at 5 years of age, with hearing coming and going, but
progressively deteriorating to severe hearing loss (Figure 3.14).
While this mutation is not novel, it is only the second reported case world-wide.
The p.R93X nonsense mutation was first reported in a very small southern Italian family.
p.R93X was present in the male proband who suffered from moderate to severe bilateral
hearing loss. This is the same audioprofile seen in Family 2102, though time of onset was
not available for this Italian family. The proband received the mutant allele from his
mother. The mother stated that she hasnorrnal hearing, although no audiological
evaluation of any kind was carried out. A healthy brother of the proband did notcarrythe
p.R93X mutant allele and did not possess any forrn of hearing loss (Donaudyeta1.2003).
Several possibilities could explain the Italian mother's supposed norrnal hearing:
I) The mother does in fact have the same hearing loss as her son, 2) this family
segregates an ARforrn of deafness and digenic inheritance is responsible for this hearing
loss phenotype, or 3) the trait is not 100 % penetrant. While many types of hearing loss
are caused by a mutation in one single gene, digenic inheritance requires the interaction
of two genes for phenotypic expression. If the mother does not have hearingloss,despite
carrying the p.R93X mutation, she may not have hearing loss because this trait is an AR
forrnofhearinglossand segregates in a digenic manner. She would not inherit the
second disease causing mutation in the putative second unknown gene. Additionally,if
thetraitisnotfullypenetrantthenthistoocouldexplainthemother'snorrnalhearing.
Detection of the p.R93X mutation is simple and does not require sequencing because the
mutation is easily identified by digestion ofPCRproducts, as the mutant allele destroys
an Avail restriction site. A further avenue of research for Family 2102 would be to attain
DNA from the affected Italian individuals previously reported to create an ancestral
haplotype, as done previously for Family 2094. It could then be deterrninedwhetheror
not Family 2102, from Newfoundland, share a common ancestor with the previously
reported Italian family (Donaudyetal. 2003).
Candidate Gene TECTA
TECTA encodes the protein Alpha-tectorin. The tectorial membrane is an
extracellular matrix that covers the Organ of corti sensory epithelium in the ear. Sound
waves induce a vertical movement of the basilar membrane, and tltis movement evokes a
deflection of stereocilia against the tectorial membrane. Alpha-tectorinisoneofthe
major noncollageneous components of the tectorial membrane. Mutations in the TECTA
gene have been shown to be responsible for ADNSHL, with audioprofiles similar to some
of the 28 Newfoundland probands understudy (Verhoeven et al. 1998).
Exons sequenced included 5, 9-14, 17-18, and 20. However, no hearing loss
mutations were discovered among the 28 AD Newfoundland probands. This does not rule
out the possibility that hearing loss in one or more of these Newfoundland probandsif
caused by mutations in TECTA within an exon that was not sequenced in this research
project. A total ofl3 exonswere not sequenced, andtltis gap represents an 0 pportunity
for further research, as TECTA remains a strong candidate gene for hearing loss in
Non-Founder Mutations in a Founder Population
As previously discussed, the province of Newfoundland & Labrador is a founder
population, due to its cultural and geographic isolation. Since the second major wave of
settlement, taking place in the late 18th and early 19th centuries, little immigration or
outmigration has occurred. These original colonists have contributed to several founder
mutations that cause specific diseases. For example, an exon 8 deletion in MSH2, a gene
causing hereditary non-polyposis colorectal cancer, has been found in 5 different
Newfoundlandfamilies(N=74carriers)(Frogattetal.1996;Stucklessetal.2006),and
the c.782+3delGAG mutation found in the deafness gene TMPRSS3 has been reported in
2 different Newfoundland families (Ahmed et al. 2004; Young et aI. unpublished data).
This study sought to potentially identify AD hearing loss founder mutations in
Newfoundland. No founder mutations were identified. All three of the mutations
identified in this study - p.P5lP/S, p.Ser269del, and p.R93X in the genes COCH,
KCNQ4, and MY01A respectively - were each reported in one family only, after
screening 68 Newfoundland & Labrador hearing loss probands. We identified three
separate mutations in three separate genes causing hearing loss with three separate
phenotypes. Additionally, these mutations were found to cause hearing 10ssinthree
Newfoundland families that are geographically separated from one another. So while the
genetic history and nature ofNewfoundland's population, combined with previous
successes (Young et aI. 2001; Ahmed et aI. 2004) implies that the future discovery of
hearing loss founder mutations in Newfoundland & Labrador is still a possibility, the
results of this study unexpectedly point to Newfoundland's genetic diversity,ratherthan
its homogeneity. This isn't the first time this has happened. An increased leveI of genetic
diversity was noted when, for example, nine mutations in six genes were detected in 21
families with Bardet-Biedl syndrome (Webb et aI. 2009). I speculate here that the solved
familiesinthisstudy,2094,2071,and2102,alldescendfromoriginalbutseparate
groups ofNewfoundland colonists. These colonists would likely have been from several
different areas of Ireland or England. The geographical isolation of their origin home
towns could account for the potential genetic diversity seen in the identification of these
three separate hearing loss mutations. These findings, therefore, do not marginalize the
efficacy of the Newfoundland population in the search for novel gene discovery or for
The clinical and diagnostic utility of these identified mutations is significant for
the families in question, as they are now able to screen new family members, receive
much irnproved genetic counseling, and hopefully, benefit from improvedtreatment
options. However, identification of a Newfoundland founder mutation would be of
increased clinical and diagnostic utility. Anymutationthatisprevalentthroughoutalarge
portion of native Newfoundlanders is screened for at birth, and would thusbeidentified
in all future cases born in Newfoundland. The aforementioned benefits would therefore
apply to a much wider range of people than a single family, as is the case for non-founder
mutations. This study, therefore, does not reduce the strong clinical and diagnostic
potentiaithatcanbefulfilledthroughthediscoveryofNewfoundlandfoundermutations,
nor does it point to an inefficacy of the Newfoundland population as a medium of novel
gene discovery.
A Changing Landscape of Gene Identification Methodology
Despite the increase in hearing loss gene identification, many deafness causing
genes and loci remain undiscovered. High density SNP arrays, which are a type of DNA
microarray used to detect polymorphisms across large portions of a genome have been
successfully applied in a new approach to fmd hearing loss genes. Shahin et al .(2010)
applied SNParray-based homozygosity mapping of families with a high degree of
consanguinity. Homozygosity mapping is a powerful method oflocalizing genes for
autosomalrecessivedisorders.Usingthisapproach,Shahinetal.(2010) identified five
genome regions likely to harbor novel genes for pre-lingual non-syndromic hearing loss
in six Palestiniankindreds. This approach is currently being investigatedforARhearing
disorders in the Newfoundland population. Traditionally this method has been limited to
families who share a recent common ancestor, but Hildebrandtetal. (2009) have recently
demonstrated that this technique can be used onoutbred populations. They performed
homozygosity mapping on 72 single affected individuals of 54 kindreds ascertained
worldwide using a 250 K SNP array. This discovery could potentially open up further
opportunities for novel gene discovery in Newfoundland & Labrador as many specialty
clinics have access to cohorts of individuals from out-bred populations.
A second technological advance having huge implications on novel gene
discovery is the advent of next-generation sequencing (Schuster, 2008). Next-generation
sequencing allows for the easy production of millions of DNA sequence readsinasingle
run. Next-generation sequencing instruments can generate as much data in 24 hoursas
several hundred traditional DNA capillary sequencers, butareoperatedbyasingleperson
(Schuster, 2008). A recent study ofnon-syndromic hearing loss used targetedgenome
capture combined with next-generation sequencing to analyze 2.9 Mb of the DFNB79
interval on chromosome 9q34.3 (Rehman et al. 2010). Rehman et al. (2010) detected a
nonsense mutation in the predicted gene C90rj75, which they renamed taperin (TPRN). A
nonsense mutation is a change in DNA sequence that results in a premature stop codon,
leadingtoanincomplete,andusuallynonfunctional,proteinproduct.Rehman et al.
(20 I0) next performed irnmunolocalization experiments on the TPRN protein in a mouse
cocWea,andsawprominentexpressioninthetaperregionofhaircellstereocilia.
Athirdstrategyshowingrecentsuccess(Meyeretal.2007)andstrongprornise
for gene identification, specifically for AD hearing loss, is the use of AudioGene
Audioprofiling. Audiogene is a computer program that uses a machine-learning approach
to analyze audioprofiles as a method of prioritizing genes formutation screening in small
families segregating AD hearing loss. The audiogene dataset has recently been expanded
to include a total of 16 DFNA loci, including CaCH, KCNQ4, and TECTA (Hildebrand
et al. 2009). This could be very useful in the investigation ofNewfoundland families
segregatingADhearingloss,andmanyofthesefarniliesaresmallwithlirnitedrecorded
data. Hildebrand et al. (2009) performed an experiment where a series of audiograms
were analyzed by a panel of hearing loss experts, and concurrently by AudioGene. The
accuracy of matching the audiograms with the genotypic cause was 55 % for the human
experts, and 88 % for AudioGene (Hildebrand etal. 2008). Furthermore, as thesizeof
this database increases, so too will its predictive capacities. For now, it represents a
promising avenue for Newfoundland AD hearing loss research at almost zero cost, and
should be the next strategy employed for mutation detection in the 25 remaining
Newfoundland AD probands.
These are just some examples of recent advances in technology leadingtonovel
gene discovery, and as these technologies become more common, their use will be
instrumental in new investigative disease causing studies not just in the Newfoundland
popuiation, but all over the world. The ability of next-generation sequencing to perform
somany'reads'soquicklywillbeinvaluabletofuturehearinglossstudiesin
Newfoundland. Screening candidate genes and potentially mutated chromosomal regions
willbesignificantlyeasier,allowingforthe'quick'discoveryofnovel(and existing)
causative hearing loss mutations inNewfoundlandprobands.
Limitations of this Study
Despite the discoveries discussed above, the candidate gene approachundertaken
in this study does present various limitations in the searchforhearingloss mutations.
These limitations vary widely, and while mentioned above throughout this thesis, a short
summary of them will serve to illuminate the path forward both in filling any gaps, and in
approaching mutation detection in various untried ways up to this point.
Firstly, it is important to note that mutations in WFSl may not be more common
than other hearing ioss mutation just because they are more commoniy reportedin
Newfoundland. The reason the p.A716T mutation in WFSlis so widely reported is due in
large part to its pathognomonic character. A pathognomonic sign is aparticularsign
whose presence is characteristic fora certain disorder beyond anydoubt. The phenotype
ofp.A716T mutation in WFSJ is one such pathognomonic trait. Local audiologists are
able to both distinguish this pattern of hearing loss and recognize surnames of the
extended family thus far affected, and contact us directly when they have patientsthat
may be related to these originally reported families (Young et al. 2001). ClinicaI
applicationlikethismakesitlikelythatthehighfrequencyofreportedWFSJ-related
hearing loss is an overstatement, not describing the true situation (Tranebjaerg2008).
It is also possible that one or more of the families under investigation may be
incorrectly classified as AD due toa lack of sufficient data. Many individualsinthese
pedigrees(Figure2.1)areascertainedthroughrelatives'wordofmouth,andsoitis
entirely possible that digenic inheritance, penetrance, or even mitochondrialmutations
may be obscuring the proper ascertainment ofinheritancepattemand thus the searchfor
causative hearing loss mutations. These possibilities should undoubtedlybeinvestigated
in future studies on the 25 remaining AD families.
Thepossiblepresenceoflargergenomicabnormalitiesatworkisanother
lirnitationofthisstudy,whichdidnotsearchforanysuchpossibleoccurrence. This study
investigates genes through targeted gene sequencing. However, largergenomic
abnormalities have been shown to cause hearing loss phenotypes (Lisenka et al.2003;
Shafferetal.2006).Genomicabnormaiities,therefore,mayaccountforhearing loss in
some of the Newfoundland families under investigation. Large genomic rearrangements,
deletions, inversions, etc. can cause and affect the degree and severity 0 fdiseases,and
such large-scale anomalies are not detected through traditional DNA sequencing methods
(Lisenkaetal. 2003; Idbaihet al. 2010). The possible presence of such abnonnalities
should be investigated in future studies.
Tbe presence of phenocopies in Family 2071 is also a relevant pit-fall in this
study of AD hearing loss families. While phenocopies are common, they are also often
difficult to prove beyond any doubt. A routine aspect of the clinical ascertainmentisa
request of patients and family members to fill out a detailed hearing loss questionnaire.
This includes specific questions about noise exposures, head injuries, usageofdrugs
known to be ototoxic, etc. In this study, the cause of hearing loss in Family 2071 's
putative phenocopies is unknown. These unanswered questions obscure the full picture of
hearing loss in Family 2071. The continued investigation of this family is, therefore,
essential to gain a more complete understanding of hearing loss in this family and to
confinn beyond any doubt that several individuals within Family 2094 are phenocopies.
Lastly, the approach taken in this study is also a limitation unto itself. This study
was a "targeted" candidate gene approach which focused oruyon genes previously
associated with hearing loss. While this improved the likelihood of detecting hearing loss
mutations,itrestrictedthechanceofidentifyingpotential"geneticsurprises"regarding
genotype-phenotype. And while several exons within KCNQ4, COCH, TECTA, and
MYOJA not previously associated with hearing loss were bi-directionally sequenced, this
approach was lirnited by the two year tirne-frame ofa master's thesis.
Chapter 5: Summary
The aim of this thesis was to detennine the genetic etiology of AD hearing loss in
28 large, multi-generational Newfoundland families. Probands were frrst screened for
hearing loss alleles previously reported in the Newfoundland population: specifically the
full GJB2 gene, the del13S 1830 mutation in GJB6GJB2, GJB6, and the p.A716T in
WFSI. The next step was a systematic functional candidate gene search for genes and
mutations from the primary literature and the NCBI database. Genotype-phenotype
evaluationofpotentialcandidategenes,andfrequencyofmutationsfoundpreviously,
helped to narrow the list down to four likely functional candidate genes: COCH, KCNQ4,
TECTA, and MYOIA. These genes all code for proteins that play an important role in
human hearing, and harbor hearing loss mutations recurrent in Caucasian populations.
Once a mutation was identified, we were then able to highlight common patterns among
the phenotypes ofNewfoundland probands and the phenotypes of known mutations in
AD deafness causing genes. Figure 2.2 illustrates the progression of this study from the
stage of experimental design to the discovery of novel and known causative mutalions.
In Newfoundland Family 2094 a known mutation (p.P51 PIS) within COCH was
discovered to be the cause of hearing loss. Thep.P5IP/S mutation causes a late-onset
progressive high-frequency hearing loss, and is associated with severevestibulardefects,
such as vertigo and motion sickness. Using DNA from a Dutch p.P51 PIS family, and
Family 2094, an ancestral haplotype was created through successful fragmentanalysis,
confinning Family 2094's p.P5IP/S transition to be a Dutch founder mutation. However,
no other Newfoundland families were explained by this mutation. No further genealogy
was done to elaborate on this shared ancestry.
In Newfoundland Family 2071, a novel 3 bp deletion in exon 5 of KCNQ4 has
been found to be the cause of hearing loss. This discovery also provides further evidence
ofthe current genotype-phenotype correlation, whereby deletions in KCNQ4 cause a
milder, later onset, high-frequency loss in patients compared to KCNQ4 missense
mutations (Nie, 2008). This mutation was not detected in any additional Newfoundland
probands.
In Newfoundland Family 2102, the cause of hearing loss was identified to be a
nonsense mutation in exon 4 of MYOIA (p.R93X). All affected individuals are reported
to have suffered from hearing loss from the age of five, with hearing coming and going
but progressively deteriorating. Again, this mutation was notreported in any additional
Newfoundland hearing loss families. No hearing loss causing mutations were discovered
within the TECTA gene, but sequencing of this gene should be completed in the future to
rule it out completely as a candidate gene for hearing loss.
Intheintroduction,atablewaspresentedindicatingallknowndeafnessrelated
genes and their mutations within the Newfoundland population. An updated version of
this table is seen in Table 5.1. Of the 28 Newfoundland families suffering from AD
hearing loss at the beginning of this study, three families have now been solved.Further
research on the remaining 25 unsolved Newfoundland families is of paramount
importance. Genomic DNA from four of these 24 families has recently been sent for a
genome wide scan (GWS). The data gained from this GWS will inevitably enable further
successful identification oftbe genetic cause of hearing loss intbese families. AudioGene
Audioprofiling also presents a promising avenue of detecting furthermutationswitbintbe
remaining 25 probands, and should be investigated. The determination of these hearing
loss causing mutations must remain of critical importance to researchers and clinicians
alike. Witb a greater understanding oftbe genetic mutations causing variousfamilies'
hearing loss, comes a greater understanding oftbe patbogenic mechanismsand a greater
chance of improved treatment options and screening abilities.
Table 5.1 Deafness Genes Identified in Newfoundland Population at End of This
Study
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Appendix A: PCR Primer Sequences and Expected PCR Product Sizes.
Gene Amplified Primer Name Primer Sequence Size of
Exon Fragment (bp)
KCNQ4 lA 4700-1AF agttggagtcggaaagagca 567
4700-1AR CGCAAALrCACATGAAGACG
KCNQ4 lB 4700-1BF AGCCATGCGTLrLrGAGC 564
4700-1BR ctgggagatcagggettagg
KCNQ4 2 4700-2R ccagggaattccaattctga 456
4700-2F gaagcctctttccaccttca
KCNQ4 3 4700-3F ggaatcgtcaagtccaggaa 358
4700-3R agggtcagagtcgggattg
KCNQ4 4 4700-4F tactcccaatcccgactctg 486
4700-4R ttagacctcgcctcctgcta
KCNQ4 5 4700-5F tgggaggagctgagaaagaa 351
4700-5R tgagtcaggagtcacgatgg
KCNQ4 6+7 4700-6&7F ccctcatgatcaggctccta 554
4700-6&7R gtcagcacacagggttgaca
KCNQ4 8 4700-8F ccacaactggaccaaggact 356
4700-8R aaggacactccaggctctga
KCNQ4 9 4700-9F tccaccctgtcctattctgg 397
4700-9R aaggcaggtctgagagagga
KCNQ4 10 4700-10F catccttgttccatcccaag 494
4700-lOR ccaaagacggtccatcagtt
KCNQ4 11 4700-11F ctggtggtttggcatacaag 287
4700-11R ggctggtctcaaactcctga
KCNQ4 12 4700-12F tccatctcatccctgtttctg 392
4700-12R ggcctcagacttcattcagg
KCNQ4 13 4700-13F ggtgccttctccttcatcag 394
4700-13R cgggtttatgggaatgtctg
KCNQ4 14A 4700-14AF ctagccaagctccacctttc 383
4700-14AR GCLrLrGAGAAGTCCLrCAGT
KCNQ4 14B 4700-14BF GACLrGLrGTIGGGmLrA 418
4700-14BR gctgctgctgccctctgt
TELrA 5 5422-5F accctgactcggctatgaaa 480
5422-5R ccattacccagcggagagat
TELrA 9A 5422-9AF gggcagaccgtgtctttatc 497
5422-9AR ALrCCAGGAAGGAGLrGTIG
TELrA 9B 5422-9BF GmGTGCGGmLrACAAT 488
5422-9BR acctggaagggaagtcctga
TELrA lOA 5422-lOAF gcactcacaaacacacatgc 496
5422-10AR AAGGTGAGGTAGTGGCCGTA
TELrA lOB 5422-10BF mLrGGGTGGACLrGGALr 499
5422-lOBR tttctttggattccggacct
Appendix A: PCR Primer Sequences and Expected PCR Product Sizes (cont).
Gene Amplified Primer Name Primer Sequence Size of
Exon Fragment (bp)
TECTA 11A 5422-11AF ctgctcaaacttccctctgg 499
5422-11AR AAGGCAGCGTICTGGTIG
TECTA 11B 5422-11BF ACCCTGATGATGACCTGGAG 497
5422-11BR tcagttccaaagtgcatatcct
TECTA 12 5422-12BF tgcctttcatctccctgagt 415
5422-12BR cgaacacgacgctcttcata
TECTA 13A 5422-13AF catttgagttgaggccgttt 494
5422-13AR AGTAGACGGGCGAAATGATG
TECTA 13B 5422-13BF CGTCGCAACGTGATICAG 470
5422-13BR acctggtcactgtgtgtgga
TECTA 14 5422-14F cagaatggagtcgttgagacag 499
5422-14R aggcattcctcattcacacc
TECTA 17 5422-17F atgcccaggttactgctttg 493
5422-17R gcagatcaccctgaagttgg
TECTA 18 5422-18F gccatttctccactttcagg 354
5422-18R tagggcatcaaagacaaacg
TECTA 20 5422-20F gcatttctgccatttatggtg 381
5422-20R gatgattccagtccggtcac
MY01A 3 5379-3F gcctctggctgtggatatgt 399
5379-3R acgcaggttcatccactctc
MY01A 4 5379-4F gcccagtctgctccaagtag 297
5379-4R tggagggtcaggtctaggtc
MY01A 6+7 5379-6&7F tgagccctagaccctcttcc 500
5379-6&7R gttgggaagtctccttgacg
MYOlA 10 5379-10F atgaatccattagggcaagg 495
5379-10R aggcagaaagcagaaatcaaa
MY01A 11+12 5379-11&12F caccagtgtctcaggcagtt 490
5379-11&12R tcatcctccctactctgctca
MY01A 18 5379-18F gcaccgtgtgcagcatag 395
5379-18R ttcacccagcttcagcagat
MY01A 22 5379-22F actcaggtctttgcgtggtt 281
5379-22R gcagactgaggaaactcttgg
MY01A 25 5379-25F ggtgctgatgtcttggtcct 374
5379-25R caaacacagcctgccatct
eaCH 2+3 4086-2&3F tctgtgtcctctctcctctgc 499
4086-2&3R atgggagaaacaggtgagca
COCH 4 4086-4F ctggaatggtatggaagggta 463
4086-4R tatccaggagaaccgtgaaa
eaCH 5 4086-5F agcgagacgccatcaaataa 395
4086-5R ccatcaaggttaaagaggctga
Appendix A: PCR Primer Sequences and Expected PCR Product Sizes (cont).
Amplified
Exon
Primer Sequence Size of
Fragment (bp)
4086-12AF tttgccactctcgtcacaat 492
4086-12AR TTTGCCTAAATGGCTGTIGA1--.,....,.---+-.,....,.----+--'-=40=86-=-12":":BF'----+---c::'GA--=-TG=Tc-"-'-:AT~CA-':'-'GA'":"-:GG:.".:CA'==TTT:::'-:G=-T _+_----,,.,..,.-----1
1----+----+--'-=:~=:~-=:~~=~~'----+--=~~=~~=~-=~~A'-'-',A~G=:-'c:'GrzTI-"'-~::..:..:A~':'-"~=~~'-=-~-+------,...,..,------1
f----=-=:-:--+--=-=--+---:-::~=:~~:~~=~~'------t-::T=~G=T~A':.:::~A=C~::-:::-~~:=-:-:;:-"'-~::..:..:A~':'-"~~=~~'-=-~T-+------,-,--------1
L--_----'-----_-----'----:..::40=86-...::.::12=DR:.......L.---=c=aga=ttg=gt=cttt=cca=ca=tga=-------'-----__-'
Appendix B: Mutations Previously Found Within the Four Selected Candidate Genes
KCNQ4, COCH, TECTA, and MYOIA.
Mutation Protein Domain Exon Reference
KCN 4- .W276S PoreRe ion 5 CouckeetaI.1999.
KCN 4- .L274H PoreRe ion 5 Kubischetal.1999.
KCN 4- .L281S PoreRe ion 6 Talebizadehetal.l999.
KCN 4- .G285S PoreRe ion 6 Kubischetal.1999.
KCN 4- .G285C PoreReion 6 CouckeetaI.1999.
KCN 4- .G321S S6Transmembrane 7 Couckeetal.1999.
KCN 4- .G455H PoreRe ion N/A Van Laeretal. 2006.
KCNQ4-
,.Q7IfsXI38 Transmembrane I Kamadaetal.2006.
KCNQ4- .FS71 N-TerminalCyto lasmic I Couckeetal.1999.
COCH- .VI04del FCH 5 Nagyetal.2004.
COCH- .P5IP/S FCH 4 Fransenetal.1999.
COCH- .V66G FCH 4 Robertsonetal.1998 .
COCH- .G87W FCH 5 Collinetal.2006.
COCH- .G88E FCH 5 Robertson et al. 1998.
COCH- .ll09N FCH 5 Kamarinos etal. 2001.
COCH- .W117R FCH 5 Robertsonetal.1998.
COCH- .A119T FCH 5 Usamietal.2003.
COCH- .C542F vWFA2 12 Streetetal.2005.
TECTA- .N864K N/A 9 Hutchinetal.2005.
TECTA- .CI057S Zona Adhesion 10 Balciunieneetal.1999.
TECTA- .C1352Y N/A II Hutchinetal.2005.
TECTA- .C1509G vWFD4 13 Pfister et al. 2004.
TECTA- .C1619S Zona Adhesion 14 Alloisioetal.1999.
TECTA- .Ll820F ZonaPellucida 17 Verhoeven et al. 1998.
TECTA- .G1824D ZonaPellucida 17 Verhoeven et al. 1998.
TECTA- .C1837G ZonaPellucida 17 Moreno-Pelayo, 2001.
TECTA- .Y1870C ZonaPellucida 18 Verhoevenetal.1998.
TECTA- .R202IH ZonaPellucida 20 Iwasaki etal. 2002.
TECTA-
.F119fsX131 N/A 5 Hutchin etal. 2005.
MYOJA-p.R93X Motor Domain 3 Donaudy et ai, 2003
MYOJA-p.V306M N/A 10 Donaudy et ai, 2003
MYOJA-p.E385D Motor Domain 12 Don+audy et ai, 2003
MYOJA-p.G662E N/A 18 Donaudyetal,2003
MYOJA-p.G674D N/A 18 Donaudyetal,2003
MYOJA-p.S797F N/A 22 Donaudyet ai, 2003
Appendix B: Mutations Previously Found Within the Four Selected Candidate Genes
KCNQ4, COCH, TECTA, and MYOIA (cont).
Appendix c: caCH Microsatellite Marker Primer Sequences and Expected peR
Product Sizes.
Marker
Name
D145262-F
D145262-R
D145975-F
D14S975-R
D1451021-R
D1451021-F
D145257-F
D145257-R
D1451071-F
D1451071-R
D1451040-F
D1451040-R
D1451034-F
D1451034-R
D1451060-F
D1451060-R
D14S70-F
D14570-R
D1451014-F
D1451014-R
Primer Sequence Size of
Fragment (bp)
GCAGTGGACTGATGCTCC 200
CCATGAAACTGGTCCCG
CATACACAGACACACGGAGA
TGCCAAATAATCAGTITIGC
AGTCGTGTATCCTGGGCAT
GCGCTGGTGTGAATCTTTA
CAGTGAGCCATGACTGTG
TIGGTAAAGTGGTAAAAGGC
AGTGATCCACCCACCTIC
GGCTCAACTACGTGTIGCT
GGCACTATGAAACCAATITIAAC
GGCCTGCTGAATCAGA
CGTAGATGCTCCAAATCCTAC
TAGACAAATCGCTGGTCACT
GTIAAAATGGGCCACAATAAAT
CTGTIATGTATCAGACCAACCC
ATCAATTIGCTAGTTIGGCA
AGCTAATGACTIAGACACGTIGTAG
AGCTATICAGGTCAAAAAGGTC
AATCCCTACCCTIGTGGTG
Appendix D: Fragment Analysis of Microsatellite Markers Flanking the CDCH gene.
Marker Allelel Allele 2
8am Ie
OP06-115 014SI021 262 262
JC07-184 014SI021 262 262
KM06-227 014SI021 262 262
JS07-182 01481021 262 274
19126 01481021 268 268
19135 01481021 262 268
19149 014SI021 262 268
AP07-66 014SI021 262 274
OP07-270 01481021 262 274
CP07-187 01481021 262 268
CC07-269 01481021 262 268
OP06-115 014S975 163 171
JC07-184 014S975 163 171
KM06-227 0148975 167 171
JS07-182 014S975 171 171
19126 0148975 163 171
19135 0148975 167 171
19149 014S975 167 171
AP07-66 014S975 163 171
OP07-270 0148975 163 171
CP07-187 014S975 163 171
CC07-269 014S975 165 171
OP06-115 014SI040 234 234
JC07-184 014SI040 232 234
KM06-227 014SI040 234 234
J807-182 01481040 232 234
19126 014SI040 214 234
19135 014SI040 232 234
19149 01481040 232 234
AP07-66 014S1040 232 234
OP07-270 014SI040 232 234
CP07-187 014SI040 232 234
CC07-269 0I4SI040 232 234
OP06-115 014SI071 277 281
JC07-184 014SI071 275 281
KM06-227 01481071 281 281
JS07-182 014SI071 277 285
19126 01481071 277 281
19135 014SI071 275 281
19149 014SI071 275 281
AP07-66 014SI071 285 281
19149 014SI060 201 207
Appendix D: Fragment Analysis of Microsatellite Markers Flanking the CaCH Gene
(cont).
8am Ie Marker Allele! Allele 2
OP07-270 01481071 285 281
CP07-187 01481071 275 281
CC07-269 01481071 275 281
OP06-115 01481034 169 173
JC07-184 01481034 169 177
KM06-227 01481034 169 173
J807-182 01481034 173 175
19126 01481034 169 177
19135 01481034 169 175
19149 01481034 169 175
AP07-66 01481034 169 175
OP07-270 01481034 169 175
CP07-187 01481034 169 169
CC07-269 01481034 169 179
OP06-115 0148262 200 200
JC07-184 0148262 200 200
KM06-227 0148262 200 200
J807-182 0148262 200 202
19126 0148262 204 204
19135 0148262 200 204
19149 0148262 200 204
AP07-66 0148262 200 202
OP07-270 0148262 200 202
CP07-187 0148262 200 198
CC07-269 0148262 200 204
OP06-115 0148257 179 177
JC07-184 0148257 179 191
KM06-227 0148257 179 179
J807-182 0148257 171 177
19126 0148257 179 179
19135 0148257 179 191
19149 0148257 179 191
AP07-66 0148257 179 171
OP07-270 0148257 179 171
CP07-187 0148257 179 191
CC07-269 0148257 179 191
OP06-115 01481060 201 207
JC07-184 01481060 201 191
KM06-227 01481060 201 191
J807-182 01481060 201 197
19126 01481060 201 205
19135 01481060 201 207
Appendix E: Medical Hearing Loss Questionnaire
Newfoundland and Labrador
Hearing Loss Study
Medical Information Questionnaire
Ad:lpk-dfrom:
THE HARVARD CEr\TRE
FOR HEREDITARY HEARl "G LOSS
Appendix E: Medical Hearing Loss Questionnaire (cont)
ECTIOI 1 - GE ERAL INFORMATIO
Your Namc__. _
E·moil Addrcss(ifyou haveonc) _
ToyourknowledIlC.o.reyourparentsrelated.evendiSUlntly'! _ Yes No -lJon'tKno"
PIeae ......«tloe'........q.tioa .. bcol'o...... lfy·ouh.,'C.··nth..-doclOr.plca""gi,eUllhcnamc
andaddrns.ifpoosible. Ifroouthinkyoo"",, SCCtIlbcmhul)ouan:nol.urecftheirnam .. orwhen)ou w
Ibcm.justindiClllCIPProximatcdale.f.,..examplc. W (lWano,tJiol(jf:is' /()J (Jl' ogo i"CralldFolI-. If you
have nOl had an appoint"""'t with Ihe medical penon lililed. tiel 00:mJ mo,,, 10 the next question. Any
information you = provide "ill be helpful.
" HavcyouevC'f\'isited3nyofthcfollowint;.doclors'?
An ENT Doctor? (E:tr. Nose:ll1d TII""'l)
Ifycs.whcredidyou..,.,them: _
An Audiologist'? (PcrwnpcrforminghcaringtcSls)
Ifycs.wheredidyouseethcm: _
An Eye Doclor'? (Ophthalmologist)
Ifycs.whcredidyousecthcm: _
A GcnclicsDoctor?(Gcnclicist)
Ifycs~wheTCdidyuusectht:nl; _
A doctor who Ue.3llii di5t.":J.ses of the nervous system".' (~eurolog~~~
Ifycs.whcrcdidyousccthem: _
Ifycs. where did yousccthcm: _
4. H.,·cyouevcrbecnudmittcdtohospit.I'?lfycs.pICOSCl:ivcnomcofhospitallUld.pproxlmat
dalC(.)ofadmisison.
Appendix E: Medical Hearing Loss Questionnaire (cont)
ECTIO II - MEDICAL HI TORY
Right=:
Ifhcari i.1 thanno
nothin~ hcarinJ!.aid c:ochl=implant
Ri~htE:Jr: nothing hcaringaid cochlcarimplMt
Were you oom with hcarini loss? .
Ifyes.uckaff.'Ctcdcar . ....~ Right
Ifno. when did it st3rt?.......... OurinvChildhood OuringT<'CnYcars ,OuriniAduJthood
8. Did your hearing loss bcgin during or soon after:
bcingprellJW1l .
an uirplancflighL .
scubadiving. .
hemotherapyforeaneer .
ascven:infcction.sucb meningitis? ....
exposuretoauddDloudnoise .
prolo~exposureloloudDOi:o:.....
carsurgCf)·CincludiniillS<"TtionofT-tubcs)...
injurYlothheudorthccur.
Appendix E: Medical Hearing Loss Questionnaire (cont)
)'aUt.:rn of HCllrin~ Lo~s. l)k"':~ tdl us ..,'hi·h ~r has hearing lo~s b~ 'lr1~wcring the: folluwinl; ~uC'stjlJns.
9. Your h~arin~ i~:
Swbk tha...; not chanJ:cd "1UCn O\'t.:f scvr.:ral ~c~r~}.... Right '",'''-\
Fluctuating (sometime:!: bt.'1tc:r. ""m1ctimc); Yd.>r1'CI..... Rj~hl
"Iowl:", pm~n:ssjn1: (~':Hin~ WLH"5C ovcr years)....... Ri~hl
Suddcnhcaringloss ...
Right
B. Palienl'sMedicaIHislory. Havcyoucverhadonyofthefollowinll:
rrcmamr~gl"3,.ingofh:Jirb\:forc3~,,30 .
(Notjustattht:lcmplc:s)
DiabclCS mcltilus {··sugardiaoctes··l.....
Thyroidproblcms(goilcr.undcracti\'c.oVCr3C'tivc)....
II J$1thCn:anylhingcls,cwhichyouthinlo;weshoulc.Jkno..\aboulyourmcPlcuIhislm''V?
Appendix E: Medical Hearing Loss Questionnaire (cont)
You ha"ebeea luked to bke partin a research study. Ifill up to you cudecldewh thertobe
Intbe.tudyornot. Be-rorClyou.dec'de,youD«dtouDd~nrandwll.fthe,tudylsr..r.wh.t
risksyoum'ahttakeaandwh•• benent youmi&htr«eive. Tbi8 consent form explain. the
nud)'.
• dbcuntbenudywitbyou
• anlweryourquestioDS
• keep confidential any io(ormation whlc:bc:ould identify you personaIly
• be avaUable duriagthe study to dealwUh problem andaaswerqucs.ions
Some forms of deafness are heredilary. ThatmcansthattheYllJ1:inheritedinfamilicsasarcultof
an altered gene. A gene is a piece of genetic material (DNA) which is po.ssed from parenlS to
children. rfwccanidcntifythcgcnesthata.rcaltcrcdineachflUtlily.itwouldallowustobc:ner
understand the process of hearing. We might also learn what 8oe! wrong in some forms of deafness
nndhowitmighlbetrealed.
If you agrec to take part in this study. you will be: asked to:
• Tell US aboul your hearing and Ihc hearing of other members of your family . and
other relAted a~pects of your health.
• HaveyourhearingtcstedbYOIrcgisteredaudiologisl.
• IIavcDbioodsamp1cdmwnforD Atcsting.
• Complclcaheannglos:lqUt....,tionnairc.
Wcmiihtalsowanttoreviewyournl(.-dicaJrcc.:onbrelatcdtoyourdeafnes.
Appendix E: Medical Hearing Loss Questionnaire (cont)
4. LflIethoftim.:
If you Ulk.part in thissludy. the inlervi.wwill lasl J0-60 minutes includinithe blood
samplini. The hCllrini t.st will Ulk.aboul 30 minutes. [twill belllTlll1g.d.,orime th.t is
convenient for you. The ",seo",h maylDk. us several years but you will nol have 10 be
involvedoiain. W.willkeepyouinform.dofourfindings.
5. Po..lbl.rla....nddlllCoDl(oru:
The only dlscomfort i, that of giving °blood sample.
6. lHn.nts:
It is nol1alown whetber ,his study will benelil you.
7. Liablllty,bt.m.nt:
Slpwctlaisformch'ullSyourCOlUtnltobcillthls,llIdy.lct.llsu.tb.lyouund.rsllnd
tb.iDformation.bouttb.ruearcb'tlldy.Wb.nyouigntblsfonn,youdonotKivfUp
yourleplrlpts. R....reb.rsor.l.nci.. inolv.di.tbisres..rcb'ludy tillbav.tb.ir
legalalldprof•.,io••lr..po••ibilitia.
8. CompellsatioD:
In tbecvent that you sufferinjwy .. a dirc<:1 resull oflDking pan in lhisstudy. necessary
mcdical treatmenlnotcovered byprovin<:ial bellltb care insW1lllC. will be ovailabl. 3t no
additional COSIto you.
9. Confld••tiality:
Unless rcquin:d by law, only tbe rescan:bers may ha~ access to any confidential documents
pertaining to your participatiOIl in lhis study tbat may ideo!ify you by name. Furthermore, your
oame will oot appear in any reportorarriclepublisbedll$aresuJloflhi.,tudy.
10. GeD.ticSludi..:
10 order to int.f1"':ttbe results ofgenetic research, we need to haveCOrTeCl informatiOllabout
plIl"ots. Sometimes the reseoreh show. n.winformalionahoul hirthplll"nts. Thiscould
happen in the case ofan adoption ora mJstake in the identityofa mother or f.tb.r. This
informalion will not be given to anyone including you or olher family members.
Appendix E: Medical Hearing Loss Questionnaire (cont)
II. Future .... of'ti..ue/DIfA sample•.
In order to preserve a valuable resource, your (tissue/DNA) samples may be
stored al the end of this research project. Itis possible that these samples
maybe useful in a future research project dealing with hereditary deafness
which mayor may not be related to the current research project. Ally future
reaearch would have to be approved by a Reaearch EtIUc. Board (REBI.
Please tick ODe of the folJowingoptions:
I sgree that my (tissue/DNAI samples can be used for any approvcd research
rocetbuto . iflamcontactcd 'to 'vcconsentforthenew ro'cet.
Iagreethatmy(tissue/DNAlsamplecanbeuoedforanyapprovcdrcsearch
&:.cet ~th~ut:nta:n.:::.;.g"f:' but olll)' Ifm)' ........ callDOt be
·Includes name, MCP number or any other identifying information.
The DNA sample from this stud)' will be stored in I. John'!. L ewfoundland and Seanlc.
Washington for an indctinilc pcriod of lime.
II.Conlactlnformalion:
If you bavc nny questions aboUl taking part in this SlUdy, you can meet wilh lbe
investigatorwhoisincbargeoflbeSlUdyatthisinstilUlioo.Thalpersonis:
Oryoucnntallc to50meone who is 001 involved with lbeslUdyalaJl. bUI can odvise you on
your rights ass participanl in a rcscarchslUdy. Thispersoocaobercachc<ithrough:
Appendix E: Medical Hearing Loss Questionnaire (cont)
Signature Page
Studylitl.: Th.c"n.tiesofH....dil...yDesrn... inNewfoundland
NameofprincipaJ invadc.tor: Dr. Terry-Lynn Youue
TohefiUedouland.ip.dbyth.participanl:
Yes {I No{.
Y.s II Noll
PlcUsechcckas ppmpriate:
Yes {. No{ I
Yes {. No{ I
Yes {} Nol}
Yes {I No( I
I bavercadthcconscnt(andinlbnnation.hect).
I bavebad the opportunity 10 uk queSlionsilO discuss thi.study.
lbavercceivedsall.facloryanswentoaUol'myquestions.
I bavereeeivcdenouih infol111Ationobout thc study.
I bavespoken 10 Dr. Young or her rcsean:h ....istlUuandshe
bas ons_rcd my questions.
I understand thaI lamfrccto withdraw from the study
• at any time
• without having to give a reason
• withoutaffectingmyfuturecare
1 understand thnl itis my choice to be in Ihe study and Ihat [may not benefit.
• agree lhllt the study doctor or invesligalor may read the p:lrtS of my hospital
rceordswltieharerelevanllOthestudy.
I ail'ee to lakel!Jl(t inthi••ludy. Y•• {} No II
oate
pale
TobeJIgaedbytbeinvesrigalor:
I baveexplaincd this study to thc beslofmyability. I invit.cd questions and guv.onsw.rs. I believe
that the participont fully undel'SlaJ1dswhal is involvcd in beiDgiD thcSlUdy. any polenlial risksol'
the.tudyandthatheorshl'basfrcclycIloSCDlObeinthcstudy.
Signatureofinvestigalor
Telephonenumber. _
suatorminorpal"tkinantfir.ppronriateol:
SignalW'eofminoT'panicipant
R.lationsltip 10 panicipant namcd above
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Abstract
The purpose of this study was to detenninethe genetic cause of hearing loss in28
Newfoundland families with Autosomal Dominant hearing loss. AD hearing loss is
highly genetically heterogeneous, and is mainly associated with a lateonset,progressive
phenotype. After a comprehensive literature search,genotype-phenotypeevaluatioDS,and
a functional candidategeneapproach,all 28 probands were sequenced to identify
mutations in four genes known to cause autosomal dominant hearing loss, COCH,
KCNQ4, TECTA, and MfO/A. First, a known Dutch founder mutation within exon 4 of
COCH, c.151 C>CT, was found in a Newfoundland proband of Family 2094. All affected
family members (n=7) shared this mutation, while unaffected members did not. This is
only the second family found to harbor this mutation outside of Europe. Th is mutation is
strongly associated with severe vestibular decline. Affected Family 2094 members
carrying the mutation do present vestibular decline in the form of vertigo and balance
difficulties. As this mutation is considered to be a Dutch founder mutation, DNA samples
from a Dutch p.P51P/S family were genotyped and compared with Family 2094
genotypes. Fragment analysis confirmed haplotype sharing of five markers closely
bordering the c.151 C>CT mutation between Newfoundland and Dutch mutation carriers.
Second, a novel3bp deletion in exon 5 of KCNQ4 was found in 13 affected members of
Family 2071. While the mutation was not seen in four other affected family members,
audiology test results suggest that these four individuals are phenocopies.Sequencingof
the full KCNQ4 gene was done in all individuals, to rule out another mutation on the
same gene. Further investigation, through the construction ofan intragenic haplotype, did
not point to any further hearing loss associated variants within KCNQ4, and confirmed
that all deletion carriers share a common hearing loss haplorype and deletion. Third,a
nonsense mutation was found in exon 4 of MYOIA in the prohand of ewfoundland
Family 2102. This is a C7T nucleotide substitution (c.2435 C>CT) that causes a change
(p.R93X) in the motor domain of myosin lAo Offour individuals in Family 2102, three
were found to carry the p.R93X mutation, while one unaffected sibling was not. This
mutation has been reported once before in a small Italian family. No mutations were
discovered in the TECTA gene. When each of the causative mutations in COCH, KCNQ4,
and MYOIA was detected, additional Newfoundland hearing loss probands were
screened,to rule out the possibilityofa founder mutation. In no case were additional
mutation carriers identified. While no founder mutations were discovered in this study,
the genetic cause of hearing loss was identified in three families.
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Cbapter 1: Introduction
Purpose
The aim of this research project is to determine the genetic etiology ofautosomaI
dominant (AD) hearing loss in 28 ewfoundlandfamilies.
Overview
Hearing loss is the most common sensory disorder in humans. For example, one
in every 500 newborns has hearing loss (Morton & Nance, 2006). The prevalence of
hearing loss increases dramatically with age, and by puberty, the number of affected
persons doubles (Morton & Nance, 2006). Hearing loss is even more prevalent in adults,
as 60 % of people older than 70 years have a hearing loss of 25 dB or more (Gratton &
Vazquez,2003).
Hearing loss is a multi-factorial disorder caused by both genetic and
environmental factors. Genetic factors account for 50 % of all hearing loss cases, while
environmental factors cause 25 %. The remaining 25 % are classified as being of
unknown etiology (Willems, 2001). Environmental causes of hearing loss include
exposure to high sound decibel levels, head trauma, prematuriry, neonatal hypoxia, low
birth weight, prenatal infections from "TORCH" organisms (i.e., toxoplasmosis, rubella,
CMV, and herpes), and postnatal infections like bacterial meningitis (Willems, 2001;
Bitner-Glindzicz,2002).
Approximately 30 % of genetic cases aresyndromic: the phenotype includes other
signs and symptoms throughout the body in addition todeafuess. Over 400 genetic
syndromes include some degree of hearing loss (Gorlin et al. 1995; Nie et al. 2008). Two
examples are Usher syndrome (USH): hearing loss accompanied by retinitis pigmentosa,
and Pendredsyndrome: a hearing loss disorder accompanied by goiter, whichisa
swelling in the thyroid gland. However, the vast majority, around 70%, of inherited
hearing disorders are non-syndromic (Cremers et al. 1991; Van Camp et al. 1997).
Worldwide, within non-syndromic cases, 88 % of the hearing loss genes identifiedcause
autosomal recessive (AR) hearing loss, II % AD, and the remaining 1% either
mitochondrial or X-linked (Smith & Van Camp, 2007).
The five factors used to describe hearing loss are age of onset, sound frequencies
affected (low, middleorhigh),degreeofhearing loss (measured indBs),affectedpartof
the auditory system (conductive, sensorineural or mixed), and configuration(unilateral,
or bilateral).
Hearing loss has a high degree of genetic heterogeneity. A large number of
mutationswithinmanydifferentgenescausesimilarhearinglossphenotypes.AsofMay
20 I0, the Hereditary Hearing Loss Homepage listed 141 non-syndrornic deafness loci
that have been mapped and 50 genes that have been identified. Twenty-two of the 50
known genes harbor mutations that cause AD hearing loss (Table 1.1), 33 cause AR
hearing loss, and 2 cause X-linked hearing loss (Van Camp G, Smith RJH
http://hereditaryhearingloss.org). Loci fornon-syndromichearing loss are denoted
'OFNA' for AD inheritance, 'DFNB' for AR inheritance and 'OFN' for X-linked
inheritance (Griffith & Friedman, 2002). Some genes cause both AD and AR hearing
loss. For example, Grifa et aI. (1999) found a C7T change in gap junction protein, beta 6
(GJB6) that resulted in the substitution ofa highly conserved threonine residue for a
methionine at amino acid position 5 (p.T5M), resulting in nonsyndromic AD hearing
loss. While this GJB26 mutation causes AD hearing loss, Del Castillo et al. (2002)
identifieda342kbdeletioninGJB6bystudying422unreiatedsubjectsfrom Spain and
Cuba with an AR pattern of inheritance.
Pedigrees
When studying hearing loss, or any hereditary disorder, farnily members are
visualized on a pedigree chart, which in this study shows all known hearing loss
phenotypes presented at the time of clinical and audiological testing. This allows easier
identification of the inheritance pattern and of the relationships among haplotypes.A
haplotypeisacombinationofallelesthataretransmittedtogether.Whenacausative
mutation is found, alleles of linked markers are assessed in order to develop a haplotype,
orpedigreethatillustratessharedgeneticvariantsbetweenfamilymembers.These
haplotypes are then compared between members of the same family or between members
of different families that share the same mutation. A common haplotype with the same
mutation suggests acomrnon ancestor for that mutation. Furthermore,ahaplotypecan
point to associations between different variants that may be combining to affect the
phenotype.
Audiograms
Aucliograms are graphs of the minimal level of sound that a given person can hear
at various frequencies (Figure 1.1; Figure 1.2). They are produced usinganaudiometer,a
machine that tests hearing by exposing patients to a range of sounds at different pitches
and decibel (dB) levels. Duringhearingtests,separateaudiogramsareobtainedfor each
ear. Each line on the aucliogram represents one ear. The y-axis measures sound intensity
in units of dB, which increases logarithmically. The x-axis of the audiogram measures the
frequency, or pitch, of a sound in Hz (Hertz). Low pitch sounds have low frequencies «
500 Hz), medium pitch sounds have medium frequencies (500 - 2000 Hz), and high pitch
sounds have high frequencies(> 2000 Hz). Hearing loss is characterizedbyintensity,
whichcanbemild,moderate,severeorprofound,andbywhichfrequencyisaffected,
such as low, middJe or high.
An individual with normal hearing can detect soundsbelWeenOdB and 20 dB.
The minimum level of hearing, 0 dB, is equivalent to a barely audible whisper. Those
affected with hearing loss, however, have a higher than normal minimum hearing level.
ThismeansthatanygivensoundintensitymustbegreaterthanOdBforthemtohearit.
People with a mild degree of hearing loss can onJy hear sound at intensities belWeen20-
40 dB for the frequencies of500-4000 Hz. lnclividuals with moderate hearing Iosscan
onJy hear sound from 40-70 dB, and those with severe hearing loss can onJy hear sound
belWeen70-95 dB in intensity. Lastly, those with profound hearing loss cannot detect
soundatallunlessitis95dBorgreater(suchasthesoundproducedbyan.MP3player
at maximum volume; Mazzoli et al. 2003).
Figure 1.1 shows a series of simple audiograms: audiogram A shows an
individual with normal hearing, B an individual with moderate bilateral (affecting both
ears)hearingloss,andCanindividual with severe bilateral hearing loss. However,
audiogramsareoften not so simple to read. Figure 1.2 shows two additionalaudiograms:
audiogram A shows an individual with moderate to mild hearing loss in the left ear and
nonnal hearing in the right ear (unilateral), and B shows an individual with bilateral
hearing loss sloping to moderate and profound at the higher frequencies. This
audioprofile is typical ofpresbyacusis, or age-related hearing loss. 4O%ofthepopulation
older than 65 years of age isaffected,and 80 % of hearing loss cases occur in elderly
people (Gates & Mills, 2005). It is now generally accepted that presbyacusis is most often
caused by age-related declines in the auditory system, such as loss or deterioration of
sensory cells within the cochlea. Moreover, impaired temporal processing is associated
with age-related factors that affect neural synchrony of hearing (Schuknechtetal.1993;
Friedman 2003; Wu et aI. 2003; Fitzgibbons et aI. 2010). Temporal processing refers to
the processing of acoustic stimuli overtime. Temporal processingallowsusto
distinguish speech from background noise, as the decibel levelsofthebackgroundnoise
Another common and important characteristic of presbyacusis, and of any
sensorineural hearing loss, is the level of speech discrimination a patient demonstrates.
Hearing a sound does not always translate into properly distinguishing speech. Testsare
also performed to determine a patient's speech discrimination. Themeasureofspeech
discrimination is often a percentage, and describes the ability ofa patient to correctly
identify words when the sound is loud enough for them to comfortably hear. When a
patient has low speech discrimination, a hearing aid will successfully amplify soundin
the patient's ear, but will not necessarily improve speech perception. The amplified sound
remains gibberish to the patient because he/she is unable to identify the words.
(McAlister, 1990; Kodera et al. 1994). A cochlear implant, a surgically implanted
electronic device that provides sound to profoundly deaf or severely hardofhearing
individuals, has been found in many cases to markedly improve speech discrimination
(Leung et al. 2005; Cambron, 2006; Yueh & Shekelle, 2007).
Autosomal Dominant Hearing Loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) accounts for
approximately 15 % of inherited hearing loss (Hildebrand et al. 2008). To date, 59 loci
for ADNSHL have been identified, along with 22 causally related genes (Table 1.1; Van
Camp G, Smith RJH. Hereditary Hearing Loss Homepage.
http://hereditaryhearingloss.org). The majority of AR hearing loss cases are caused by
mutations in just a few genes, most notably gap junction protein beta 2 (GJB2) and GJB6.
This contrasts sharply with AD hearing loss, which is significantly more genetically
heterogeneous (Griffith & Friedman, 2002), making cost-effective screening for
diagnosis in a clinical setting highly problematic. Mutations within the genes wolfram
syndrome I (WFSI), cocWin (COCH), potassium voltage-gated channel 4 (KCNQ4), and
tectorin alpha (TECTA) are marginally more frequently reported in comparison to the
other reported causative genes. The audioprofilesometimes provides clues to the
underlyingcausativegene.Forexarnple,WFSlharborsmutationsfoundin75%0f
families segregating forAD,non-syndromic hearing loss that initially affect onJythelow
frequencies (Young et aI. 2001; Bespolovaetal. 2001).
ADNSHL is often characterized by a post-lingual, late-onset, progressive
phenotype that affects mainly adults. Post-lingual hearing loss is much more frequent
than pre-lingual hearing loss, and affects 10 % of the population by the age of60 (Van
Carnpetal.l997).Thismostoftenresultsfromdarnagetoauditoryhaircells(AHCs)or
their innervation (Gates & Mills, 2005). Forexarnple, one late-onsetprogressivehearing
loss associated gene is eyes absent homolog 4 (EYA4), a member of the vertebrate Eya
family of transcriptional activators. Mutations in this gene werefoundinBelgianand
USA families, and create premature stop codons leading to post-lingual, progressive, AD
hearing loss. EYA4 was subsequently shown to be critical in the continued function of the
mature organ of Corti, an organ in the cocWea that contains the AHCs (Wayne et aI.
2001).
Critical Considerations When Researching Autosomal Dominant
Hearing Loss
Of the 28 farniliesresearched in this study that are classified as having an AD
pattemofinheritance,oneormoremayhavebeenincorrectlyclassifiedduetoalackof
sufficient data. Many individuals in these pedigrees (Figure 2.1) areascertained through
relatives' word of mouth. For this reason, itisimportanttodiscusstheroIe that different
factors may be playing in confusing the ascertainment of individuals andthusthesearch
for causative hearing loss mutations.
Digenicinheritanceiswhenaphenotypeisexpressedonlyifaninteraction
between two mutant alleles in two separate genes occurs (Strachan & Read, 2003).
Digenic inheritance does not cause AD hearing loss, but digenic inheritance may playa
role in the hearing loss of one of the families under investigation in this study. For
example, Chen et aI. (1997) reported a small consanguineous family with three affected
and three unaffected members. Two regions shared by the three affected individuals were
identified, one on 3q21.3-q25.2 (LOD =2.78) and 19pI3.3-p13.1 (LOD = 2.78). LOD
(Logarithm (base 10) of odds) isa statistical test used to determine the likelihood of
obtaining test data if two loci are linked compared to the likelihood ofobserving the data
by chance. Chen et al. (1997) speculated that two non-allelic recessivemutations
accounted for the profound congenital deafness in this family. In a Chinese family, Liu et
aI. (2009) demonstrated through DNA sequencing that mutations in GJB2 and GJB3
interact to cause hearing loss in digenic heterozygotes. To support this,they discovered
overlapping expression patterns of GJB2 and GJB3 in the cochlea, along with co-
assembly of the GJB2 and GJB3 proteins when co-transfected in human embryonic
kidney (HEK) cells (Liu et aI. 2009). And a third example was seen recently when
mutations within ATP sensitive inward rectifier potassium channel 10 (KCNJJ0) and
solute carrier family 26, member 4 (SLC26A4) were found to cause digenic non-
syndromic hearing loss associated with enlarged vestibular aqueduct syndrome (EVA)
(Yang et aI. 2009). Mutations in SLC26A4 were previously shown to cause Pendred
syndrome (PS), a genetic disorder leading to hearing loss and goiterwithoccasional
hypothyroidism. Many individuals with an EVAlPS phenotype had only one disease-
causing variant in SLC26A4. Yang et al. (2009) identified double heterozygosity in
affected individuals from two separate families. These patients carry single mutations in
both KCNJIO and SLC26A4, and the mutation in SLC26A4 has been previously
associated with the EVAlPS phenotype. The KCNJIO mutation reduces potassium
conductance activity, which is critical forgeneratingandmaintainingproper ion
homeostasis in the ear. To add further support to theirdigenic interactionhypothesis,
Yang et al. (2009) demonstrated haploinsufficiency of Slc26a4 in Slc26a4+/- mouse
mutants resulted in reduced protein expression of KcnjIO in the innerear.
One important term to keep in mind when researching AD hearing loss is
penetrance.Penetrancereferstotheproportionofindividualswithamutationwho
exhibit clinical symptoms. For example, if a mutation in a gene responsible for a type of
AD hearing loss is 95 % penetrant, then 95 % of individuals with the mutation will
exhibit symptoms, while 5 % will not during their lifetime. Penetrance is often expressed
asa frequency at different ages because, for many hereditary diseases,onsetofsymptoms
is age-related (Strachan & Read, 2003). This is particularly important because AD
hearing loss is often late-onset and progressive. Forthisreason,afarnily'sinheritance
pattemcould appear to be sporadic, when in fact the disorder segregatesautosomal
dominantly, and the individuals understudy simply haven't yet presented the hearing loss
phenotype, as the age of onset varies widely and can range well into 50 years 0 fage.A
related but distinct potential problem isexpressivity. Expressivity refers to variations ofa
phenotype for a particular genotype. When a condition has highly variable signsand
symptoms, it can be difficult to diagnose.
Mitochondrial inheritance could also be confusing the ascertainment of the
families investigated in this study. Mitochondrial inheritance is the inheritanceofatrait
encoded in the mitochondrial genome, and is always of maternal origin. It is therefore
often also called maternal inheritance. When a woman harbors a mitochondrial mutation,
and her egg cells are forming an ovary, these egg cells contain a random distributionof
both normal and mutated copies of the mitochondrial gene(St. Johnetal. 2010).
Therefore, all children of this mother may inherit some mutated mitochondria, but if the
number of mutated mitochondria reaches a critical level, termed the "threshold effect",
then an adverse phenotype is seen (St. John et al. 2010; Van Camp G, Smith RJH.
Hereditary Hearing Loss Homepage). These mitochondrial hearing loss mutations can be
late-onset, or if the carrier is administered certain antibiotics, the phenotypewillbe
"drawn out". This is the case with mutations in MT-RNRI, which are known to cause
non-syndromic deafuess (Casano et al. 1999; Bates 2003). Mitochondrial mutations are
beyond the scope of this study, but have previously been shown to cause late-onset
hearing loss that is comparabJe to thephenotypesofFarnilies2093,21 12, and 2125
investigated here (Casano et al. 1999). While there are no incidences of male to male
transmission in these families, additional clinical ascertainment could potentially reveal a
mitochondrial inheritance pattern. This study primarily targets only genes and mutations
known to be associated with AD hearing loss, but the possibility of maternally inherited
mutations causing hearing loss in the above mentioned farnilies shouldnotberuledout,
and should be investigated in future studies.
As a result of random genetic drift in the founder population of Newfoundland,
there is an elevated incidence of particular rare disorders, such as Bardet-Biedlsyndrome
(Webb et a1. 2009). This makes the founder population ofNewfoundland ideal for the
study of genetic disorders and increases the chance of detecting novelcausativegenes
and mutations. However, due to the nature of Newfoundland as a genetic isolate, some
potential pitfalls arise. One potential pitfall is the uncertainty in inheritance
ascertainment. For example, assortative mating could confuse the ascertainment of
farnilies and therefore the search for hearing loss mutations. Assortative mating occurs
when sexually reproducing organisms choose to mate with individuals that are similar
(positive assortative mating) or dissimilar (negative assortative mating) to themselves in
some specific way. One family under investigation in this study (Family 2069) is a
potentialexampleofpositiveassortativemating(seep.42,bottompedigree,sth
generation). This is critically important. Positive assortative matingcould result in both
parents carrying a mutation that causes hearing loss. Thismay,however,sinlplybea
result of studying a genetic disorder in ahigWy isolated population, and it is possible that
this mating took place not because both individuals were affected by hearing loss, but
instead due simply to the low level of mating choice in small out-port community. Either
way, our current inheritance classification ofNewfoundland Family 2069 could possibly
beincorrectlystatedasAD,andourcandidategeneselectionwouldthenbe based on
unfounded and false assumptions. It is inlportantto keep this possibility under
unfounded and false assumptions. It is important to keep this possibility under
consideration, and to investigate and screen for comrnonlyoccurring recessivemutations
in the proband of Family 2069 as well as dominant mutations. Pseudo-dominance should
also be taken into account. This is the situation where the inheritance of an ARtrait
mimics an AD pattern, and due to the limited extent of clinical ascertainment in these
families' histories, it is possible that one of these AD families is in fact affected by an AR
mutation segregating in a pseudo-dominant fashion.
Another critical factor to judge when researching genetic hearing loss isthe
possible presence of phenocopies. A phenocopy is an affected individualwhohasthe
same disease, but due to a different cause, as relatives affected with the genetic condition
understudy.Hearinglossisaveryconunontypeofsensorylossinhumans.Many types
of environmental and genetic factors account for hearing loss so individualswithin
families affected with hearing loss can beaffiicted due to a plethoraofdifferentreasons
(Griffith & Friedman 2002). For example, a study of heterozygous WFSl mutations in
lWO low frequency sensorineural hearing loss families showed that theselWo families'
hearing loss were linked to adjacent but non-overlapping loci on 4p16, DFNA6 and
DFNAI4 (Van Camp et al. 1999). Upon further study, it was found that an individual in
the DFNA6 family who had a recombination event excluding the DFNA 14 candidate
region was actually a phenocopy. The cause of hearing loss in this phenocopy was
reported as unknown, but as a consequence they were able to detennine that DFNA6 and
DFNAI4 are allelic (Bespalova et al. 2001).
Throughout this study genes are investigated through targeted gene sequencing.
However, it must be mentioned that it is possible larger genomic abnonualities may
account for hearing loss in some of the NewfoundJand families under investigation
(Lisenkaetal. 2003; Shafferetal.2006). Large genomic rearrangements, deletions,
inversions, etc. can cause and affect the degree and severity of diseases, and these large-
scale anomalies are not detected through traditional DNA sequencing methods (Lisenka
etal. 2003; Idbaihetal. 2010).
The Pioneering of Hearing Loss Gene Discovery
The first genes to be implicated in hearing loss were found in the syndromic
disorders. Syndromic fonus of hearing loss are classified by their associated symptoms.
For example, Waardenburg syndrome (WS) is the most common cause of AD syndromic
hearing loss. WS is characterized by varying degrees of hearing loss associatedwith
pigmentationanomaliesandneuralcrestdefects.ltwasfirstdescribedin1951, but it took
several decades to identify the causative genes. Asher and Friedrnan (1990) studiedrnice
and hamsters with four mutations causing phenotypes similar to those seen in human WS
patients. They used the chromosomal locations and syntenic relationships associated with
three of these four mutant mouse genes to predict human chromosomal locations for the
causativeWSgene.Syntenyisthesituationwherebyorgarusmsofrelatively recent
divergence show similar blocks of genes in the same relative positions in the genome.
Asher and Friedman (1990) predicted four possible locations for the causative gene, and
oneturnedouttobecorrect.InI992,mutationscausingWSwerediscovered in the
paired box gene (PAX3) gene (on chromosome 2q) (Tassabehji et a1. 1992). A second
common cause of AR syndromic hearing loss is Usher syndrome (Toriello et al. 2004).
Usher syndrome was first described in 1858 when Van Graefe reported the case of a deaf
and "dumb" male patient presenting with retinal pigment degeneration, who had two
similarly affected brothers (Van Graefe, 1858). This was the first syndrome to
demonstrate that phenotypes, in this case deafness aod blindness, cou1dbe inherited in
taodem. Usher syndrome is characterized by profound congenital hearingimpairment,
retinitispigmentosa, and vestibular dysfunction. Ithasthreeclinicaltypes, denoted as I,
II, andIII,indecreasingorderofseverity(Saihanetai. 2009). In 1995 oneofseveral
causative genes for Usher Syndrome Type I was discovered. Weil et a1. (1995) chose
myosin 7A (MYOVlIA) as a functional candidate gene, based on observations that
cytoskeletal abnormalities seen in Usher syndrome patients are also seen in mouse
mutants with myosin mutations. Two different premature stop codons, a six bp deletion,
and two different missense mutations were detected in five unrelated families. In one
family, these mutations were identified in both aJleles, and resulted in the absence ofa
functionaiproteinandsubsequentUshersyndrome(Weileta1.1995).CurrentlY,IO
different types of Usher syndrome have been recognized, with more than I 00 pathogenic
mutations alone for the two most common molecular forms, Usher IB (USHIB) and
Usher 2a (USH2A; Ahmed et al. 2003; Saihao et al. 2009).
The first ADNSHL family investigated was from the small town of Taras, Costa
Rica. The hearing loss was described as low frequency AD with a post-lingual age of
onset at 10 years of age (Leon etal. 1981). Leon et aI. (1992) performed linkage analysis
to determine that the causative gene was linked to markers defining a 7 cM critical region
on chromosome 5q31. Genetic markers are DNA sequences with a known location on a
chromosome,andareusefulinlinkageanalysisbecausetheyareeasilyidentifiable,
associated with a specific locus, and highly polymorphic. LODscoresfor linkage of
deafness to markers in the 7 cM region showed a score of 13.55 at markers D5S2119 and
D5S20 I0 (Leon et aI. 1992). This was not only the first AD critical region described, but
the first autosomal non-syndromic hearing loss gene to be mapped altogether.ltwasnot
until 1997,26 years afterfirstbeingreported,thatthe region was narroweddownfurther.
Positional cloning, sometimes referred to as reverse genetics, is the cloningofanarea
known to be associated with a disease. It involves the isolation of overlapping DNA
segments that progress along the chromosome toward a candidate gene. Lynch et aI.
(1997) performed fine mapping using positional cloning techniques to narrow the critical
region to I cM. This revealed protein diaphanous homolog I (DIAPHI), a previously
unidentified human gene. DIAPHI, in this case, is a positional candidate gene, a gene
identified based upon a determined critical region. This differs from functional candidate
genes, which are known to play a role in the disease pathology, or have been previously
shown to harbor mutations that cause a disease, like the p.A716T mutation in WFSI in
Newfoundland (Young et aI. 2001; Bespalova et aI. 2001). Lynch et aI. (1997) sequenced
the positional candidate gene DIAPHI in all affected family members using Single Strand
Conformation Polymorphism (SSCP) analysis. SSCP is the electrophoretic separation of
single-strandednucleicacidsbasedondifferencesinsequenceswhichbringabouta
different secondary structure and thus a measureabledifference in mobility through a gel.
The causative mutation, a G7T substitution, was now revealed, and DIAPHI was also
found to be higWy expressed in the cochlea (Lynch et a1. 1997). Lynchetal. (1997)
speculate that the protein this gene encodes, protein diaphanous homolog l,plays a role
in the regulation of actin polymerization in the hair cells of the cochIea.
Founder Populations & Mutations
No surnmary of hearing loss associated genes and mutations would becomplete
without mentioning the importance of founder populations, the foundereffect,and
founder mutations. A founder population isa small subpopulationthat has been isolated
due to geography, culture, religion or a combination of these. This subpopulation has a
significantly decreased amount of genetic diversity, causing certain genetic traits to either
vanish or become very abundant in further generations. When a founder populationis
isolated individuals in later generations are likely to share many genes, because a
mutation in a founder will be passed onto a large proportion of the populationin
subsequent generations (Nurhousen, 2000). Founder populations, therefore,possessmuch
promise in determining the genes involved in genetic diseases. As thereislittlegenetic
heterogeneity, the majority of the individuals with a given disease will carry the same
gene mutation. For example, the Ashkenazi Jews were a reproductively isolated
population in Europe for roughly a thousand years, with very littleout-migration or inter-
marriage with other groups (Nebel et al. 2005). As a result of this event, the GJB2
mutation c.167delTwas found to be highly prevalent in the Ashkanazi Jewish population
(Morell et al. 1998). Other examples of founder populations include the Canadian
province of Quebec, which was established by as few as 2600 individuals, the United
States Amish population, and the populationofPingelap, a small island in Micronesia.
A founder mutation is a mutation found as an allele and shared by several
individualsfromafounderpopuJationandderivedfromasingleancestor.For example,
COCH p.P51P/S mutation carriers are considered to have originated from a common
ancestor (de Kok et aJ. 1999). A second example was recently seen when Park et al.
(2010) investigated the 3-bp deletion in intron7(c.991-15_991-13del) ofDFNA5, and
identified a conserved haplotype between a Korean family and a Chinese family
segregating the deletion in DFNA5, suggesting that this deletion represented a founder
mutation originating from a common ancestor.
Colonization of Newfoundland: A Founder Population
The island ofNewfoundland makes up a large part of the Canadian province of
Newfoundland & Labrador. It is the most easterly landmass on the North American
continent. In 1497 the European explorer Giovanni Gabotto (John Cabot) "discovered"
Newfoundland, though Vikings had landed earlier. Europeans voyaged across the North
Atlantic from England, Scotland, Ireland, France and Portugal to harvest the rich fish
stocks. When each fishing season ended they returned to their countries, as permanent
thoseconsideringpermanentsettlement,andwithalackofbasicsupplieseven a one year
stay would have been very difficult (poole & Cuff, 1994). This deterrence lessened
throughout the 17th century, however, as small groups of English, Scottish, and Irish
settlerssetsailfromwesternEnglandin16l0andthroughoutthel71h century.These
colonists excluded other nations from fishing off ofNewfoundland's east coast, but were
discouraged in their settlement by the English government, who saw their presence as a
threat to the monopoly control that Western England fishing centers had established.
Meanwhile,fishermanfromFrancedominatedtheisland'ssouthcoastandnorthem
peninsula (Bennett, 2002). Throughout the l600s, the French began to permanentlysettle,
but in 1713, with the Treaty of Utrecht, the English gained control of the south and north
shores of the island. Permanent settlement increased rapidly by the latel8 th century,
peakingintheearlyyearsofthel800s.
The colonization ofNewfoundland began in earnest in the early 191h century
mainly from Southwest England and Southeast Ireland. Fisherman brought their families
to the island, intending to settle permanently, and these families are the foundersofmuch
of today's Newfoundland population. Ninety percent ofNewfoundland's population
descends from roughly 30 000 founders (parfrey et al. 2009). Farniliessettledinsmall
inlets along Newfoundland's coast in groups of one or two families. These communities
developed in geographical and cultural isolation, and can becharacterized by large
families, and a strong founder effect (Bear et al. 1987). This isolation aIso directly led to
manygenerationsofinterbreeding(Poole&Cuff,1994;Hancock, 1989).
families, and a strong founder effect (Bearet a1. 1987). This isolationalso directly led to
many generations of interbreeding (poole & Cuff, 1994; Hancock, 1989).
Largeextendedpedigreesfromgeneticisolateshavebeeninstrumentalinthe
identificationofgeneticcausesofhereditarydisorders.Severalfoundermutationshave
been identi.fied in Newfoundland. For example, an exon 8 deletion in MSH2, a gene
causing hereditary non-polyposiscolorectal cancer, has been found in five different
Newfoundland families (N=74 carriers), and an intron 5 splice site mutation
(c.942+3A>T) has been found in 12 different Newfoundland families (N=151 carriers)
(Frogattetal, 1996; Stucklessetal.2006). A third example is a founder mutation
(c.782+3deIGAG) found in the deafness gene TMPRSS3 in two different Newfoundland
families (Ahmed et al. 2004; Young et al. unpublished data). These are just a few
examples of founder mutations identified in Newfoundland, and serve to higWight the
importance of genetically isolated Newfoundland families in the study of hearing loss. At
the beginning of this study, only six hearing loss associated genes had been identified in
the Newfoundland population (Table 1.2). There is a possibility that a founder mutation
exists and could be found in some of these 28 Newfoundland families. When a founder
mutation is identified,theprevalenceofthis mutation indifferent worldwide populations
canbecompared,and better estimates of risk for individuals in the founderpopulation
can be calculated. The presence of founder mutations in Newfoundland could thus have
strong clinical implications in terms of improved diagnosis and the abilityto routinely
screen individuals if a founder mutation is common enough in the population.
with Bardet-Biedl syndrome (Webb et al. 2009). So while many Newfoundlanders can
trace their roots to roughly 30 000 founders, it is critical to keep in mind that these
founders came from different towns and different regions. The current population of
Newfoundland & Labrador, according to a 2006 census, is 505 469. A map of
Newfoundland & Labrador is seen in Figure 1.3.
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Figure 1.1 Examples of Audiograms. A) Audiogram of an individual witb normal
bearing in botb ears. B) Audiogram of an individual witb moderate bearing loss in
botbears. C) Audiogram of an individualwitb severe bearing loss in botb ears.
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Table 1.1 AD Non-Syndromic Deafness Genes Identified Worldwide to Date (Van
Camp G, Smith RJH. Hereditary Hearing Loss Homepage.
http://hereditaryhearingloss.org,May2010)
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Table 1.2 Deafness Genes Identified in the Newfoundland Population at Beginning
of This Study.
Denoi~~;et aI.
Del Castilloet aI.
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Chapter 2: Methods & Materials
Human Subjects & Pedigrees
This study is one part ofa larger study to determine the genetic cause of hearing
loss in Newfoundland & Labrador. Family members were recruited through the
Newfoundland Provincial Genetics Program, and a province-wide ascertainment drive.
Informed consent was obtained from all participants, granting researchers permission to
access medical records and family history. Blood samples were collected and genomic
and mitochondrial DNA was extracted from peripheral leukocytes from participants.
Audiological tests were performed to determine the type of hearing loss of each subject
and to confirm normal hearing in unaffected subjects. Audiograms are available for all
individualsmarkedwithanasteriskinFigure2.I,andforeachoftheseindividuals
several audiograms are available at different test ages, with new ones routinelybeing
collected. DNA from several Dutch individuals was provided by Dr. Hannie Kremer of
the Radboud University Medical Centre in Nijmegen, Netherlands. This project was
approved by The Human Investigations Committee (HlC) (Research Ethics Board of
Memorial University, Newfoundland & Labrador) (# 01.186).
So far, 128 probandshave been recruited to the study. All probands in the study
were routinely screened for mutations previously identified to causehearinglossinthe
Newfoundland population. Of these, 28 probands are members of multiplex families with
a family history of hearing loss consistent with AD inheritance, and were chosen for this
study (Figure 2.1). Inheritance patterns were determined through an extensivefamily
history questionnaire, and pedigrees were electronically stored using the computer
program Progeny. Many individuals' hearing loss was determined by word 0 fmouth
from family members. In these cases, the age of onset and the degree and severity of
hearing loss are not known. For this reason, the determination of an AD pattern of
inheritance is not certain in some cases, but these fanJ..ilies were deemedtolikelyhavean
AD form of hearing loss, and it was therefore worth testing them for potential AD
hearing loss mutations. Due to the extent of genealogy work possible in Newfoundland
up to this point, it is important to keep other potential forms of inherited hearing loss,
such as nJ..itochondrial inheritance, innJ..ind when searching for causative mutations.
Experimental Design: Functional Candidate Gene Mutation Screening
GenonJ..ic DNA from probands (n=28) was screened using a functional candidate
gene approach. A comprehensive literature search was done to collect information on all
AD hearing loss genes. One recent review (Hilgert et aI. 2009) discussed in depth the
genes causing AD hearing loss. It describes how each gene associated with AD hearing
loss functions in the ear, and what types of hearing loss they cause. For each of these
genes, the mutations found both worldwide and within Caucasianpopulations are
described in detail. Many of these genes may be causative in Newfoundland families
(Table 2.1).
This literature search formed the basic foundation from which genotype-
phenotype evaluation was performed. Potential candidate genes were investigated for
specificcase-by-case details on the hearing loss phenotype each mutationcaused, and in
what population and ethnicitytheywere reported. These phenotypes were then cross
checked with the phenotypes of the 28 families to further narrow down the functional
candidate gene list to four: COCH, KCNQ4, TECTA, and MYOIA (see Figure 2.2). This
approach is a form of audioprofiling, a method ofcategorizingphenotypic data to make
genotypic correlations. The audiological data of several members in a family, or in this
case several probands from different families, associates with a specific unknown
genotype as a function of time (Meyer et aI. 2007). From this, we have drawn correlations
to the overall phenotype of the group of probands and used this as afoundation for
selecting candidate genes previously reported to cause hearing loss with a similar
phenotype.
Information on all known hearing loss mutations in these four candidate genes
was next collated, including which domain and exon each mutation was reported in
(Appendix A). This allowed the identification of the exons most likely to harbor
causative mutations in the Newfoundland probands. For example, the majority of
mutations reported in COCH are reported in the factor c homologous (FCH) domain,
spanning exons 4 and 5, and so this area of COCH was screened first.
COCHhas a total of12 exons, and causes a late-onset, progressive hearingloss
most often associated with vestibular dysfunction (Kemperman et aI. 2005), which
correlates with several AD Newfoundland families. COCH is important in maintaining
structural support within the cocWea (Kommareddi et al. 2007). Exons screened
were 2-5, and 12. Two deletions within KCNQ4 have been reported to cause a late-onset,
progressive hearing loss (Couckeetal. 1999; Kamadaetal. 2006),matching the
phenotype of many AD Newfoundland probands. This gene is critical in ion homeostasis
withtheear(Kubischetal.1999),andiscodedbyI4exons,allofwhichwerescreened.
Missense mutations within TECTA, a second gene important in structural support within
the auditory system, have been shown to cause late onset hearing loss (\ferhoevenetal.
1998). Codedby23 exons intotai,exons 5, 9-14, 17, 18, and 20 were screened. The last
canclidategene,MYOIAisthoughttoplayaroleinsoundprocessingthroughion
transport (Donaudy et al. 2003),and again, causes alate-onset, progressive hearing loss
phenotype. Coded by a total of28 exons, exons3,4, 6, 7,10-12, 18,and22 were
screened.
While the more "targeted" candidate gene approach outlined above is likelyto
lead to the identification of mutations, it does restrict the chance of identifying potential
"genetic surprises" regarding genotype-phenotype. This method allows for a complete
investigation of possible genetic mutations in a given set of promisingcandidategenes
within the two-year time frame ofa Master's thesis. However, exons within these
canclidate genes that have never before been associated with hearing 10ssmutationsare
bi-directionallysequencedinthisstudy,andsothereispotentialfor"genetic surprises".
Because Newfoundland is a founder population, it is possible that families would
share the same mutation, particularly if those families are from the same geographic area.
When a mutation is discovered in an AD Newfoundland proband, all otosclerosis, AD,
and AR Newfoundland probands (n=68) are subsequently screened for that mutation.
Whenappropriate,apparentfoundermutationsareconfinnedbyhaplotypeanalysis, to
deterrninethe level of sharing fora selection of linked microsatellite markers bet>veen
families with the same mutation (see Figure 2.2).
General Strategy for PCR and Sequencing of Candidate Genes
Both forward and reverse strands of specific exon PCR products in each gene werebi-
directionallysequenced,alongwithallintronJexonboundariestoensurethe entire coding
region of each exon was covered. PCR primers were designed using Primer 3 software (v.
0.4.0, http://frodo.wi.mit.eduJprimer3/). Theseprimersequencescan be found in
AppendixB.
D A Preparation, PCR Thermocycling, and Electrophoresis
D A was extracted from whole blood and diluted tolO ngllli. This blood was
stored at 4 °c (performed by research assistant). I ilL of diluted (stock) D A was added
to 2 ilL lOX PCR Buffer (containing MgClz), 0.4 ilL dNTPs (10 mM), 0.08 ilL KapaTaq
D A Polymerase (5 U/IlL) (Kapa Biosystems, Boston, MA), 12.92 ilL of distilled dHzO,
1.0 ilL offorward primer (10 11M) and 1.0 ilL of reverse primer (10 11M), as per standard
PCR protocol. The amount of dHzO was reduced to add betaine or Dimethyl Sulfoxide
(DMSO) when necessary to achieve a successful amplified PCR product. This mix was
centrifuged and addeqd to wells in 20 ilL aliquots in a 96-well PCR plate, where it was
then sealed, centrifuged, and placed in the GeneAmp PCR System 9700 thennal cycler
(Applied Biosystems, Foster City, CA). PCR products were electrophoresed on a 1%
agarose gel (1.5 g agarose/1 00 mL TBE) stained with SybrSafe and viewed under UV
light on a Kodiak GEL LOGIC 100 Molecular Imaging system (Rochester, Y, Version
4.01,2005).
Preparation for ABI Cycle Sequencing
Sepbacryl S-300HR was resuspended and 300 ilL aliquots were added to wells
on a Millipore Multi-screen HTS plate, which was placed over a corresponding 96-well
waste plate to catch flow-through. Plates were then balanced and centrifuged at 3000 rpm
for 5 minutes. Flow-through was discarded and PCR products were added to wells on the
Multi-screen HTS plate. The Multi-screen HTS plate was then positioned and placed over
a clean PCR plate, balanced, and centrifuged at 3000 rpm for 5 minutes. The flow-
through product collected in the PCR plate contains the purified PCRproducts.
Successfully amplified PCRproducts, visualized as bands of the correct size
(using a 100bp marker) when electrophoresed on an agarose gel,werecyclesequenced
using the following reaction mix: 0.5 ilL of Big Dye Terminator V. 3.1 Sequencing Mix,
2 ilL of5X sequencing buffer, 0.32 ilL of Primer (10 11M), I ilL of purified PCR product
DNA template, and 16.l8IlLofdH20, per the Big Dye Terminator V. 3.1 protocol
(Applied Biosystems, Foster City, CA). This equals a total reaction volume of20 ilL per
well ina sequencing plate. The resulting plate was centrifuged briefly,loadedontothe
thermal cycler, and subjected to a thermal cycling program according to ABI BOT V. 3.1
protocol (Applied Biosystems, Foster City, CA).
Upon completion,S ilL of 125 mM EDTA followed by 65 ilL of95% Ethanol
(EtOH) was added to each reaction well. Plates were briefly centrifuged and then
incubated overnight in the dark at ambient temperature. The plate was then centrifuged at
3000 x g for 30 minutes, inverted to decant EtOH, and briefly centrifuged while inverted
at 200 rpm for 4 - 5 seconds with folded paper towels placed underneath the sequencing
plate to absorb residual ethanol. 150 ilL ono % EtOH was added to each sample, and the
plate was centrifuged at 3000 g for 15 minutes. Tbe plate was again inverted to decant
ethanol and spun at 200 rpm for 4 - 5 seconds over a paper towel. Samples were left to
air dry in the dark at room temperature for 10 - 15 minutes. 15 ilL of Hi-Di Formamide
was subsequently added to each well and the plate wasvortexed and centrifugedbriefly.
The final mix was denatured at 95°C for 2 minutes on a thermal cycler. Once denatured,
samples were kept on ice until placed in the ABI 3130 XL DNA Analyzer.
Automated Sequencing Using the ABI 3130 XL
Automated sequencing was performed using either the ABI 3130 XL DNA
Analyzer (Applied Biosystems, Foster City, CA) available in the lab or the ABI 3730
DNA Analyzer in the Genomic & Proteomics Facility, at CREAlT, Memorial University
ofNewfoundland. The raw sequence data were initially analyzed for quality using
Sequencing Analysis software (Version 5.2, Applied Biosystems, Foster City, CA). High
quaJity sequences were imported into Mutation Surveyor (Version 3.0,Softgenetics,State
College, PA). Mutation Surveyor identifies DNA sequence variants in the sample
sequence DNA by comparing it to a reference gene sequence.
Tracing Variants Through Families: Genotype & Haplotype Analysis
Sequencing variants were traced through the pedigrees to see if they co-
segregated with hearing loss. Haplotype analysis was performed when necessary.Table
3.4 isa list of microsatellite markers used to characterize the p.P51 PIS haplotype shared
between a Newfoundland family and a Dutch family. This was done to confmn the
founder hypothesis for the CaCH mutation p.P5IP/S (de Kok et al. 1999), identified in
this study in a Newfoundland proband. Markers were selected based on location as well
asdegreeofheterozygosityinordertoconfirmhaplotypesharingbetweenthetwo
families, which provided further evidence that p.P5IP/S is a Dutch founder mutation.
Initial setupforgenotypingrequired running PCR under standard conditions.
Each reaction mix contained 8.5 ~L of Hi-Di Formarnide, 0.5 ~L Genotyping Size
Standard G8500 (-250) LIZ, and 1 ~L of DNA, per manufacturers standard protocol
(Applied Biosystems, Foster City, CA). Post-PCR products were electrophoresed on a
1% agarose gel (I g agarose/l 00 mL TBE, pH 8.0) containing 4.0 ~L of SybrSafe 10-
000 X concentrate in DMSO (Invitrogen, Eugene, OR) and viewed under UV light on a
Kodiak GEL LOGIC 100 Molecular Imaging system (Rochester, NY, Version 4.01,
2005). The PCR product was then diluted based on its band intensity to a suitable
concenlration.Opticalplatescontainingthesesampleswerebrieflyvortexed and then
centrifuged at 1250 rpm for 10 seconds, denatured on a thermal cycler, and immediately
loaded onto the ABI 3130 XL D A Analyzer for genotyping. The PCR products from
the fluorescently labeled primers were detected by the ABI Prism 3130 XL DNA
Analyzer and genotyped using GeneMapper Software (ABI Prism, Version 4.0).
GeneMapperassisted in making allele calls at each marker for each individual,
which were then compared with other individuals and families. Once a pedigree was
conslrUcted using the software Progeny (progeny Software LLC, Delray Beach,FL),
markers were integrated for each selected individual. Allele calls, SNPs, and/or common
variants were then inpulted into each individual's data set to createapedigreeilluSlrating
the segregation of different haplotypes (Progeny Software LLC, Delray Beach, FL;
Figure 3.5; Figure 3.10).
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Table 2.1 Candidate genes for ewfoundland Families Having Late-Onset AD
Hearing Loss (Adapted from Hilgert et al. 2009).
Candidate Number of Number of Original
Gene Mutations Mutations Reference
Found Found in
Worldwide Caucasians
KCNQ4
COCH
MY06
GJB3
POU4F3
CRYM
Hair BundJe,Cytoskeletal
Formation
Transcri tionFactor
Unknown
Hair Bundle, Motor Protein
Hai.r Bundle, Motor Protein
HairBundle,Cytoskeletal
Formation
Jon Homeostasis
Ion Homeostasis
Kubischet
al.1999
Robertson
etal.1998
Donaudyet
al.2003
Verhoeven
etal.1998
Zhuetal.
2003; Van
Wijketal.
2003
Wayneet
al.2001
Donaudyet
al.2004
Melchionda
etal.2001
Liuetal.
1997
Nazetal.
2004
Van Laeret
al.1998
Xiaetal.
1998
Vahavaet
al.1998
Kurimaet
al.2002
McGuirtet
al.1999
Abe et al.
2003
Petersetal.
2002
Table 2.1 Candidate Genes for Newfoundland Families Having Late-Onset AD
Hearing Loss (Adapted from Hilgert et al. 2009) (cont).
Hair Bundle, Motor Protein
HairBundle,Cytoskeletal
Formation
HairBundle,Cytoskeletal
Formation
Lalwaniet
a1.2000
Modarnio-
Hoybjoret
a1.2007
Lynchet
a1.1997
Chapter 3: Results
Overview
The purpose of this study was to detennine the genetic etiology of hearing Iossin
28 autosomal dominant hearing loss Newfoundland probands using a functional
candidate gene approach. Candidate genes COCH, TECTA, KCNQ4, and MY01A were
chosen primarily because they have a higher frequency of mutations in autosomal
dominant families (Hilgert et al. 2009). The full GJB2 gene and the del13Sl830 mutation
in GJB6, which underlies the majority of congenital deafness worldwide, were first
excluded in all 28 probands. A heterozygous mutation in WFSl - a gene now known to
cause both syndrornic and non-syndromic deafness (Young et al. 2001; Bespalovaetal.
2001)-previouslyfound to cause autosomal dorninant hearing loss (p.A71 6T)inalarge
Newfoundland family (Young et al. 2001) was also excluded in all 28 probands. Figure
2.2 illustrates the research projects experimental progression.
Results of candidate gene screening revealed three distinct mutationscausing
hearing loss in three separate Newfoundland families. First, a C~T base change in exon
40fCOCHintheprobandofFamily2094resultedinthesubstitutionofaconserved
proline residue fora serine residue at amino acid position 51 (p.P51 P/S).Second,anovel
3bp heterozygous deletion in exon 5 of KCNQ4 was found in the proband of Family
2071. Third, a nonsense mutation was discovered at amino acid position93withinexon4
of MYOIA. This nonsense mutation, p.R93X, is due to a C~T nucleotide change, and
was found in the proband ofNewfoundland Family 2102.
Family 2094
Within COCH, exons 2, 3, 4,5, and 12 were sequenced in all 28 AD hearing loss
families. Of the 28 probands, one proband was identified with a C~T base change in
exon 4 of COCH The proband is a member of a family (Family 2094) with four
generations of documented hearing loss. The complete pedigree documents 44
individuals and extends back six generations. A partial pedigree is seen inFigure3.1.
Twelve family members have been diagnosed with AD hearing loss. A summary of
audiologyreportsandaphenotypesurnmaryarefoundinTables3.2and3.3respectively.
Theproband0l-2,Figure3.l),isa39-year-old female presenting with hearingloss.
Reports showed a bilateral hearing loss sloping to moderate lossathigh-frequencies
(Figure 3.3). Three more audiology tests were conducted over the nextthreeyears,
showing a gradual worsening of high-frequency hearing loss.
The proband is heterozygous for the C~T base change in exon 4 of COCH,
which substitutes a highly conserved proline residue fora serine residueatarninoacid
position 51 (p.P5lP/S) (Figure 3.2). Upon identification ofp.P5lP/S in the proband,
DNA from all available individuals was amplified and sequenced for exon 4. Seven out
of seven with documented hearing loss harbored the C~T transition; one unaffected (IV-
10) did not.
Search for a Vestibular Phenotype in Family 2094 Mutation Carriers
Previous studies of mutation carriers ofp.P51P/S show severe vestibular
phenotypesassociatedwithhearingloss(deKoketal.1999),somedicaJand audiological
records for all available family members were reviewed (see Figure 3.1). The proband
01-2) has not yet had any episodes of vertigo or associated vestibularproblems.Shehad
a Computed Tomography (CT) scan at 40 years of age which did not detect any
abnormalities. The probands cousin, V-6, complained of episodes 0 fdizzinessand
vertigo at age 32. She has had twoCT scans at ages 36 and 38, which did not detect any
abnormalities. Her hearing loss was first reported at age 35 as mild hearing loss in the
high-frequency range. This cousin also first reported a scratch on her left cornea at age
31. IV-I has stated he has had balance problems when walking at night since his early
50's. He had a CT scan at age 62, which detected no abnormalities. His hearing loss was
diagnosed at age 49 as moderate in the high-frequency range. 1V-5 reportedbalance
problems and episodes of dizziness from the age of 50. Audiology testingatage57
showed a moderate bilateral loss that over the foUowing 15 years progressed to severe
hearing loss across all frequencies. 1V-7 presented the typical p.P51P/S hearing loss
phenotype,andalsohadoccupationalnoiseexposure.IV-IOisanunaffectedwoman
who has not reported any vestibular problems and is not affected withhearingloss.IV-11
reported spinning dizziness and unsteadiness, along with balance problems in his early
30s.Hishearinglosswasfirstdocumentedatage49,andfurtheraudiologytests over the
following 15 years show bilateral loss beginning in thehigh-frequenciesand then
flattening out later in life to profound hearing loss across all frequencies. III-6 had
documented hearing loss from middle age, but no other data was available.
Because Newfoundland is a founder population, and this study is focused 0 nthe
identification of founder mutations, all otosclerosis, AD, and AR probands in the
Newfoundland hearing loss study (n=40) were screened for this mutation, but no
additional cases were found.
Identification of a Dutch Founder Mutation
Asp.P5IP/8 is widely believed to beaDutch founder mutation (de Koketal.
1999; Fransenetal. 2001), we genotyped the seven affected Family 2094 members,a1ong
with three Dutchp.P5IP/8 carriers, for seven microsatellite markers closely flanking the
CaCHgene, (Fransenet a1. 2001) in order to construct an ancestral haplotype. Affected
Farnily 2094 individuals and the Dutch affected individuals share a contiguousfive-
microsatellite-markerhaplotype at markers D148257, D1481071, D1481040, D1481034,
and D148 1060: 179-281-234-169-20 I. caCH sits -0.4 Mb downstream of marker
D148257. These markers closely flank the CaCH gene and constitute a total minimum
shared region of-2.1 Mb on chromosome 14ql2 (Figure 3.4; Table 3.5). The full hearing
loss haplotype shared among Newfoundland and Dutch families is shown in their
respective pedigrees in Figure 3.5. Unaffected individual IV-IOdoes notsharethis
haplotype. Furthergenotypingwasconductedforadditionalmicrosatellite markers
upstream ofD 14S 1060. Markers D 14S70 and D14S I0 14 both displayed allelic disparity
between the two families, demonstrating the relatively short length of this putative
ancestral haplotype (Table 3.5).
Family 2071
Of the 28 probands,one proband was identified to have a novel 3 bpdeletion,
p.Ser269del in exon 5 of KCNQ4 (DFNA2A). The proband is a member of a family
(Family 2071) with four generations ofdocurnented hearing loss. Thecompletepedigree
docurnents 97 individuals, extends back five generations, and reports no cases of
consanguinity (Figure 3.7). Twenty-four family members have been diagnosed with AD
non-syndromichearingloss.Asurnmaryofaudiologyreportsforparticipating
individuals is found in Table 3.7, with phenotype data shown in Table 3.6.
The proband (III-12, Figure 3.7) is a 62-year-old male presenting with abilateTa!
hearing loss sloping to moderate loss at mid-frequencies and profound at high-
frequencies. The proband harbors a novel heterozygous 3 bpdeletion,p.Ser269del,in
exon 5 of KCNQ4 (Figure 3.8). All available family members were sequenced for exon 5.
Thirteen members with documented hearing loss shared p.Ser269del. No unaffected
family members (n=18) carried the deletion, and of90 ethnically matched population
controls, none carried the deletion. While p.Ser269del is not seen in four members with
hearing loss, these four individuals present a distinctly different audioprofile(Figure3.9;
Table 3.6). Audiology reports of affected relatives with the novel deletionshowahigh-
frequency,lateonsethearingloss(Figure3.9).
This deletion predicts an in-frame removal ofa serine residue at amino acid
position 269 within the P-Ioop domain of the KCNQ4 protein (Figure 3.10). We next
constructed an intragenic haplotype using commonly occurring SNPsand variants within
and surrounding exon 5 ofKCNQ4. This was done to determine whether or not any
interesting and possibly causative variants within KCNQ4 were shared by affected
individuals of Family 2071, and to determine the level of sharing among of intragenic
SNPs and variants among deletion carriers. No markers brought any additional interesting
information, and no farnily members without the deletion, or without hearing Ioss,shared
this hearing loss haplotype.
Upon discovering this novel deletion, all otosclerosis, AD, and AR probands in
the Newfoundland hearing loss study (n=68) were screened to determine whether or not
anyadditionalNewfoundlandfamiliessharedthemutation,therebysuggestingapossible
founder mutation. However, no additional cases outside of Farnily 207 I were detected.
All exons (1-14) were sequenced in the 28 AD probands for this gene.
Family 2102
A third proband was identified with a C7T base change in exon 4 ofMYOJA
(DFNA48). The proband is a member of a family (Family 2102) with four generations of
documented hearing loss. The complete pedigree documents 22 individuals, extends back
five generations, and indicates two consanguineous marriages in early generations
(Figure 3.12). Three family members have been diagnosed with AD non-syndromic
hearing loss from age 5 with progressive deterioration. A summary of audiology reports
is found in Table 3.9. The proband (N-l) is heterozygous for a C7T nucleotide change,
which substitutes a higWyconserved arginine residue fora stop signal at aminoacid
position 98 in exon 4 ofMYOIA (Figure 3.13). DNA from four available family members
was sequenced for exon 4 of MYOIA. Three members with documented hearing loss (II1-
I; IV-l; IV-5) shared the mutation, and one unaffected (III-2) did not. All affected
individuals first reported their hearing loss near the age of five, with hearing coming and
going but progressively deteriorating (Figure 3.14).
Again, all otosclerosis, AD, and AR probands in the Newfoundland hearing loss
study (n=68) were screened to determine if this was a Newfoundland founder mutation.
No additional cases were found. Exons3-4,6-7, IO-12,18,andexon22weresequenced.
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Figure 3.3 Hearing Loss Pbenotype of COCH p.P51P/S carriers ID-6 , IV-ll, and V-
2 in Newfoundland Family 2094 (Figure 3.1). Hearing loss is most pronounced in tbe
bigbfrequencies.*Audiologyreportswererandomlyselected,andtbe same trend is
observed for for remaining Family 2094 members, wbicb can be seen in Table 3.2.
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Figure 3.5 p.P51P/8 Family Haplotypes. B) Haplotype for Dutch p.P51P/8 family
(partial pedigree); associated haplotype is colored yellow. 8haringbetweenfamilies
is seen for markers D148257, D1481071, D1481040, D1481034, and D1481060,
spanning a minimum shared region of -2.1 Mb.
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Figure 3.6 Genotype Examples From Fragment Analysis of Newfoundland and
Dutch Families. Homozygosity and Heterozygosity at a marker is described in
GeneMapper by the number of times a strong vertical peak is present• If only one
strong vertical peak is present, the person is a homozygote; ifmorethan one strong
vertical peaks are seen, the person is heterozygous. The numbers in the boxes under
these vertical peaks represent the genotypes, or alleles, for that individual.A)U-lis
a Dutch individual (Figure 3.SB) and is a heterozygote (262,268) for marker
D1481021. B) Family 2094 individual lV-I (Figure 3.1) is a homozygote (262) for
marker D1481021. C) Family 2094 individual lV-IO (Figure 3.1) is a heterozygote
(262,274)formarkerDI481021.
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Figure 3.14 Hearing Loss Phenotype of Newfoundland Family 2102 MY01A
Nonsense Mutation Carriers IV-I, UI-l, and IV-S (Figure 3.12). Onset of hearing
loss is 5 years of age.
Candidate Gene
Table 3.1 Candidate Genes Screened For Mutations in Newfoundland Families
Having Late-Onset Autosomal Dominant Hearing Loss.
Number of Number of
Mutations Found Mutations
in Caucasian Associated with
I---K=C=M-:::-4:-----t--=-lo-,nH,.,--o-me-os-tas-,---iS-+------=..cPo"'-'u~~a=tion=s --j-....:...Pr=o=re=ss:,:.::~e=A=DHL=-j
COCH Extracellular Matrix 8 6
MY01A Unknown 8 4
TECTA Extracellular Matrix 7 7
Table 3.2 Audiology Summary For Family 2094 Family Members (pedigree shown
in Figure 3.1).
Family Member Age OnsetlvrsJ sex _Hea---=ring'---Thr_esh_old'---ldBJ ~
Right left Right left Right left Right left Right left
Female 30 35 50 40 60 60 85 90 90 90 63
M ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
Male 65 55 70 65 65 65 80 80 11011062
Male 50 45 70 70 90 110100 11095100 63
Female 45 30 55 40 70 60 90 90100 100 30
Female 45 40 60 50 70 70 85 90100 100 18
Female 10 10 20 10 30 25 35 30 25 20 35
Table JJ Pbennfn)e Summary of Famil}' 2094 Indi"idual~ (pedigl'ft ~hown in
FigureJ.l).
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Table 3.4 Physical Location of Markers Used to Create the p.P51P/S Deafness
Haplotype. The markers were taken from Fransen et aI, 2001.
Genomic Starting Type of Nucleotide Heterozygosity
Position on 14q12 Repeat
(bp)
DI48262 28,630,354 Dinucleotide
DI48975 29,749,271 Dinucleotide
01481021 30,341,868 Dinucleotide
COCH 30,413,441 N/A N/A
0148257 30,799,447 Dinucleotide 0.69
D1481071 30,898,090 Dinucleotide 0.72
D1481040 31,281,164 Dinucleotide 0.73
01481034 31,537,191 Dinucleotide 0.75
01481060 32,485,191 Dinucleotide 0.79
D14870 33,528,945 Dinucleotide 0.76
Tabl~ 3.5 Haplotype Sbaring Across Marktn Nearby lh~COCH Gtnt Btno"ttn
Ntwfoundland Fami/)' 2094 and a Dutch p.P5IPIS Famil)'.
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Table 3.6 Phenotypic Features of Affected Family 2071 Individuals. Shown first are
family members with the deletion, and at the bottom, those without the deletion
(pedigree shown in Figure 3.7).
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Table 3.7 Audiology Testing Results of Affected Family 2071 Individuals. Sbown
first are family members witb tbe deletion, and tben tbose witbout tbe deletion
(pedigreesbown in Figure 3.7).
OlnkllfeatlftSoffamllymembeflwtth __1CII5denT
Family Member Age sex HearingThresholdld8)
------ ----
Ri8ht left Ri8ht left Right left Right left Right left
...12 70 Male 30 35 50 40 60 60 85 90 90 90 63
MI·" 60 Female N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
67 Male 65 55 70 65 65 65 80 80 110 110 62
66 Male 50 45 70 70 90 llO 100 llO 95 100 63
39 Female 45 30 55 40 70 60 90 90 100 100 30
20 Female 45 40 60 50 70 70 85 90 100 100 18
64 Female N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
94 Female llO 75 115 80 120 100 120 100 100 100 90
44 Male 25 30 55 40 55 50 60 75 60 60 40
40 Female 30 30 35 35 45 45 70 70 85 70 39
38 Female 25 25 30 35 35 35 60 65 90 90 33
43 Female 30 25 35 40 50 50 50 45 70 60 41
34 Female 50 50 60 55 60 55 85 85 90 90 32
Cllnlc.alFeatu~sofAHectedFamilyMembersw/outdell!tlon
55 Female N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
71 Male 10 80 10 75 10 70 50 80 30 80 67
86 Male 30 30 35 50 40 50 60 70 60 70 83
46 Femate 10 60 15 50 10 35 5 40 15 40 44
Table 3.8 KCNQ4 Variants Used to Create tbe Intragenic KCNQ4 Haplotype
KCNQ4SequencingVariants Exon/lntron Pathogenic
c.34690A>AT Exon3 41056458 No
35184G>GC 41056958 No
35224A>AG 41056992 No
c.35905T>TC Exon5 41057674 No
c.35934_35936del Exon5 41057702 Yes
c.47646T>TG Exon10 41069414 No
Table 3.9 Audiologieal Su",n'ary off.",ily 21021ndividuab With & Withoul the
p.R93X Nonwnw MUlalion,
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Chapter 4: Discussion
The aim of this thesis was to detenninethe genetic etiology oflate onset
autosomal dominant (AD) hearing loss in 28 Newfoundland families. This was
investigated by screening the genomic DNA of28 probands for mutations in four genes
known to cause AD hearing loss, specifically KCNQ4, COCH, TECTA, and MYOJA. All
28 families were first genotyped to exclude the p.A716T mutation in WFSJ, a mutation
previously found to cause AD hearing loss in the Newfoundland population, as well as
the full GJB2 gene and the del13S 1830 mutation in GJB6.
Family 2094 Hearing Loss Caused by COCH Mutation
Of the 28 probands, one was found to have a mutation in COCH. COCH encodes
cochlin,andhaspreviouslybeenshowntobeprominentlyexpressedinariboon-like
pattern in the basilar membrane of the cochlea, providing evidence that it is involved in
the structural regulation of that membrane (Kommareddi et al. 2007). Cochlin's exact
role, however, remains unknown. COCHmaps to chromosome l4q12-l3. Cochlin is
predictedtobe550aminoacidslongandishighlyconserved.ltcomprisesashort
predicted signal peptide, an N-tenninal factor C homology domain, and two von
WillebrandfactorA-likedomains.
Seven missense mutations within COCH that cause hearing loss have previously
been reported: six of these cause a very recognizable phenotype characterizedbyalate
onset, progressive hearing loss associated with parallel vestibular decline. All six are
found in the Factor C Homologous (FCH) domain of the cochlin protein (Kemperman et
aI. 2005). Of the FCH domain mutations, three originate in North America (p.V66G,
p.G88E, and p.WII7R); one is a founder mutation (p.P5IP/S) present in many Dutch and
Belgian families, one originated in Australia (p.ll 09N), and one in Japan (p.A119T). This
audiological phenotypeoflate-onset high-frequency hearing loss caused bythese
mutations is in close correlation with the audiological phenotype of many of the 28 AD
Newfoundland probands being studied in this research project and was the primary
reason for choosing this gene for screening.
In Newfoundland Family 2094 a known mutation causing a heterozygous C-7T
hasechangewasfoundintheproband. This resulted in the substitution ofa conserved
proline residue for a serine residue at amino acid position 51 (p.P5lP/S) (Figure 3.2). All
seven affected members of Family 2094 shared the mutation, while an unaffected relative
did not harbor the mutation (Figure 3.1). lnclividualsharboringthep.P5IP/S variant
suffer from a late onset, progressive, high-frequency hearing loss with an 0 bviousonset
from-40yearsofageonwards(Bischoff,2005).A11affectedfamilymemberssharethe
same audiological profile (Figure 3.3), matching the pattern of hearing loss seen in
previous cases (deKok etal. 1999). The progressive nature of hearing loss in Family
2094 also matches previously reported casesofp.P5IP/S carriers (de Kok etal. 1999).
This mutation is also associated with vestibular dysfunction, such as motion
sickness and vertigo, which in most cases develops to complete vestibular areflexia or
vestibularhyporeflexia(Verhagenetal. 2001; Bischoffet aI. 2005). Onset of progressive
vestibular failure presents earlier, from the fourth into the sixth decade oflife,declines
more rapidly, and is eventually more complete than the associated hearingimpairrnent
(Bischoffetal.2005). Five out of seven Family 2094 members have so far experienced
these vestibular problems.
1n2009,HiIdebrandetal. reported ap.P5IP/S case with the very rare disease
Superior Semicircular Canal Dehiscence (SSCD), which is characterized by the absence
ofboneoverlyingthesuperiorsemicircularcanal,creatingathirdlabyrinthinewindow.It
was suggested that individuals with CaCHmutations like p.P5IP/S should be given a CT
scan to screen for SSCD (Carey et a1. 2007). Of the Family 2094 individuals who have
had CT scans; V-2, V-6, and IV-I, none were diagnosed with SSCD, though it has been
suggested that diagnosis ofSSCD often requires the doctor to be specificallylookingfor
the defect (Hildebrand et a1. 2009). This therefore represents both a clinical and a
scientific opportunity to learn more about this possible association. Carrierscould
undergoaCTscantolookforthisraredefect,andiffound,thatindividuaI can have
surgery done, as SSCD's severe vestibular symptoms can be fully corrected with surgery
(Careyet al. 2007). This would also add to the current literature on the possible
association between these two rare disorders.
Previous studies have also demonstrated a link between CaCH mutations like
p.P5l PIS and vertical corneal striae. Two families carrying the p.P5l PIS mutation were
foundtohavea93%anda78%prevalenceofthesestriae,respectively;ageof onset is
late40stolate50s(Bischoffetal.2007).lnFamily2094, V-6 was reported to have a
corneal scratch in the right eye. This was firstreportedattheageof31,which falls close
to the previously reported age of onset for corneal striae in p.P5IP/S carriers. This scratch
was not reported to be due to any physical injury to the eye, though no othermedical
information is available. Clinical follow-up is currently ongoing; this may be further
evidenceofa link between vertical corneal striae and hearing loss mutations within
COCH,likep.P5IP/S.
Confirmation of p.P51P/S as a Dutch Founder Mutation
The p.P5IP/S mutation has been reported in ten Belgian, seven Dutch, and one
American family and is widely accepted to be a Dutch founder mutation (de Kok et al.
1999; Fransen et al. 2001). This study is only the second reported occurrence of this
mutation outside of Europe. An opportunity to confirm this Newfoundland p.P5IP/S
occurrence as a Dutch founder mutation arose at the 2010 Association forResearchin
Otolaryngology MidWinter conference. While attending this conference, I met with Dr.
Hannie Kremer, a scientist working in the Netherlands, who has published on the
p.P51 PIS vestibular phenotype (Bischoff et al. 2005). Dr. Kremer offered to contribute
Dutch p.P51 PIS DNA, allowing me to confirm the Dutch founder hypothesis. Using
DNA from this Dutch fanlily and Newfoundland Family 2094, a series of microsatellite
markers were genotyped to develop ancestral haplotypes (Figure 3.5). These haplotypes
demonstrate allelic sharing between the two fanlilies for five contiguous markerscloseto
the COCH gene, spanning a total genetic distance of -2.1 Mb (Figure 3.4; Table 3.5).
The probability of these two families sharing this five marker haplotype by chance is low,
and therefore, it is likely that these two families are distantly related and originate from a
common ancestor in the Netherlands. The genealogy of this shared ancestry was not
followed upon, as the objective was to provide further support to the current Dutch
founderhypothesisforp.P51P/SDNA,andbecausenofurthergenealogyonthese
families is available. However, individuals in Family 2094 could be researched using the
Newfoundland Genealogy Database and the Heritability Analytics Infrastructure
(population Therapeutics Research Group, St. John's, Newfoundland & Labrador) to
tracethegenealogyofFamily2094.lfsuccessful,thiswouldprovidetheopportunityto
increase the power of this linkage association, and possibly directly link itto the Dutch
family with which it shares an ancestral haplotype. This avenue warrants further
investigation. It is interesting to note that mutation carriers in Family 2094 possess an
uninterrupted Newfoundlander ancestry, going back at least sixgenerations. Up until
recently,p.P51P/S had never been seen outside of central Europe(FransenetaI.2001).
Its recent discovery in a United States family (Hildebrand et aI. 2009), and now in a
family living here inNewfoundland,Canada,could be evidence of an ancientorigin.If
true, this would have strong implications for cochleovestibular diagnostic screening of
p.P5l PIS and other mutations within the COCH gene, as the older a mutation's origin,
the more likely it is to be widespread throughout all populations and ethnicities.
Family 2071 Bearing Loss Caused By Novel KCNQ4 Deletion
KCNQ4 (potassium Voltage-Gated Channel 4) encodes the protein potassium
voltage-gated channel subfamily KQT member 4. This protein is part of a family that
fonns channels to transport positively charged potassium ions between neighboring cells.
Moreimportantlyforhearing,thepotassiumchannelsthatthisproteinfonnsarethought
to play an indispensable role in the regulation of neuronal excitability, particularly in the
sensory cells ofthecochlea(innerear),wheretheyareexpressed (Kubischetal.1999).
ExpressiongradientsofKCNQ4inspiralgangJionandinthesecochlearhair cells
correlate very closely with progressive hearing loss (Beisel etal. 2001).
Twelve mutations have been reported in KCNQ4 (DFNA2): ten missense and two
deletions. The missense mutations are believed to cause hearing Iossbeginningata
young age (Hilgertetal. 2009). The deletions are thought to cause a milderphenotype,
haveanolderageofonsetandprimarilyaffectperceptionofhighfrequencies(Topsakal
etal.2005). While both late-onset and early-onset hearing loss can be caused by
mutations in KCNQ4, this gene is also associated with age-related hearing loss. One
research team has demonstrated that several SNPs associated with age-related hearing
lossintwoindependentCaucasianpopulationswerealllocatedinthesame13kbregion
in the middle of the KCNQ4 gene (Van Eyken et al. 2006).
The first KCNQ4 deletion (c.2Ildel13) was discovered in a Belgian family.
Affected individuals lacked 13 nucleotides between positions2ll and 224. This resulted
in a frame-shift after Gly70 (p.fsX71), followed by 63 novel amino acids and a premature
stop codon (Couckeetal. 1999). Consequently, the protein is truncated before the first
transmembrane domain and is rendered nonfunctional (Nie, 2008; Figure 3.11). More
recently, tbe second deletion was found in a Japanese family, and is al bpdeletion
(c.211delC).Sinlllarlytothepreviouscase,atruncated,nonfunctionalKCNQ4proteinis
generated (Karnada etal. 2006). The milder high frequency phenotype of cases reported
to harbor these two KCNQ4 deletions correlates closely with the phenotype ofseveralof
the 28 Newfoundland probands under study in this research project, and so KCNQ4 was
chosen as a functional candidate gene to screen for potential causativemutations.
The proband of Newfoundland Family 2071, III-12 (Figure 3.7), was found to
carry a novel 3bp heterozygous deletion in exon 5 ofKCNQ4 (Figure 3.8). Upon
sequencing other Family 2071 individuals, thirteen affected individuals were found to
share the 3 bp deletion. This is the third deafness causing deletion found in KCNQ4, and
the first outside of exon I (CouckeetaI.1999;Karnadaetal.2006).Audiologyreportsof
deletioncarriersdemonstrateahigh-frequency,late-onsethearing loss (Figure 3.9),
supporting the current genotype-phenotype correlation that KCNQ4 deletionsassociate
with a late-onset and milder hearing impairrnent (high-frequency loss) than
corresponding KCNQ4 missense mutations (Kamada et al. 2006).
This deletion predicts an in-frame removal ofa serine residue at amino acid
position 269 within the P-Ioop domain of the KCNQ4 protein (Figure 3.11). Interestingly,
the P-Ioopdomain is a mutational hotspot where ten missense mutationscausing early
onset hearing loss have previously been described (Couckeetal. 1999; Kubischetal.
1999; Talebizadeh et al. 1999; Van Hauwe et al. 2000; Kamada et al. 2006).
In order to detenninethe level of variant sharing among deletion carriers and
between all individuals of Family 2071, and to verify whether further hearing loss
patternsolightbeseen,wenextconstructedanintragenichaplotypeusingcommonly
occurring variants within and flanking exon 5 of KCNQ4. WhiIe these markers did not
singuIarly provide any additional interesting information regarding affected individuals
not harboring the deletion, all deletion carriers shared this deafness associated haplotype.
AdditionalIy,of90 ethnically matched controls, and of alI unaffected relati ves,none
shared this deafness associated haplotype. This haplotype, used primarily as a method of
further investigation and mutation confirmation, contrasts sharply with the
aforementioned p.P51P/S haplotype, which was constructed to demonstrateancestral
linkage between Newfoundland Family 2094 and a Dutch family, and which can be taken
as evidence for p.P51P/S being a Dutch founder mutation.
While this deletion is not seen in four Family 2071 members, these four
individuals present a distinctly different audioprofilecompared to deletioncarriers
(Figure 3.10; Table 3.6; Table 3.7). The cause of hearing loss forthesefour individuals is
likely due to several separate genetic or environmental predispositions, thusmakingthem
phenocopies. Environmental factorscouId also be the cause of hearing loss in these
individuals. The medical records show no indication of noise exposure or physical injury
to the ears in these four individuals. To ruIe out a different mutation on thesarnegeneas
the cause of hearing loss in these individuals, they were screened for all exons within
KCNQ4. No additional mutations were detected, and they did not share any particular
variants orSNPs at the locus when observed in the intragenichaplotype.
A further avenue of research for Family 2071 would he functionaJ studies.
Because KCNQ4 is strongly expressed in the sensory cells of the cochlea (Kubisch et aJ.
1999;BeiseletaJ.2001),studiesondeletioncarriersshouldheconducted to investigate
whether the 3 bp deletion negatively affects the potassium ion channels formed by
KCNQ4, whether these ion channels remain structurally and functionaJly intact, and
whether potassium ions are able to effectively move through these channels to complete
themechanoelectrical transduction pathway. This could potentiaJlyshed furtherlighton
the molecular pathways underlying this hearing loss mutation and couldprovide added
credence to the current genotype-phenotype correlation.
Family 2102 Hearing Loss Caused By MYOIA Mutation
MYOIA encodes the protein myosin la, which is present in the inner ear and plays
a role in human hearing (Donaudy et al. 2003). DonaudyetaJ. (2003) postulatedthat
MYOIA plays a role in ion transport. More recently, Hilgert & Smith (2009) present a
slightly different hypothesis. At the brush bordersurfaceofintestinaJ epitheliaJcells,
myosin la is a major component of the actin-rich cytoskeleton, where it is involved in
membrane trafficking. It could serve thesarne function in the inner ear, hecausethe
cytoskeleton of the intestinaJ cells and the inner ear cells (hair cells and supportingcells)
are very similar. The specific expression patlem in the inner ear has not yet heen
established, by may provide further clues in the future (Hilgert & Smith,2009).
MY01A was chosen as a candidate gene for the same reason as all the functional
candidate genes in this study: a phenotype correlation between individuals with hearing
loss due to mutations previously found within MY01A and the audioprofile seen in some
of the 28 Newfoundland probands under study. While most of the 28 probands suggest a
late-onset hearing loss, some are reported as early-onset, but still progressive and
autosomal dominant. Four mutations in MYOIA have been associated with an early-onset
AD, progressive, phenotype (Donaudy et al. 2003). These four mutations were all found
in ltalianprobands.
A heterozygous nonsense mutation was discovered at amino acid position 93
within exon 4 of MY01A in the Family 2102 proband IV-3 (Figure 3.12). This nonsense
mutation, p.R93X substitutes an arginine residue for a stop signal in the motor domain
(Figure 3.13). All three affected Family 2102 individuals shared the mutation,and
reported their first hearing loss at 5 years of age, with hearing coming andgoing,but
progressively deteriorating to severe hearing loss (Figure 3.14).
While this mutation is notnovel,itis only the second reported case worId-wide.
The p.R93X nonsense mutation was first reported in a very small southern Italian family.
p.R93X was present in the male proband who suffered from moderate to severe bilateral
hearing loss. This is the same audioprofile seen in Family 2102, though time of onset was
not available for this Italian family. The proband received the mutant allele from his
mother. The mother stated that she has norrnal hearing, although no audiological
evaluation of any kind was carried out. A healthy brother of the proband did not carry the
p.R93X mutant allele and did not possess any forrn of hearing loss (DonaudyetaI.2003).
Severalpossibilitiescouldexplainthe/talianmother'ssupposednormalhearing:
1) The mother does in fact have the same hearing loss as herson, 2) this family
segregates an AR form of deafness and digenic inheritance is responsible forthi shearing
loss phenotype, or 3) the trait is not 100 % penetrant. While many types of hearing loss
are caused by a mutation in one single gene, digenic inheritance requires theinteraction
of two genes for phenotypic expression. If the mother does not have hearing loss, despite
carrying the p.R93X mutation, she may not have hearing loss because this trait is an AR
form of hearing loss and segregates in a digenic manner. She would not inherit the
second disease causing mutation in the putative second unknown gene. Additionally, if
the trait is not fully penetrant then this too could explain the mother's nomla1hearing.
Detection of the p.R93X mutation is simple and does not require sequencing because the
mutation is easily identified by digestion ofPCRproducts, as the mutantalleledestroys
an AvaIJ restriction site. A furtheravenueofresearchforFamily2102wouldbetoattain
DNA from the affected Italian individuals previously reported to create an ancestral
haplotype,asdonepreviouslyforFamily2094./tcouldthenbedeterminedwhetheror
not Family 2102, from Newfoundland, share a common ancestor with the previously
reported Italian farnily (Donaudy et a1. 2003).
Candidate Gene TECTA
TECTA encodes the protein Alpha-tectorin. The tectorial membrane is an
extracellular matrix that covers the Organ of corti sensory epithelium in the ear. Sound
waves induce a vertical movement of the basilar membrane, and this movement evokes a
deflection of stereocilia against the tectorial membrane. Alpha-tectorinisoneofthe
major noncollageneous components of the tectorial membrane. Mutations in the TECTA
gene have been shown to be responsible for ADNSHL, with audioprofiles similar to some
of the 28 Newfoundland probands under study (Verhoeven et al. 1998).
Exonssequencedincluded5,9-14, 17-18, and 20. However, no hearing loss
mutations were discovered among the 28 AD Newfoundland probands. This does not rule
out the possibility that hearing loss in one or more of these Newfoundland probandsif
caused by mutations in TECTA within an exon that was not sequenced in this research
project. A total ofl3 exonswere not sequenced,and this gap represents an opportunity
for further research, as TECTA remains a strong candidate gene for hearing loss in
Newfoundlandfarnilies.
Non-Founder Mutations in a Founder Population
As previously discussed, the province of Newfoundland & Labrador is a founder
population, due to its cultural and geographic isolation. Sincethesecondmajor wave of
settlement, taking place in the late 18th and early 19th centuries, little immigration 0 r
outmigration has occurred. These original colonists have contributed toseveralfounder
mutations that cause specific diseases. For example, an exon 8 deletion in MSH2, a gene
causing hereditary non-polyposiscolorectal cancer, has been found in 5 different
Newfoundland families (N=74 carriers) (Frogattet aI. 1996; Stucklessetal. 2006), and
the c.782+3deIGAG mutation found in the deafness gene TMPRSS3 has been reported in
2 different Newfoundland families (Ahmed et aI. 2004; Young et al. unpublished data).
This study sought to potentially identify AD hearing loss founder mutations in
Newfoundland. No founder mutations were identified. All three of the mutations
identified in this study - p.P5lP/S, p.Ser269del, and p.R93X in the genes COCH,
KCNQ4, and MYOJA respectively - were each reported in one family only, after
screening 68 Newfoundland & Labrador hearing loss probands. We identified three
separate mutations in three separate genes causing hearing loss with threeseparate
phenotypes. Additionally, these mutations were found to cause hearing loss in three
Newfoundland families that are geographically separated from one another. So while the
genetic history and nature ofNewfoundland's population, combined with previous
successes (Youngetal. 2001; Ahmed et aI. 2004) implies that the future disCQveryof
hearing loss founder mutations in Newfoundland & Labrador is still a possibility, the
results of this study unexpectedly point to Newfoundland's genetic diversity, rather than
its homogeneity. This isn't the first time this has happened. An increased level of genetic
diversity was noted when, for example, nine mutations in six genes were detected in 21
families with Bardet-Biedl syndrome (Webb et al. 2009). I speculate here that the solved
families in this study, 2094,2071,and2102,a1l descend from original butseparate
groups ofNewfoundland colonists. These colonists would likely have been from several
different areas of Ireland or England. The geographical isolation of their origin home
towns could account for the potential genetic diversity seen in the identification of these
three separate hearing loss mutations. These findings, therefore, do not marginalize the
efficacy of the Newfoundland population in the search for novel gene discovery or for
The clinical and cliagnostic utility of these identified mutations is significant for
the families in question, as they are now able to screen new family members,receive
much improved genetic counseling, and hopefully, benefit from improved treatment
options. However, identification of a Newfoundland founder mutation would be of
increased clinical and diagnostic utility. Any mutation that is prevalent throughout a large
portionofnativeNewfoundlandersisscreenedforatbirth,andwouldthusbeidentified
in all future cases born in Newfoundland. The aforementioned benefits would therefore
apply to a much wider range of people than a single family, as is the case for non-founder
mutations. This study, therefore, does not reduce the strong clinical and diagnostic
potential that can be fulfilled through the discovery of Newfoundland founder mutations,
nor does it point to an inefficacy of the ewfoundland population as a medium of novel
gene discovery.
A Changing Landscape of Gene Identification Methodology
Oespitetheincreaseinhearinglossgeneidentification,manydeafnesscausing
genes and loci remain undiscovered. High density SNP arrays, which are a type of 0 A
microarray used to detect polymorphisms across large portions of a genome have been
successfullyappliedinanewapproachtofindhearinglossgenes.Shahinetal.(201O)
applied SNP array-based homozygosity mappingoffarnilieswith a high degree of
consanguinity. Homozygosity mapping is a powerful method of localizing genes for
autosomairecessivedisorders.Usingthisapproach,Shahinetal.(2010)identified five
genome regions likely to harbor novel genes for pre-lingual non-syndromic hearing loss
in six Palestiniankindreds. This approach is currently being investigated for AR hearing
disorders in the Newfoundland population. Traditionally this method has been limited to
families who share a recent common ancestor, but Hildebrandtetal. (2009) have recently
demonstrated that this technique can be used onoutbred populations. They performed
homozygositymappingon72singleaffectedindividualsof54kindredsascertained
worldwide using a 250 K SNP array. This discovery could potentially open up further
opportunities for novel gene discovery in Newfoundland & Labrador as many specialty
clinics have access to cohorts of individuals from out-bred popuiations.
A second technological advance having huge implications on novel gene
discovery is the advent of next-generation sequencing (Schuster, 2008). Next-generation
sequencing allows for the easy production of millions of ONA sequence reads in a single
run. Next-generation sequencing instruments can generate as much data in24hours as
several hundred traditional ONAcapillarysequencers,butareoperatedbyasingleperson
(Schuster, 2008). A recent study ofnon-syndromic hearing loss used targetedgenome
capture combined with next-generation sequencing to analyze 2.9 Mb of the DFNB79
interval on chromosome 9q34.3 (Rehman et aI. 2010). Rehman et aI. (2010) detected a
nonsense mutation in the predicted gene C90rj75, which they renamed taperin (TPRN). A
nonsense mutation is a change in DNA sequence that results in a premature stop codon,
leading to an incomplete, and usually nonfunctional, protein product. Rehman et al.
(2010) next performed immunolocalization experiments on the TPRN protein in a mouse
cocbJea, and saw prominent expression in the taper region ofbaircell stereocilia.
A third strategy showing recent success (Meyer et al. 2007) and Slrongpromise
for gene identification, specifically for AD hearing loss, is the use of AudioGene
Audioprofiling. Audiogene is a computer program that uses a machine-learning approach
to analyze audioprofiles as a method of prioritizing genes formutation screening in small
fanliliessegregatingADhearingloss.Theaudiogenedatasethasrecentlybeenexpanded
to include a total of 16 DFNA loci, including CaCH, KCNQ4, and TECTA (Hildebrand
etal.2009). This could be very useful in the investigation ofNewfoundland farnilies
segregating AD hearing loss, and many of these families are small with limitedrecorded
data. Hildebrand et aI. (2009) performed an experiment where a series of audiograrns
were analyzed by a panel of hearing loss experts, and concurrently by AudioGene. The
accuracyofmatchingtheaudiograrnswiththegenotypiccausewas55%forthehuman
experts, and 88 % for AudioGene (Hildebrand et aI. 2008). Furthermore, as thes.izeof
this database increases, so too will its predictive capacities. Fornow,it represents a
promising avenue for Newfoundland AD hearing loss research at almost zero cost, and
should be the next strategy employed for mutation detection in the 25 remaining
Newfoundland AD probands.
These are just some examples of recent advances in technology leading to novel
gene discovery, and as these technologies become more common, their use will be
instrumental in new investigative disease causing studies not just in the Newfoundland
population, but all over the world. The ability of next-generation sequencingtoperform
somany'reads'soquicklywillbeinvaluabletofuturehearinglossstudiesin
Newfoundland. Screening candidate genes and potentially mutated chromosomal regions
willbesignificantlyeasier,allowingforthe'quick'discoveryofnovel(and existing)
causative hearing loss mutations in Newfoundland probands.
Limitations of this Study
Despite the discoveries discussed above, the candidate gene approachundertaken
in this study does present various limitations in the search for hearing lossmutations.
These limitations vary widely, and while mentioned above throughout this thesis, a short
summary of them will serve to illuminate the path forward both in filling any gaps, and in
approaching mutation detection in various untried ways up to this point.
Firstly, it is important to note that mutations in WFSJ may not be more common
than other hearing loss mutation just because they are more commoniy reportedin
Newfoundland. The reason the p.A7l6T mutation in WFSJis so widely reported is due in
large part to its pathognomonic character. A pathognomonic sign is a particularsign
whose presence is characteristic fora certain disorder beyond anydoubl. The phenotype
ofp.A7l6T mutation in WFSI is one such pathognomonic trait. Local audiologists are
able to both distinguish this pattern of hearing loss and recognize surnames of the
extended family thus far affected, and contact us directly when they have patientsthat
mayberelatedtotheseoriginallyreportedfarnilies(Youngetal.2001).Clinical
applicationlikethismakesitlikelythatthehighfrequencyofreportedWFSI-related
hearing loss is an overstatement, not describing the true situation (Tranebjaerg2008).
It is also possible that one or more of the families under investigation may be
incorrectly classified as AD due toa lack of sufficient data. ManyindividuaIs in these
pedigrees (Figure 2.1) are ascertained through relatives' word of mouth, andsoitis
entirely possible that digenic inheritance, penetrance, or even rnitochondrialmutations
may be obscuring the proper ascertainment of inheritance pattern and thus the search for
causative hearing loss mutations. These possibilities should undoubtedlybeinvestigated
in future studies on the 25 remaining AD families.
Thepossiblepresenceoflargergenomicabnorrnalitiesatworkisanother
limitation of this study, which did not search for any such possibleoccurrence.Thisstudy
investigates genes through targeted gene sequencing. However, largergenomic
abnorrnalities have been shown to cause hearing loss phenotypes (Lisenkaetal. 2003;
Shafferetal.2006).Genomicabnorrnalities,therefore,mayaccountforhearing loss in
some of the Newfoundland families under investigation. Large genomic rearrangements,
deletions, inversions, etc. can cause and affect the degree and severityofdiseases,and
such large-scale anomalies are not detected through traditional DNA sequencing methods
(Lisenkaetal. 2003; Idbaihetal. 2010). Thepossiblepresenceofsuchabnonnalities
should be investigated in future studies.
The presence of phenocopies in Family 2071 is also a relevant pit-fall in this
study of AD hearing loss families. While phenocopies are common, they are also often
difficuItto prove beyond anydoubl. A routine aspect of the clinical ascertainmentisa
request of patients and family members to fiJI out a detailed hearing loss questionnaire.
This includes specific questions about noise exposures, head injuries, usageofdrugs
known to be ototoxic, etc. In this study, the cause of hearing loss in Family 2071 's
putative phenocopies is unknown. These unanswered questions obscure thefullpictureof
hearing loss in Family 2071. The continued investigation of this family is, therefore,
essential to gain a more complete understanding of hearing loss in this family and to
confinn beyond any doubt that several individuals within Family 2094 are phenocopies.
Lastly, the approach taken in this study is also a limitation unto itself. Thisstudy
was a "targeted" candidate gene approach which focused only on genes previously
associated with hearing loss. While this improved the likelihood of detecting hearing loss
mutations, it restricted the chance of identifying potential "geneticsurprises" regarding
genotype-phenotype. And while several exons within KCNQ4, COCH, TECTA, and
MYOIA not previously associated with hearing loss were bi-directionally sequenced, this
approach was limited by the two year time-frame ofa master's thesis.
Chapter 5: Summary
The aim of this thesis was to detennine the genetic etiology of AD hearing loss in
28 large, multi-generational Newfoundland families. Probands were first screened for
hearing loss alleles previously reported in the Newfoundland population: specificaJlythe
fuJI GJB2 gene, the del13S1830 mutation in GJB6GJB2, GJB6. and the p.A716T in
WFSI. The next step was a systematic functional candidate gene search for genes and
mutations from the primary literature and the NCBI database. Genotype-phenotype
evaluation of potential candidate genes, and frequency of mutations found previously,
helped to narrow the list down to four likely functional candidate genes: eOCH, KCNQ4,
TECTA. and MY01A. These genes all code for proteins that play an important role in
human hearing, and harbor hearing loss mutations recurrent in Caucasian populations.
Once a mutation was identified, we were then able to highlight common patterns among
the phenotypes ofNewfoundland probands and the phenotypes of known mutations in
AD deafness causing genes. Figure 2.2 illustrates the progression of this study from the
stage of experimental design to the discovery of novel and known causative mutations.
In Newfoundland Family 2094 a known mutation (p.PSl PIS) within eOCH was
discovered to be the cause of hearing Joss. The p.PS IPIS mutation causesa late-onset
progressive high-frequency hearing loss, and is associated with severevestibulardefects,
such as vertigo and motion sickness. Using DNA from a Dutch p.PSl PIS family, and
Family2094,anancestralhaplotypewascreatedthroughsuccessfulfragmentanalysis,
confirmingFamily2094'sp.PSlP/StransitiontobeaDutchfoundermutation.However,
no other Newfoundland families were explained by this mutation. No further genealogy
was done to elaborate on this shared ancestry.
In Newfoundland Family 2071, a novel 3 bp deletion in exon 5 ofKCNQ4 has
been found to be the cause of hearing loss. This discovery also provides further evidence
of the current genotype-phenotype correlation, whereby deletions in KCNQ4 cause a
milder, later onset, high-frequency loss in patients compared to KCNQ4 missense
mutations (Nie, 2008). This mutation was not detected in any additional Newfoundland
probands.
InNewfoundlandFamily2102,thecauseofhearinglosswasidentifiedtobea
nonsense mutation in exon 4 ofMY01A (p.R93X). All affected individuals are reported
to have suffered from hearing loss from the age of five, with hearingcomingandgoing
but progressively deteriorating. Again, this mutation was not reportedinanyadditional
Newfoundland hearing loss families. No hearing loss causing mutations were discovered
within the TECTA gene, but sequencing of this gene should be completed in the future to
rule it out completely as a candidate gene for hearing loss.
In the introduction, a table was presented indicating all knowndeafnessrelated
genes and their mutations within the Newfoundland population. An updated version of
this table is seen in Table 5.1. Of the 28 Newfoundland families suffering from AD
hearing loss at the beginning of this study, three families have now been solved. Further
research on the remaining 25 unsolved Newfoundland families is of paramount
importance. Genomic DNA from four of these 24 families has recently been sent for a
genome wide scan (GWS). The data gained from this GWS will inevitably enable further
successful identification of the genetic cause of hearing loss in thesefamilies.AudioGene
Audioprofiling also presents a promising avenue of detecting further mutations within the
remaining 25 probands, and should be investigated. The determination of these hearing
loss causing mutations must remain of critical importance to researchers and clinicians
alike. With a greater understanding of the genetic mutations causing variousfamilies'
hearing loss, comes a greater understanding of the pathogenic mechanismsandagreater
chance of improved treatment options and screening abilities.
Table 5.1 Deafness Genes Identified in Newfoundland Population at End of This
Study
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Appendix A: PCR Primer Sequences and Expected PCR Product Sizes.
Gene Amplified Primer Name Primer Sequence Size of
Exon Fragment (bp)
KCNQ4 lA 4700-1AF agttggagtcggaaagagca 567
4700-1AR CGCAAACTCACATGAAGACG
KCNQ4 lB 4700-1BF AGCCATGCGTCTCTGAGC 564
4700-1BR ctgggagatcagggcttagg
KCNQ4 2 4700-2R ccagggaattccaattctga 456
4700-2F gaagcctctttccaccttca
KCNQ4 3 4700-3F ggaatcgtcaagtccaggaa 358
47DO-3R agggtcagagtcgggattg
KCNQ4 4 4700-4F tactcccaatcccgactctg 486
4700-4R ttagacctcgcctcctgcta
KCNQ4 5 4700-5F tgggaggagctgagaaagaa 351
4700-5R tgagtcaggagtcacgatgg
KCNQ4 6+7 4700-6&7F ccctcatgatcaggctccta 554
4700-6&7R gtcagcacacagggttgaca
KCNQ4 8 4700-8F ccacaactggaccaaggact 356
4700-8R aaggacactccaggctctga
KCNQ4 9 4700-9F tccaccctgtcctattctgg 397
4700-9R aaggcaggtctgagagagga
KCNQ4 10 4700-10F catccttgttccatcccaag 494
4700-10R ccaaagacggtccatcagtt
KCNQ4 11 4700-11F ctggtggtttggcatacaag 287
4700-11R ggctggtctcaaactcctga
KCNQ4 12 4700-12F tccatctcatccctgtttctg 392
4700-12R ggcctcagacttcattcagg
KCNQ4 13 4700-13F ggtgccttctccttcatcag 394
4700-13R cgggtttatgggaatgtctg
KCNQ4 14A 4700-14AF ctagccaagctccacctttc 383
4700-14AR GCCTCTGAGAAGTCCCTCAGT
KCNQ4 14B 47DO-14BF GACCTGCTGTIGGGmCTA 418
4700-14BR gctgctgctgccctctgt
TECTA 5 S422-SF accctgactcggctatgaaa 480
5422-5R ccattacccagcggagagat
TECTA 9A 5422-9AF gggcagaccgtgtcmatc 497
5422-9AR ACTCCAGGAAGGAGCTGTIG
TECTA 9B 5422-9BF GmGTGCGGmCTACAAT 488
5422-9BR acctggaagggaagtcctga
TECTA lOA 5422-lOAF gcactcacaaacacacatgc 496
5422-10AR AAGGTGAGGTAGTGGCCGTA
TECTA lOB 5422-10BF mCTGGGTGGACCTGGACT 499
5422-lOBR tttcmggattccggacct
Appendix A: PCR Primer Sequences and Expected PCR Product Sizes (conI).
Gene Amplified Primer Name Primer Sequence Sileof
Exon Fragment (bp)
TECTA 11A 5422-11AF ctgctcaaacttccctctgg 499
5422-11AR AAGGCAGCGTTCTGGTTG
TECTA 11B 5422-11BF ACCCTGATGATGACCTGGAG 497
5422-11BR tcagttccaaagtgcatatcct
TECTA 12 5422-12BF tgcctttcatctccctgagt 415
5422-12BR cgaacacgacgctcttcata
TECTA 13A 5422-13AF catttgagttgaggccgttt 494
5422-13AR AGTAGACGGGCGAAATGATG
TECTA 13B 5422-13BF CGTCGCAACGTGATTCAG 470
5422-13BR acctggtcactgtgtgtgga
TECTA 14 5422-14F cagaatggagtcgttgagacag 499
5422-14R aggcattcctcattcacacc
TECTA 17 5422-17F atgcccaggttactgctttg 493
5422-17R gcagatcaccctgaagttgg
TECTA 18 5422-18F gccatttctccactttcagg 354
5422-18R tagggcatcaaagacaaacg
TECTA 20 5422-20F gcatttctgccatttatggtg 381
5422-20R gatgattccagtccggtcac
MY01A 3 5379-3F gcctctggctgtggatatgt 399
5379-3R acgcaggttcatccactctc
MY01A 4 5379-4F gcccagtctgctccaagtag 297
5379-4R tggagggtcaggtctaggtc
MY01A 6+7 5379-6&7F tgagccctagaccctcttcc 500
5379-6&7R gttgggaagtctccttgacg
MYOlA 10 5379-10F atgaatccattagggcaagg 495
5379-lOR aggcagaaagcagaaatcaaa
MY01A 11+12 5379-11&12F caccagtgtctcaggcagtt 490
5379-11&12R tcatcctccctactctgctca
MY01A 18 5379-18F gcaccgtgtgcagcatag 395
5379-18R ttcacccagcttcagcagat
MY01A 22 5379-22F actcaggtctttgcgtggtt 281
5379-22R gcagactgaggaaactcttgg
MY01A 25 5379-25F ggtgctgatgtcttggtcct 374
5379-25R caaacacagcctgccatct
COCH 2+3 4086-2&3F tctgtgtcctctctcctctgc 499
4086-2&3R atgggagaaacaggtgagca
COCH 4 4086-4F ctggaatggtatggaagggta 463
4086-4R tatccaggagaaccgtgaaa
COCH 5 4086-5F agcgagacgccatcaaataa 395
4086-5R ccatcaaggttaaagaggctga
Appendix A: PCR Primer Sequences and Expected PCR Product Sizes (cont).
Amplified
Exon
Primer Sequence Size of
Fragment (bpI
4086-12AF tttgccactctcgtcacaat 492
4086-12AR TTIGCCTAAATGGCTGTIGA
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Appendix B: Mutations Previously Found Within the Four Selected Candidate Genes
KCNQ4, COCH, TECTA, and MYO/A.
Mutation Protein Domain Exon Reference
KCN 4- .W276S PoreReion 5 CouckeetaL 1999.
KCN 4- .L274H PoreRe ion 5 Kubischetal.1999.
KCN 4- .L281S PoreRe ion 6 Talebizadehetal.l999.
KCN 4- .G285S PoreReion 6 Kubischetal.1999.
KCN 4- .G285C PoreRe ion 6 CouckeetaI.1999.
KCN 4- .G32IS S6Transmembrane 7 Couckeetal.1999.
KCN 4- .G455H PoreRe ion N/A Van Laeretal.2006.
KCNQ4-
,.Q7IfsXI38 Transmembrane I Kamadaetal.2006.
KCNQ4- .FS71 N-TenninalCyto lasmic I Couckeetal.1999.
COCH- .V104del FCH 5 Nagyetal.2004.
COGH- .P5IP/S FCH 4 Fransen et al. 1999.
COCH- .V66G FCH 4 Robertsonetal.1998.
COCH- .G87W FCH 5 Collin etal. 2006.
COGH- .G88E FCH 5 Robertsonetal.1998.
COCH- .1109N FCH 5 Kamarinosetal.200!.
COGH- .W117R FCH 5 Robertsonetal.1998.
COCH- .A119T FCH 5 Usamietal.2003.
COGH- .C542F vWFA2 12 Street et al. 2005.
TECTA- .N864K N/A 9 Hutchinetal.2005.
TECTA- .CI057S Zona Adhesion 10 Balciunieneetal.1999.
TECTA- .C1352Y N/A II Hutch in et al. 2005.
TECTA- .CI509G vWFD4 13 Pfisteretal.2004.
TECTA- .C1619S Zona Adhesion 14 Alloisioetal.1999.
TECTA- .L1820F ZonaPellucida 17 VerhoevenetaJ.1998.
TECTA- .G1824D ZonaPellucida 17 Verhoeven et al. 1998.
TECTA- .C1837G ZonaPellucida 17 Moreno-Pelayo,200!.
TECTA- .Y1870C ZonaPellucida 18 Verhoevenetal.1998.
TECTA- .R202IH ZonaPellucida 20 IwasakietaJ.2002.
TECTA-
.F119fsX131 N/A 5 Hutchinetal.2005.
MYOJA-p.R93X Motor Domain 3 Donaudyet ai, 2003
MYOJA-p.V306M N/A 10 Donaudyet ai, 2003
MYOJA-p.E385D Motor Domain 12 Don+audyet ai, 2003
MYOJA-p.G662E N/A 18 Donaudyetal,2003
MYOJA-p.G674D N/A 18 Donaudyetal,2003
MYOJA-p.s797F N/A 22 Donaudy et ai, 2003
Appendix B: MUUltions Previously Found Wilhin the Four Selected Candidllie Genes
KCNQ4, COCH. TECTA, and MYOIA (coni)
Appendix c: caCH Microsatellite Marker Primer Sequences and Expected peR
Product Sizes.
Marker
Name
D14S262-F
D14S262-R
D14S975-F
D14S975-R
D14S1021-R
D14S1021-F
D14S257-F
D14S257-R
D1451071-F
D1451071-R
D14S1040-F
D14S1040-R
D14S1034-F
D14S1034-R
D14S1060-F
D14S1060-R
D14S70-F
D14S70-R
D14S1014-F
D14S1014-R
Primer Sequence Size of
Fragment (bp)
GCAGTGGACTGATGCTCC 200
CCATGAAACTGGTCCCG
CATACACAGACACACGGAGA
TGCCAAATAATCAGTITIGC
AGTCGTGTATCCTGGGCAT
GCGCTGGTGTGAATCTTIA
CAGTGAGCCATGACTGTG
TIGGTAAAGTGGTAAAAGGC
AGTGATCCACCCACCTIC
GGCTCAACTACGTGTIGCT
GGCACTATGAAACCAATITIAAC
GGCCTGCTGAATCAGA
CGTAGATGCTCCAAATCCTAC
TAGACAAATCGCTGGTCACT
GTIAAAATGGGCCACAATAAAT
CTGTIATGTATCAGACCAACCC
ATCAATTIGCTAGTTIGGCA
AGCTAATGACTIAGACACGTIGTAG
AGCTATICAGGTCAAAAAGGTC
AATCCCTACCCTIGTGGTG
Appendix D: Fragment Analysis of Microsatellite Markers Flanking the CaCH gene.
Marker A1lelel Allele 2
8am Ie
OP06-115 01481021 262 262
JC07-184 01481021 262 262
KM06-227 01481021 262 262
J807-182 01481021 262 274
19126 01481021 268 268
19135 0148102\ 262 268
19149 01481021 262 268
AP07-66 01481021 262 274
OP07-270 01481021 262 274
CP07-187 01481021 262 268
CC07-269 01481021 262 268
OP06-115 0148975 163 171
JC07-184 0148975 163 171
KM06-227 0148975 167 171
J807-182 0148975 171 171
19126 0148975 163 171
19135 0148975 167 171
19149 0148975 167 171
AP07-66 0148975 163 171
OP07-270 0148975 163 171
CP07-187 0148975 163 171
CC07-269 0148975 165 171
OP06-115 01481040 234 234
JC07-\84 01481040 232 234
KM06-227 01481040 234 234
J807-182 01481040 232 234
19126 01481040 214 234
19135 01481040 232 234
19149 01481040 232 234
AP07-66 01481040 232 234
OP07-270 01481040 232 234
CP07-187 01481040 232 234
CC07-269 01481040 232 234
OP06-115 01481071 277 281
JC07-184 01481071 275 281
KM06-227 01481071 281 281
J807-182 01481071 277 285
19126 01481071 277 281
19135 01481071 275 281
19149 01481071 275 281
AP07-66 01481071 285 281
19149 01481060 201 207
Appendix D: Fragment Analysis of Microsatellite Markers Flanking the CDCH Gene
(cont).
Sam Ie Marker Allelel Allele 2
OP07-270 DI4SI071 285 281
CP07-187 DI4SI071 275 281
CC07-269 DI4SI071 275 281
OP06-115 DI4SI034 169 173
JC07-184 DI4SI034 169 177
KM06-227 DI4SI034 169 173
JS07-182 DI4SI034 173 175
19126 DI4S1034 169 177
19135 DI4SI034 169 175
19149 DI4SI034 169 175
AP07-66 DI4SI034 169 175
OP07-270 DI4SI034 169 175
CP07-187 DI4SI034 169 169
CC07-269 DI4SI034 169 179
OP06-115 DI4S262 200 200
JC07-184 DI4S262 200 200
KM06-227 DI4S262 200 200
JS07-182 DI4S262 200 202
19126 DI4S262 204 204
19135 DI4S262 200 204
19149 DI4S262 200 204
AP07-66 DI4S262 200 202
OP07-270 DI4S262 200 202
CP07-187 DI4S262 200 198
CC07-269 DI4S262 200 204
OP06-115 DI4S257 179 177
JC07-184 DI4S257 179 191
KM06-227 D14S257 179 179
JS07-182 D\4S257 17\ 177
19126 DI4S257 179 179
19135 DI4S257 179 191
19149 DI4S257 179 191
AP07-66 DI4S257 179 17\
OP07-270 DI4S257 179 171
CP07-187 D14S257 179 191
CC07-269 DI4S257 179 191
OP06-115 DI4SI060 201 207
JC07-184 DI4S1060 201 191
KM06-227 DI4SI060 201 191
JS07-182 DI4S1060 201 197
19126 D14SI060 201 205
19135 DI4SI060 201 207
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Appendix E: Medical Hearing Loss Questionnaire (cont)
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PkI.etickoMofthebllowinaoptiona:
I ...... tbltlll1ltiMue/O~Al_plnocon t.IlMd b ..y Il'I'f'I"oed reaell'dl
tal. Ill..,.-..-~ to . <::OnIentblhe_ eel.
'Include. name, MCP n\Ullbe. or any other ide'n~&information.
111< DN.... 1Impl< from thi. Olldy ....m bo: I<lml in Sl. John' .. ~"Wundl»J I'ftd S=n~.
WllS/l,/Ill'OI'I tar ""inddjt\i,c p<riodo(o"",.
II. CHtOff 10''''''''
If)'Ollbaveao;yquaeioftsaboollakin&parcialbisllUdy.)'OIICllllI'fttwitblhc
iII.............. ia;.,chlr&cofltlcllUdylldoiainatiturioa.ThacpcnDl'liJ:
Or)'OllCllltal1l:lO_,.hois_im.oIveclwithltlcllUdy_.oIJ.butCUl8dvUo)'Oll'"
yow ripu .. 0 pllti(ipIIII ina raarclI aDdy ThiJpcnoIICIII1lcradllOd.dlro\lP'
Appendix E: Medical Hearing Loss Questionnaire (cont)
ignacurePage
tudy tide: The aeneries or He",ditllrY Deafo in New~ uodland
ame or prindpal iave:sdptor: Dr. Terry-Lynn V.UBI
To befilkdoutudsill'ed by Ibepor1idpout'
Yes t I Not I
Yes t I No{}
Plcnsechcck ooDmpriacc:
Yes f. Not I
Yes f. Not.
Yes f} No II
Yc t} Nof I
IbavcrcadtbccoRSCDI[lIIldinfonnationsbcct].
IbacbadtheopportunirylOul<qucstions/lO<fucuuthisstudy.
lhavcreceivcdssllsfaetoryansWCf'StoaJlofmyql>CStions.
lhavcreceivcdcoouabinfonnarionobouttbcstudy.
I have spoken to Dr. Youogorhcrresean:h ....istanllllldshe
has answrTCd my qucshOOS.
I undcntantIthal [am frcc 10 wilhdrllw &om tbcstudy
• t any time
• withouthavingtogivearcason
• withoulail'cetingmyfururecare
1 undcrslandthnlilismychoicelohc inlhc study and Ihac I may no' bencfi,.
I agree lhat tbc sludy doclor Dr inveslignlor may rclld tbc pans of my hospital
rccDrds whlcharerclcvanl 10 thc study.
I alltec to ,akcl!lJ(l inlhi,slUdy. Ve.l} . No 11
Dale
1have explained this study 10 tbcbestofmy obiliry. I invil<:dqucsrionsandgnve"""wcrs. lbelievc
that thcpsrticipent fully UDdcrslandswbat Is involved in bcing in tbcstudy. any po,enriaJ riok>Df
lheswdylllldlbatbcorsh~hasfrcclycho!cnlObcintbcswdy.
Signatun:ofinvestigator
Telcphoocnwnbcr. _
atofminorparticipaarlirappropriatd=
SignatutCofmillOl'participanl
RelationsltiplOparticipantnamedobovc




